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INVASIVE PULMONARY ASPERGILLOSIS, EPIDEMIOLOGY AND 
PATIENT GROUPS 
 
Aspergillus is a saprofytic fungus that grows in humid environments on decaying organic 
matter.  Its ability to adapt to a wide variability of conditions accounts for its worldwide 
distribution. Invasive aspergillosis (IA) is a disease characterised by invasion of normal 
tissue by Aspergillus organisms, resulting in significant tissue damage and necrosis. Most 
commonly, IA develops in patients with impaired host defence.  Factors that 
predispose patients to develop IA include prolonged granulocytopenia, the 
development of graft-versus-host disease, immunosuppressive therapy, the use of 
adrenal corticosteroids, and the prolonged reduction of host defences associated with 
diseases such as chronic granulomatous disease [1].   
The most common route of infection is the inhalation of fungal spores, and therefore 
the majority of IA patients (± 90%) develop an invasive pulmonary aspergillosis (IPA). 
Other manifestations of the disease include IA of the paranasal sinuses, skin, wounds 
and eyes [2].  
 
There are several factors that make IPA a challenging fungal infection to manage:   
• IPA is currently a major direct or contributory cause of death in severely 
immunocompromised patients such as haemato-oncological patients receiving 
chemotherapy [3], and its incidence has shown a significant increase in the past few 
decades [4,5]. 
• IPA is difficult to diagnose, especially in the early stages of the disease.  
• The treatment of IPA is suboptimal, with reported response rates below 55% in 
leukaemia- and bone marrow transplant patients. [6].  
 
 
PATHOGENESIS OF INVASIVE PULMONARY ASPERGILLOSIS 
 
Pathology 
Exposure to Aspergillus occurs via inhalation of the ubiquitous conidia, which are small 
enough (diameter 3 to 5 µm) to reach the alveoli. The most important determinant of 
infection is the immune status of the patient, not the intensity of exposure [7]. In 
neutropenic patients, Aspergillus can invade the lung through the alveoli or the 
tracheobronchial tree. Invasion through the submucosa, into the cartilage, and into 
contiguous blood vessels is common. This invasive growth leads to hemorrhagic 
infarction and necrosis [8]. Neutrophils are seen in lesions of neutropenic patients 
whose bone marrow function has returned, as well as in tissues of less neutropenic 
patients. The pulmonary infiltrates may be single or multiple and tend to be enlarging, 
rounded infiltrates, often involving a large proportion of the lung.  Grossly, the 
involved lung has the appearance of an infarct, being dark red and very firm, often with 
concentric rings of haemorrhage and necrosis with poor demarcation at the advancing 
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front of the infarct.  Intra-pulmonary hematogenous dissemination, occurring in less 
than 10% of cases, produces myriads of small target lesions that are referred to as 
miliary micro-abscesses [9]. Extra-pulmonary hematogenous dissemination occurs in 
25-35% of patients with IPA, affecting especially the central nervous system, and less 
commonly liver, skin, kidneys, pleura, heart, and other sites [4,10].  
 
Host  immune response  
As stated above, the respiratory tract is the portal of entry in human IPA. It is 
postulated that innate immunity is the principal pathway by which Aspergillus is cleared 
from the lung. This innate response consists of alveolar macrophages, which represent 
the first line of defence against conidia entering the lung, and recruited neutrophils. 
Neutrophils are believed to kill conidia that have survived to form hyphae and cause 
invasive infection [11]. Various cells of  the monocytic lineage can engulf and kill 
Aspergillus conidia in vitro [12,13] and in vivo [14,15]. Both  macrophages [16] and 
neutrophils [11,17] have been shown to damage hyphae in vitro.  
Both cyto-and chemokines may play an important role in the pathogenesis of IPA. In 
murine studies on IA, production of Th1 and Th2 cytokines occurred differently in 
mice resisting or succumbing to the infection. Development of protective acquired 
immunity was associated with the activation of CD4+ Th1 cells producing IFNγ and 
macrophages producing IL12. In contrast, production of IL4 and IL10 by CD4+ Th2 
cells was associated with disease progression [18]. In addition, the production of the 
pro-inflammatory cytokine TNFα was associated with survival in several studies 
[19,20]. Chemokines also seem to play a role in IPA. Two in vivo studies have 
demonstrated that intra-tracheal inoculation of mice with Aspergillus fumigatus results in 
an increased production of the chemokines MCP-1, MIP-1α and MIP-2 by broncho-
alveolar lavage (BAL) cells or as measured in whole lung homogenates [21,22].   
 
 
DIAGNOSIS 
 
Clinical signs  
Clinical signs of IPA are often non-specific. Cough, usually unproductive, and fever are 
the most frequent presenting symptoms in neutropenic patients. Two other symptoms 
that are significant and that raise the possibility of IPA in the appropriate clinical setting 
are pleuritic chest pain (due to small pulmonary infarctions secondary to vascular 
invasion) and haemoptysis that is usually mild but could be massive. However, these 
symptoms are only present in a proportion of patients.  Other symptoms of IPA may 
be due to dissemination of the fungus to extra-pulmonary organs, leading to 
corresponding symptoms [4] . 
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Radiological signs 
The chest radiograph often shows non-specific changes. Rounded densities, pleural-
based infiltrates that are suggestive of pulmonary infarctions, and cavitation are only 
seen in a proportion of patients on the chest radiograph [23,24] . In contrast, CT 
scanning of the chest has had a major impact on the management of patients with IPA 
[25,26].  It is more sensitive and specific than chest radiography [25] and is particularly 
valuable when chest X ray is negative or shows only subtle changes. Typical chest CT 
scan findings in patients with IPA are multiple nodules, the “halo”- sign, which is an 
early radiological sign that appears as a zone of low attenuation due to haemorrhage 
surrounding the pulmonary nodule [27], and the “air crescent” sign, which is a crescent 
shaped lucency, formed after retraction of a central necrotic mass. In addition, 
cavitations also suggest an invasive fungal infection [28]. Whereas “halo”-signs are 
often seen in the early course of the disease, the “crescent” – sign and cavitation usually 
correlate with recovery from neutropenia and are relatively late findings [29]. These 
three radiological signs are relatively specific for IPA, but they are neither sensitive nor 
pathognomonic, since other fungal infections and also some non-fungal conditions may 
have a similar appearance [27,28].   
 
Histopathology and culture 
The only definite method to diagnose IPA is to demonstrate the presence of septate, 
acute, branching hyphae in a lung tissue sample in combination with a culture that is 
positive for Aspergillus from the same site. However, large biopsies are often precluded 
by trombocytopenia or by the critical condition of the patient, whereas the yield of 
transthoracic fine needle aspirates is often disappointing.  
With regard to fungal culture, studies have shown that sputum- and BAL-fluid samples 
that are positive for Aspergillus in patients with leukaemia or in those who have 
undergone BMT have a positive predictive value of 80 to 90% [30-32]. On the other 
hand, a respiratory sample that is negative for Aspergillus does not exclude the diagnosis 
of IPA, since negative cultures have been noted in up to 70% of patients with 
confirmed IPA [33].  Blood cultures rarely have positive results [34].  
 
 
MOLECULAR TESTS 
 
Antibody and antigen detection 
In theory, the detection of antibodies to Aspergillus sp. may be a useful aid in the 
diagnosis of IPA. However, in practice antibody tests are often negative because of the 
poor immune status of the patients. The detection of the Aspergillus cell wall component 
galactomannan (GM) has raised high hopes. Methods to demonstrate this antigen 
include a latex agglutination test (“Pastorex Aspergillus”, Sanofi Diagnostics Pasteur, 
Belgium) and a sandwich ELISA (“Platelia Aspergillus”, Bio-Rad, Naraes-La-Coquette, 
France). In comparative studies, the latter of these tests has shown to have the higher 
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sensitivity [35,36]. Several large prospective studies have shown promising results using 
the ELISA in serum for the diagnosis of IPA, with sensitivities of around 90% and 
specificities of 94-98% [37-39]. However, one large, recent study reported a much 
lower sensitivity (32%), with a specificity of 95% using the test in serum [40].  So, the 
value of the test for use in serum is not yet clear. 
GM detection can also be used in other clinical samples, such as BAL-fluid. The 
sensitivity of the test in BAL-fluid has been reported to be about 60-85% [41,42]. These 
studies suggest that the test will represent an important adjuvant in the diagnosis of 
IPA. Other antigen or metabolite detection tests are currently not clinically applicable 
[43]. A possible exemption in the future may be the detection of the fungal cell wall 
component β(1,3)-D-glucan, a test which has been studied especially in Japan as the G-
test [44]. 
 
Polymerase chain reaction 
PCR methods for the detection of Aspergillus DNA are currently being developed and 
evaluated. Positive results have been reported in urine, BAL fluid, serum and whole 
blood of patients suspected of having IPA [38,45,46]. Especially the use of the test in 
whole blood has shown promising results, with reported sensitivity and specificity of 
89% and 98% respectively [38]. Unfortunately, there is currently no well-standardised 
technique that can be routinely applied appropriately in most clinical laboratories. 
Problems with specificity are an important drawback to the widespread use of these 
very sensitive tests, since fungal spores are ubiquitous present in the environment, 
including PCR reactants [47].  
 
 
TREATMENT  
 
The mortality rate of IPA remains high despite recent advances in therapy. Antifungal 
treatment should be started as soon as there is clinical suspicion of IPA, since early 
therapy improves outcome [48]. However, the outcome of treatment not only depends 
on early diagnosis and start of treatment, but also on the absence of dissemination and 
the recovery of the underlying host defence defect, such as the resolution of 
neutropenia or the tapering of immunosuppressive therapy [49,50].  
Until recently, the most widely used drug for the treatment of IPA has been 
amphotericin B (AMB). It’s usual dose is 0.6 to 1.5 mg/kg. Even with optimal 
treatment, the response rate is still disappointing and varies between 33% and 54% in 
leukaemia and bone-marrow transplant patients [6].  
 
Lipid formulations of AMB 
AMB-desoxycholate (Fungizone) causes serious side effects such as nephrotoxicity, 
electrolyte disturbances, and infusion related reactions. Newer lipid-based preparations 
of AMB have been introduced in an effort to minimise the side effects of AMB. Lipid 
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formulations show a slightly reduced activity when compared with regular AMB, 
together with clinically significant reduction of toxicity, especially nephrotoxicity [51]. 
However, the daily acquisition prices of lipid formulations of AMB are much higher 
than that of AMB – desoxycholate.  At this moment there are three commercially 
developed lipid formulations, all with different confirmations and pharmacokinetics 
[52]. AMB- lipid complex (ABLC, Abelcet) consists of tightly packed ribbon-like 
structures of bilayered membranes containing AMB. AMB-colloidal dispersion (ABCD, 
Amphocil  / Amfotec) is composed of disk-like structures of cholesteryl sulphate 
complexed with AMB. Liposomal AMB (L-AMB, AmBisome), the only true 
liposomal product, consists of small uniformly sized unilamellar vesicles with a 
diameter of 80 nm.  
Of these three lipid compounds L-AMB seems to be the most promising since it is the 
only lipid compound of that has shown to have clinical response rates superior to that 
of AMB [53]. To date, the optimal dose of L-AMB in the treatment of IPA is still 
unclear. Clinical evidence indicates that AMB (both AMB deoxycholate and lipid 
formulations) may produce a dose response in IPA cases [54,55]. This concept was 
challenged in a randomised trial which compared L-AMB given at 1 mg/kg/day with L-
AMB given at 4 mg/kg/day; this study found no difference in the overall response rate 
[56]. However, in the subset of patients with documented IPA, the response rate was 
37% and 58% in the 1 and 4 mg/kg/day groups, respectively. Therefore, the optimal 
dosing regime of L-AMB remains an interesting subject of investigation. 
 
 
Other antifungals 
 
Azoles 
Currently, the most important azoles that are used for the treatment of IPA are 
itraconazole and voriconazole. Itraconazole’s fungicidal activity is not as efficient as 
that of AMB, because inhibition of sterol synthesis takes longer than directly creating 
channels in the cell membrane [57]. To overcome problems with variable absorption, 
itraconazole has now been solubilised in cyclodextrin, with substantial improvement as 
an oral solution [58,59].  Also, a new i.v. formulation was recently approved by the US 
FDA for the treatment of IPA in patients who are intolerant or have infections 
refractory to AMB.  
Voriconazole is a new second-generation triazole synthetic derivative of fluconazole. 
Both fungicidal and fungistatic activity against Aspergillus have been demonstrated [60]. 
Voriconazole shows +/- 90% bioavailability, and has good CSF penetration [61]. The 
main side effects of voriconazole include reversible visual disturbances in as many as 
33% of treated patients, occasional elevated hepatic transaminases and occasional skin 
reactions likely due to photosensitization [60,62].   
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The newest antifungal agents in the azole group include posaconazole and 
ravuconazole. The clinical value of these agents in the treatment of IPA is still in an 
early stage of investigation. 
  
Echinocandins 
Caspofungin is a water-soluble semisynthetic derivative of the natural product 
pneumocandin B [63]. The drug blocks the synthesis of β(1,3)-D-glucan, which is an 
essential component of the cell wall of numerous fungal species. It has linear 
pharmacokinetics, is hepatically excreted, and has few side effects. Parenteral 
administration must be used because of the low bioavailability when administered orally 
[64]. Fungal growth is required for killing to occur, and the rate of killing is significantly 
longer than for AMB [65]. Several animal models show equivalent efficacy of 
caspofungin and AMB for treatment of IA [66]. Caspofungin was approved by the US 
FDA in February 2001 and is indicated for patients with refractory aspergillosis or 
intolerance to other therapies.  
The newest echinocandins are micafungin and anidulafungin, which are still in primary 
stages of investigation [67]. 
 
 
ANIMAL MODEL OF IPA 
 
Clinical studies on the diagnosis and treatment of IPA are difficult and time- and 
money consuming. First, large numbers of high-risk patients in a study are needed to 
obtain sufficient power, because only a minority of these high-risk patients develops the 
disease. Second, it is hard to identify patients with proven IPA, because diagnosis is 
difficult and proven cases are rare. Finally, the appearance of the disease may be 
different in different types of patients. Consequently, animal models of IPA may be 
helpful in the investigations to improve diagnosis and management of this disease. 
A number of animal models of IA have been described. A considerable proportion of 
these models are mice models of systemic IA, in which Aspergillus conidia are 
administered by the intavenous route [68]. However, one could argue that the natural 
route of infection in patients is through the respiratory tract, and these models may 
therefore lack clinical correlates. Also, in many models immunosuppression is achieved 
by corticoids. This may make extrapolation of data to neutropenic patients 
questionable, especially in studies on pathogenesis. Only a few animal models combine 
neutropenia by chemotherapy with inoculation through the respiratory route [69-72]. In 
our laboratory, an animal model was developed in rats by Leenders et al., which also 
combines these features [73,74]. The model was based on the rat model of Klebsiella 
pneumoniae pneumonia, described by Bakker-Woudenberg et al. [75].  Granulocytopenia 
in the model of IPA was induced by repeated injections of  90 mg/kg 
cyclophosphamide intraperitoneally (i.p.) at 5 days before and 60 mg/kg at 1 day before 
and 3, 7 and 11 days after fungal inoculation. This resulted in a persistent neutropenia 
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(granulocytes < 0.1 x 109 / L).. At day 0, animals were inoculated with 104 conidia A. 
fumigatus in the left lung. This resulted in a left-sided IPA with 100% mortality around 
day 9 after fungal inoculation. Fungal dissemination to the contra-lateral right lung and 
other organs occurred from around day 5 after fungal inoculation. Treatment in the 
model with a standard dose of 1 mg/kg AMB daily (started at 40 h after fungal 
inoculation) resulted in 10-20% survival at day 11 after inoculation. This animal model 
closely mimics the clinical situation in humans in various aspects. First, in humans 
pulmonary aspergillosis is often initially detected in one of both lungs and then 
progresses to the contra-lateral lung. Second, the chemotherapy-induced 
granulocytopenia of < 0.1 x 109/L is very similar to the situation in the most important 
patient group at risk for IPA, i.e. haematological patients receiving chemotherapy. 
Third, standard treatment with AMB in the model still results in relatively high 
mortality, which is comparable to the situation in persistently neutropenic patients with 
IPA. Finally, treatment in the model is started when hyphal growth of the fungus is 
present, and the infection is already established. 
In experiments preceding the work described in the following chapters, the animal 
model was slightly modified for further optimising. The first dose of cyclophosphamide 
at 5 days before fungal inoculation was lowered to 75 mg/kg. Further, antifungal 
treatment was started earlier, at 16 h after fungal inoculation (fungal growth was present 
at this time point). These changes resulted in 100% mortality of untreated rats around 
day 11 after inoculation and around 50 % mortality of AMB-treated rats at day 11. This 
modified model allowed us to better compare other treatment regimes, either superior 
or inferior, to standard treatment with AMB. 
 
 
OUTLINE OF THE THESIS 
 
To improve outcome in patients with IPA, more insight into the pathophysiology, 
diagnosis, treatment and monitoring of IPA is warranted. In this thesis, we address 
these issues using both the animal model and patients. 
 
The aim of this thesis is to answer the following questions: 
• What are the changes in general physiology and lung mechanics caused by the 
disease, and what causes death in the rat model? 
• What parameters of fungal infection are most useful to describe the course of the 
disease and to monitor antifungal treatment? 
• What is the function of the immune system, especially cytokines, in IPA and what 
is the effect of antifungal treatment on the expression of cytokines? 
• What is the value of PCR, galactomannan detection and scintigraphic imaging for 
an early diagnosis of IPA? 
• How can efficacy of antifungal treatment be optimised by using AMB and lipid 
formulations of AMB? 
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In Chapter 2, clinical symptoms and general and pulmonary pathophysiology of the 
disease are investigated in the rat model. Chapter 3 describes the kinetics of several 
parameters of fungal infection and cytokines in the model, and the effect of antifungal 
treatment on these parameters. In Chapter 4, the value of PCR and galactomannan 
detection for the diagnosis of IPA are compared in the animal model. Chapter 5 is a 
clinical study, investigating the value of galactomannan for diagnosing IPA in 
neutropenic patients. In Chapter 6, several scintigraphic techniques are compared for 
detecting IPA in the rat model, whereas the most useful of these techniques is further 
evaluated in the model in Chapter 7. In Chapter 8, treatment regimes using L-AMB, 
monotherapy or in combination with AMB, are compared for their efficacy in treating 
IPA in the rat model.   
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ABSTRACT 
 
Question of the study: Because little is known about the pathophysiology of invasive 
pulmonary aspergillosis (IPA), we examined changes in general physiology and lung 
mechanics during this disease in an animal model. 
Materials and methods: In a model of fatal left-sided IPA, 19 persistently neutropenic 
rats were monitored for clinical signs including body temperature, body weight and 
respiratory distress. A separate group of 9 rats with IPA was used for measurements of 
arterial blood pressure, arterial O2 and CO2 pressure, lung compliance and surfactant 
function.  
Results: Body temperature and body weight decreased, whereas respiratory distress 
increased during progression of the disease. Compared to uninfected controls, in rats 
with IPA arterial blood pressure and lung compliance were significantly lower, and left 
lung minimal surface tension was significantly higher.  Right lung surfactant function 
was not affected. Arterial O2 and CO2 pressures were not different between rats with 
IPA and uninfected controls.  
Answer to the question: Infection with A. fumigatus in neutropenic rats resulted in 
hypothermia, body weight loss and respiratory distress. Loss of left lung function was 
probably compensated by the uninfected right lung, even in a late stage of the disease.  
Circulatory failure was a major feature in the terminal phase of the infection. 
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INTRODUCTION 
 
An increase in the number of immunocompromised hosts in the last decades has led to 
an increase in the number of severe fungal infections such as invasive pulmonary 
aspergillosis (IPA) [1]. The most common and best-characterised risk factor for IPA is 
neutropenia. The mortality rate of IPA in neutropenic patients remains high and 
exceeds 50% despite antifungal treatment [2]. Therefore, there is a need to expand our 
understanding of pathogenesis and pathophysiology of IPA during neutropenia in order 
to develop better strategies of intervention. 
Histopathologically, IPA is a narcotising pneumonitis characterised by hyphal 
proliferation in the pulmonary parenchyma and invasion of pulmonary bronchi and 
blood vessels, resulting in thrombosis and hemorrhagic infarction. Haematogenous 
extrapulmonary dissemination occurs especially to the brain, liver and kidneys [3].  
However, little is known about the way in which this fungal disease influences 
pulmonary function and general physiology. Studies in patients with IPA are hampered 
by difficulties in identifying patients with proven IPA and by the impact of co-
morbidity in these patients.  Animal models of IPA do not have these ancillary 
problems and may therefore be helpful in studying the pathophysiology of this disease.  
In our laboratory, we have developed a model of unilateral IPA in rats that closely 
mimics human disease.  The model is characterised by prolonged severe 
granulocytopenia, inoculation through the respiratory route, fungal broncho- and angio-
invasion and dissemination of the fungus from the lung to other organs [4-7]. In this 
model we examined the changes in general physiology and lung mechanics caused by 
the disease.  
 
 
MATERIALS AND METHODS 
 
The experimental protocols adhered to the rules laid down in The Dutch Animal 
Experimentation Act (1977) and the published Guidelines on the Protection of 
Experimental Animals by the Council of the EC (1986). The present protocols were 
approved by the Institutional Animal Care and Use Committee of the Erasmus Medical 
Center Rotterdam. 
 
Infection model of IPA 
Our animal model, first described by Leenders et al. [4], was used with a few 
modifications. Specified pathogen- free female RP strain albino rats (18-25 weeks old, 
185-225 g) were employed. Profound granulocytopenia was induced by intraperitoneal 
(i.p.) administration of 75 mg/kg cyclophosphamide (Sigma-Aldrich Chemie, 
Steinheim, Germany) 5 days before fungal inoculation, followed by repeated doses of 
60 mg/kg 1 day before and 3 and 7 days after inoculation. This protocol resulted in 
granulocyte counts of less than 0.1×109 / L on the day of fungal inoculation and 
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thereafter. To prevent bacterial superinfections, animals were given daily doses of 40 
mg/kg amoxicillin intramuscularly (i.m.) starting 1 day before inoculation and a 6 
mg/kg dose of gentamicin i.m. on the day of inoculation. In addition, rats received 
ciprofloxacin (660 mg/L) and polymyxin B (100 mg/L) in their drinking water 
throughout the experiment. The rats were anaesthetised with fentanyl citrate 
(Hypnorm, Janssen, Belgium), 0.0315 mg / rat i.m. together with sodium pentobarbital 
(Nembutal, Sanofi Sante, the Netherlands), 4.5 mg / rat i.p. The left main bronchus 
was intubated. A cannula was passed through the tube and the left lung was inoculated 
with 6×104 Aspergillus fumigatus conidia in 0.02 ml phosphate buffered saline (PBS, pH 
7.4). This resulted in a left-sided IPA. A clinical isolate of A. fumigatus was used that was 
originally isolated from an immunocompromised patient with IPA.  Survival of rats was 
monitored twice daily. 
The experimental protocols used in this study adhered to the rules laid down in The 
Dutch Animal Experimentation Act (1977) and the published Guidelines on the 
Protection of Experimental Animals by the Council of the EC (1986). The present 
protocols were approved by the Institutional Animal Care and Use Committee of the 
Erasmus Medical Center Rotterdam. 
 
Clinical parameters 
Clinical parameters were measured as described before [8].  
Body temperature was measured using the ELAMS® - system (Electronic Laboratory 
Animal Monitoring System, BioMedic Data Systems, Inc. Seaford DE, USA). This 
system consisted of a portable data acquisition system connected to a detectable 
scanner wand (DAS-5002), and implantable programmable temperature transponders 
(IPTT-100).    
Body weight was measured daily throughout the experiment. 
Respiratory distress was scaled into three categories. Normal breathing was defined as a 
normal respiratory rate (85-110 / min) and no visible respiratory distress. Moderate 
respiratory distress was seen as impaired ability to expand the thorax without reduction 
of respiratory frequency. Severe respiratory distress was seen as a strongly impaired 
ability to expand the thorax ("gasping") with reduced respiratory frequency (30-
75/min).  
Wheezing was defined as an audible breathing sound, mostly a squeaking sound. This 
parameter was scored as either present or absent. 
 
Macroscopic pulmonary lesion size 
In order to measure the size of the haemorrhagic lesion of the affected lung, 
photographs were taken immediately after dissection. The photograph was taken from 
the ventral position of the lung. The morphologic extension of the lesion was measured 
on the photographs and expressed as a percentage of the total lung surface. 
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Measurements of blood pressure and pulmonary function 
At day 7 after fungal inoculation, rats were anaesthetised with 0.0315 mg fentanyl 
citrate, 1 mg fluanisone and 22.2 mg/kg natrium pentobarbital  A catheter was inserted 
into the left carotid artery and after tracheotomy, a tube was inserted into the trachea.  
Subsequently, rats were allowed to breathe freely until a regular breathing pattern was 
established. Mean arterial blood pressure was measured using a Statham P23XL 
transducer (Spectramed, Oxford, CA, USA) and recorded (Siemens Sirecast 404-1, 
Danvers, MA, USA). In blood samples obtained from the carotid artery, blood O2 
tensions were measured using an ABL 505 Radiometer (Copenhagen, Denmark).   
After the animals were killed, lung weight was determined and a static pressure-volume 
curve for both lungs was recorded using conventional techniques [9]. Maximal 
compliance (Cmax) was defined as the steepest part of the pressure-volume curve [10].  
Broncho- alveolar lavage (BAL) was performed by separate lavage of the infected left 
and uninfected right lung with 5 ml saline-CaCl2 1.5 mmol /L. Lavage fluid was 
subsequently centrifuged to remove cells and cellular debris. 
 
Minimal surface tension measurements 
Minimal surface tensions of BAL samples containing surfactant were measured using a 
modified Wilhelmy balance (E. Biegler GmbH, Mauerbach, Austria) which keeps the 
temperature constant at 37 °C [11]. The trough was filled with warm saline (37 °C) and 
calibrated. After calibration, 500 µL of the lavage sample was placed on the surface. 
Minimal surface tension was measured after 3 cycles at 20% surface area, and expressed 
as milli Newton/meter (mN/m).  
 
 
RESULTS 
 
Survival and clinical signs 
One group of persistently neutropenic rats with unilateral IPA (n=19), one control 
group of neutropenic rats without infection (n=5) and one control group of naive rats 
(n=5) were used to monitor survival and clinical signs. Infection with A. fumigatus 
resulted in 42 % mortality at day 7 after fungal inoculation and 100% at day 11 (Figure 
1). Neutropenic, uninfected rats and naive rats all survived.  
The average body temperature of the rats on day 0 was 36.9 °C. In neutropenic rats 
with IPA, a decrease in body temperature was observed during the course of the 
disease, with average temperatures declining to 30.1 °C on day 9 after inoculation 
(Figure 2). All rats in which body temperature dropped below 34 °C died within 24 h 
after that measurement.  Body temperature in neutropenic, uninfected rats and naive 
rats remained around 37 °C throughout the experiment.  
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Figure 2. Body temperature of neutropenic rats with IPA (n = 19), neutropenic 
uninfected rats (n = 5) and naive rats (n = 5). 
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Figure 1. Survival of neutropenic rats with IPA (n = 19), neutropenic uninfected rats (n = 5) 
and naive rats (n = 5). 
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The average body weight of naive rats remained about constant over time (Figure 3). 
The initial body weight of neutropenic, uninfected rats was slightly lower than that of 
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Figure 3. Body weight of neutropenic rats with IPA (n = 19), neutropenic uninfected 
rats (n = 5) and naive rats (n = 5). 
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Figure 4. Respiratory distress in neutropenic rats with IPA (n = 19). 
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naive rats at day 0, but no decrease in body weight was seen thereafter. In contrast, in 
neutropenic rats with IPA, a strong decrease in body weight occurred, up to 21% of the 
initial body weight at day 10 after fungal inoculation.  
In naive and neutropenic, uninfected rats, the respiratory rate was around 100/min 
throughout the experiment (data not shown). Starting in a proportion of rats at day 4 
after fungal inoculation, animals showed moderate or severe respiratory distress. The 
proportion of rats with respiratory distress increased with progression of the disease 
(Figure 4). Severe respiratory distress had a high positive predicting value (80%) for 
death within 24 h. However, 4 rats (21%) died without signs of respiratory distress at 
any time during the disease process. Wheezing was observed in a minority of rats 
(Figure 5). The predictive value of wheezing for death within 24 h was 100%. 
 
Pulmonary function and blood pressure 
One group of neutropenic rats with IPA (n=9), one control group of neutropenic rats 
without infection (n=7) and one control group of naive rats (n=5) were used to 
measure pulmonary function and blood pressure. Measurements were performed at day 
7 after inoculation (Table 1).  At this time point, body temperature was significantly 
lower in neutropenic rats with IPA compared to both control groups (P < 0.02 for 
both comparisons). All neutropenic rats with IPA showed signs of moderate or severe 
respiratory distress at day 7 (Figure 4). Despite this respiratory distress, the arterial O2 
pressure was not decreased in the infected rats.  In addition, the arterial CO2 pressure 
showed no difference between the three groups.    
0
5
10
15
20
0 3 4 5 6 7 8 9 10 11
Day after fungal inoculation
N
um
be
r o
f r
at
s
no wheezing
wheezing
 
Figure 5. Wheezing in neutropenic rats with IPA (n = 19).
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Systolic, diastolic and mean arterial pressures were much lower in neutropenic rats with 
IPA compared to the control groups (P < 0.003 for both comparisons). On average, 
the size of the macroscopic pulmonary lesion of the left lung in neutropenic rats with 
IPA was 67% of the total lung surface. Neutropenic, uninfected rats and naive rats had 
no pulmonary lesions.  Lung compliance, measured over left and right lungs 
simultaneously, was significant lower in neutropenic rats with IPA (P<0.001 for both 
comparisons).  The minimal surface tension of BAL- fluid samples from the infected 
left lungs of neutropenic rats with IPA was higher than that of uninfected neutropenic 
rats (P=0.01). The weight of the infected left lung in neutropenic rats with IPA was 
increased compared to both control groups (P<0.002 for both comparisons).  In 
contrast, the weight of the uninfected right lung was similar over the three groups. 
 
Table 1. Pulmonary functions and blood pressure in neutropenic rats with IPA at day 7 after 
inoculation, neutropenic uninfected rats and naive rats  
 
 
Neutropenic 
rats with IPA 
Neutropenic 
uninfected 
rats 
Naive rats 
No of rats 9 7 5 
Systolic arterial blood pressure (mm Hg) 71.2 ± 5.3* 105.4 ± 3.1 125.8 ± 7.1 
Diastolic arterial blood pressure (mm Hg) 57.0 ±  5.3* 87.0 ± 1.9 104.4 ± 5.9 
Mean arterial blood pressure (mm Hg) 62.6 ± 5.6* 117.0 ± 2.3 125.8 ± 7.1 
PaO2 (mm Hg) 96.3 ± 9.6 87.5 ± 7.7 91.5 ± 6.2 
PaCO2 (mm Hg) 49.2 ± 5.1 51.2 ± 5.2 50.7 ± 4.9 
Weight infected left lung (g) 1.40 ± 0.14* 0.68 ± 0.06 0.70 ± 0.05 
Weight uninfected right lung (g) 1.28 ± 0.09 1.26 ± 0.12 1.14 ± 0.08 
Macroscopic pulmonary lesion size (%) 67 ± 9 0 ± 0 0 ± 0 
Cmax (ml / cm H2O * kg) 3.57 ± 0.23* 6.67 ± 0.2 6.39 ± 0.24 
Minimal surface tension (mN / m) 
infected left lung  
 
30.9 ± 2.0 
 
19.7 ± 2.7 
 
n.d 
Minimal surface tension (mN / m) 
uninfected right lung 
 
18.1 ± 1.4 
 
18.7 ± 2.9 
 
n.d. 
Data are presented as mean ± SEM 
* significant difference (P< 0.05) compared to neutropenic, uninfected rats and compared to naive rats 
 significant difference (P < 0.05) compared to neutropenic, uninfected rats 
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DISCUSSION 
 
Few data are available on the pathophysiology of IPA in humans or animals with 
neutropenia. The present study describes the general and pulmonary pathophysiology 
of IPA in an experimental rat model of unilateral IPA. In earlier studies in this model, it 
was found that infection with A. fumigatus resulted in fungal tissue-, broncho- and angio 
-invasion causing increasing hemorrhagic infarcts and tissue necrosis over time [5,7].   
In the current study a 100% mortality of neutropenic rats with IPA was seen. This is 
comparable to neutropenic patients with IPA, in which mortality approaches 100% 
when the disease is left untreated [2].   
In contrast to fever, which is seen in patients with IPA, a decrease in body temperature 
was observed in the rats. This hypothermia is a phenomenon that is seen in several 
other infection models in small experimental animals, including models of fungal 
infection [12-14]. Because of the high body surface-body mass ratio of small animals, a 
relatively high heat production is necessary to maintain a high and steady temperature, 
and therefore much energy would be needed for the sustenance of fever. The 
multiplication and pathogenicity of many infectious agents is also suppressed at low and 
not only at high temperature. Therefore, it has been suggested that in small animals 
cryexia may be an alternative to fever for coping with infections [15].   
Neutropenic rats with IPA experienced a significant loss of body weight during the 
course of the disease. This weight reduction was at least partially caused by a reduction 
in food and water intake (unpublished data). In addition, an enhanced catabolic state 
may have resulted in weight loss, as seen in other rat infection models [16-19]. 
In the terminal phase of the disease, at day 7 after fungal inoculation, we investigated 
the lung function, blood pressure and lung pathology in our rat model. Inoculation of 
A. fumigatus into the left lung resulted in pulmonary hemorrhagic lesions that comprised 
more than 50% of the lung in most animals. This had a dramatic effect on lung 
mechanics as demonstrated by a decrease in lung compliance. Surfactant function was 
impaired in the infected left lung, demonstrated by a significant increase in minimal 
surface tension in BAL-fluid, resulting in loss of alveolar stability and finally atelectasis 
formation.  The impaired surfactant function may be caused by a direct influence of A. 
fumigatus hyphae on surfactant, since the fungus is able to bind surfactant proteins in 
vitro  [20]. However, the accumulation of plasma proteins in the alveoli, dose 
dependently impairs the endogenous surfactant system [9].  In the left lung of the rats 
in our study a large pulmonary hemorrhagic lesion of more than 50% was present, 
strongly suggesting accumulation of these plasma proteins. 
There have been conflicting reports on contralateral lung damage by unilateral 
pulmonary infection by induction of cytokines and/or neutrophil influx. 
Dehoux et al. demonstrated that compartmentalisation is preserved during unilateral 
pneumonia [21], whereas others found that unilateral pulmonary infections could cause 
contralateral lung damage by induction of cytokines and neutrophil influx [22]. 
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In our model, lung damage was limited to the infected lung demonstrated by both the 
normal minimal surface tension and lung weight in the uninfected right lung which 
were not increased in neutropenic rats with IPA compared to that in lungs of 
neutropenic, uninfected rats and naive rats. This suggests that the right lung was not 
affected during the disease in neutropenic rats with IPA. 
The deteriorated lung mechanics and surfactant impairment in the infected lungs of rats 
with IPA probably caused the change in respiratory rate that was observed in most rats. 
In patients with IPA respiratory distress can occur, especially in patients that succumb 
to the infection [23]. However, the arterial oxygen pressure in our model was not 
decreased in neutropenic infected rats in the terminal phase of the disease compared to 
neutropenic, uninfected rats and naive rats. This suggests that the uninfected right lung 
in neutropenic, infected rats with IPA compensates the loss of function of the left lung, 
at least until a late stage in the disease. This is probably accomplished by hypoxic 
pulmonary vasoconstriction resulting in no-shunt flow through the diseased left lung 
and only flow through the aerated right lung tissue, thus preserving oxygenation [24]. In 
all animals arterial CO2 was slightly increased caused by the respiratory depression due 
to anaesthesia. 
Bacterial pathogens can cause septic shock in man, which is a distributive shock with 
moderate-to- high cardiac output in the presence of a low systemic vascular resistance 
[25]. The cytokine TNF-α is thought to play an important role in the circulatory 
dysfunction, increased microvascular permeability and metabolic derangements [26,27]. 
Few data exist on circulatory dysfunction and the development of shock in patients 
with IPA. However, some case reports mention the development of circulatory failure 
in these patients [28,29]. The neutropenic rats with IPA in our model developed a 
circulatory failure, as demonstrated by a marked decrease in arterial blood pressure on 
day 7 after fungal inoculation. The mechanism of development of circulatory failure in 
fungal infections may be different from bacterial infections. Shock in rats with 
candidemia was found to be TNF-α independent [12], and earlier investigations in our 
rat model of IPA did not reveal increases of TNF-α in lung or serum [30].  Thus, 
circulatory failure in IPA may be induced by circulating fungal virulence factors or host 
mediators other than TNF-α. Future studies should further explore the role of 
circulatory failure in IPA. 
In conclusion, unilateral pulmonary infection with A. fumigatus in neutropenic rats 
resulted in hypothermia, loss of body weight and respiratory distress. Infection caused 
changed lung mechanics and surfactant dysfunction of the infected lung but loss of the 
left lung function was probably compensated by the uninfected right lung, even in a late 
stage of the disease.  Animals probably died from circulatory failure and not from direct 
pulmonary complications, although severe unilateral lung pathology was present.    
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ABSTRACT 
 
Objective: To acquire insight into the pathogenesis of invasive pulmonary aspergillosis 
(IPA) during antifungal treatment with amphotericin B, kinetics of various parameters 
of fungal load and cytokines were investigated.  
Methods: Neutropenic rats with left-sided IPA received either treatment with 
amphotericin B or remained untreated.  At 0, 4, 8, 16, 24, 48, 72 and 120 h after fungal 
inoculation rats were dissected. Size of macroscopic pulmonary lesions, numbers of cfu 
and chitin amounts were determined in the infected left lung. Galactomannan 
concentrations were measured both in the left lung and serum. The cytokines tumor 
necrosis factor (TNF)-α, interleukin (IL) 1-β, IL-6, interferon (IFN)-γ, IL-4 and IL-10 
and the chemokines macrophage inflammatory protein (MIP)-2 and monocyte 
chemoattractant protein (MCP)-1 were quantitatively determined by ELISA in the 
infected left lung, uninfected right lung and serum.  
Results: Amphotericin B treatment of IPA resulted in changed aspect of pulmonary 
lesions and significantly reduced  levels of left lung chitin (72 and 120 h), left lung 
galactomannan (72 and 120 h) and serum galactomannan (120 h), but not left lung cfu, 
compared with untreated, infected rats. In addition, amphotericin B treatment resulted 
in a significant decrease in levels of left lung IL-6 (72 and 120 h), MIP-2 (120 h) and 
MCP-1 (120 h). No local or systemic increases of TNF-α, IL1-β or IFN-γ were  
observed during infection.  
Conclusion: It is concluded that treatment with amphotericin B results in decreased 
fungal load in the infected lung. Probably, this reduction in fungal load results in a 
decreased local inflammatory response as measured by decreased levels of IL-6, MIP-2 
and MCP-1 in the infected lung. 
                                   
 
 
 
                                    %JCRVGT                                                 Effect of amphotericin B on fungal load and cytokines  
 
 
 39 
INTRODUCTION 
 
Aspergillus fumigatus is a ubiquitous fungus that can cause invasive pulmonary 
aspergillosis (IPA) in immunocompromised patients. Evidence suggests a recent 
increase in this disease, which has been attributed to increased use of potent 
immunosuppressive agents as part of therapy for organ transplantation and cancer 
chemotherapy in patients [1,2].  The commonest and best-characterized risk factor for 
IPA is persistent neutropenia [3]. In neutropenic patients with IPA, treatment with 
amphotericin B remains the regimen of first choice. However, this treatment often fails, 
with reported response rates below 55% in leukaemia- and bone marrow 
transplantation patientsc [4].  Greater insight into the pathogenesis of IPA during 
antifungal treatment may help develop more effective treatment regimens in the future. 
In the pathogenesis of IPA, both fungal and host factors play a role. In several animal 
models of IPA, tissue-invasive growth of the fungus was seen with an increase of 
fungal load over time [5-7]. Antifungal treatment resulted in a reduction in fungal load 
and tissue damage [8-10]. With respect to host response, cytokines seem to play an 
important role. Studies showed that resistance to systemic invasive aspergillosis was 
associated with increased systemic production of Th1 cytokines such as interferon 
(IFN)-γ. In contrast, production of interleukin (IL)-4 and IL-10 by interstitial CD4+ 
Th2 cell was associated with disease progression [11-14]. In addition, local levels of the 
pro-inflammatory cytokines tumor necrosis factor (TNF)-α, IL-1-β and IL-6 were 
elevated in animal models of IPA, and neutralization of TNF-α resulted in increased 
mortality [15,16]. Finally, both the local levels of the C-X-C chemokine macrophage 
inflammatory protein (MIP)-2 and the C-C chemokine monocyte chemoattractant 
protein (MCP)-1 were elevated in animal models of IPA, and neutralization of these 
chemokines or their receptors resulted in decreased fungal clearance [17,18]. Few data 
exist regarding the impact of antifungal treatment on patterns of cytokine release. 
In our laboratory, we have developed an inhalation model of unilateral IPA in 
persistently neutropenic rats [19].  In this model, we investigated the effect of treatment 
with amphotericin B on the kinetics of cytokines and parameters of fungal load in rats 
with IPA. 
  
 
MATERIALS AND METHODS 
 
Infection model of IPA 
The rat model of IPA was used as described before [20,21]. In brief, specified pathogen 
free female RP strain albino rats (18-25 weeks old, 185-225 g) were employed. 
Persistent neutropenia was induced by intraperitoneal (i.p.) administration of 75 mg/kg 
cyclophosphamide (Sigma-Aldrich Chemie, Steinheim, Germany) 5 days before fungal 
inoculation, followed by repeated doses of 60 mg/kg 1 day before and 3 and 7 days 
after fungal inoculation. This protocol resulted in granulocyte counts of less than 
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0.1×109 / L on the day of fungal inoculation. To prevent bacterial superinfections, 
animals were given daily doses of 40 mg/kg amoxicillin intramuscularly (i.m.) starting 1 
day before inoculation and a 6 mg/kg dose of gentamycin i.m. on the day of 
inoculation. In addition, rats received ciprofloxacin (660 mg/L) and polymyxin B (100 
mg/L) in their drinking water throughout the experiment. Rats were inoculated with a 
clinical isolate of A. fumigatus originally isolated from an immunocompromised patient 
with IPA. Infection was established by intubation of the left main bronchus under 
general anaesthesia. A cannula was passed through the tube and the left lung was 
inoculated with 6×104 A. fumigatus conidia suspended in 20 µL of phosphate buffered 
saline (PBS).  
The experimental protocols adhered to the rules laid down in The Dutch Animal 
Experimentation Act (1977) and the published Guidelines on the Protection of 
Experimental Animals by the Council of the EC (1986). The present protocols were 
approved by the Institutional Animal Care and Use Committee of the Erasmus Medical 
Center Rotterdam. 
 
Antifungal treatment 
Amphotericin B (Fungizone) was obtained from Bristol-Meyers BV (Woerden, The 
Netherlands), and was diluted in 5% dextrose. Fungizone was administered 
intravenously via the lateral tail vein in a dose of 1 mg/kg/day. Treatment was started 
at 16 h after fungal inoculation, a time point at which hyphal growth was established. 
Treatment was continued for 10 days.  
 
Survival rate 
A separate experiment was performed to observe death rate in amphotericin B – 
treated, infected rats and untreated, infected rats (n = 25 to 28 rats per group). The 
survival rate was monitored twice daily until day 11 after fungal inoculation. 
 
Parameters of fungal load and cytokines  
 
Parameters of fungal load were compared in amphotericin B - treated, infected rats and 
untreated, infected rats. Cytokines were determined in these groups, and also in 
uninfected rats. At designated time points (n = 5 to 6 rats per group per time point), 
rats were anaesthetized with 50 mg/ kg pentobarbital (Ceva Sante Animale, Maassluis, 
The Netherlands) i.p. The chest cavity was opened aseptically and the right ventricle 
was punctured to obtain blood. Subsequently, through the same needle the lungs were 
perfused with 5 mL phosphate buffered saline (PBS).  The infected left lung and 
uninfected right lung were removed, kept on ice and homogenized separately in 10 mL 
PBS with 1 x complete protease inhibitor (Roche Diagnostics, Mannheim, Germany) 
using a tissue homogenizer (The Virtis Co. Inc., Gardiner, NY, USA).  The 
homogenates were centrifuged (10 min 4000 x g, 4 º C) and supernatants were passed 
through a 0.45 µm pore size filter (Schleicher and Schuell, Dassel, Germany) and stored 
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at – 20 ºC for cytokine and galactomannan assays. The pellet was resuspended in 10 mL 
PBS and used for cfu and chitin assay.  
 
Pulmonary macroscopic lesion and histopathology 
Separate groups of rats were used for macroscopic observation and histopathology. 
The left and right lung were fixed with formalin and embedded in paraffin. Every lung 
was cut at 3 levels ± 1 mm apart. At every level 2 adjacent sections were obtained, of 
which one was stained with haematoxylin - eosin (H&E) and the other with Grocott’s 
methenamine silver [22]. 
Pulmonary macroscopic lesions were classified and measured as described before [23]. 
In brief, angio-invasive lesions, seen as macroscopic dark-red lesions, were histologicaly 
characterized by extensive hyphal broncho- and angio-invasion and haemorrhagic 
infarction. Responsive lesions, seen as macroscopic light-red coloured lesions were 
histologicaly characterized by the presence of relatively short hyphae and little angio- 
and bronchio-invasion with resulting less haemorrhagic infarction [23]. The pulmonary 
lesion size was measured from photographs of the anterior of the lungs taken 
immediately after dissection. The size of the two types of pulmonary lesions was 
expressed as percentage of the total left lung surface. 
 
Fungal cultures of organs 
Cfu in lungs were counted in 1:10 and 1:100 dilutions of left lung homogenate and 1:10 
dilutions of right lung homogenate. Dilutions of homogenates were spread onto 
Sabouraud agar plates. After incubation at 37 °C for 36 h the cfu were counted. The 
remaining homogenate was used for chitin assay and galactomannan assay.  

Chitin assay 
The chitin assay was performed as described by Lehmann et al. [24]. In brief, the lung 
homogenate was centrifuged (1800 x g, 15 min.), resuspended in 4 mL of 3% sodium 
lauryl sulfate (SDS, Sigma chemical co., St Louis, USA) and heated at 100 °C for 15 
min. After cooling, the pellet was washed once with distilled water, resuspended in 3 
mL of 120% KOH solution and heated to 130 °C for 1h. Subsequently, 8 mL of ice-
cold 75% ethanol was added, tubes were kept at 4 °C for 15 min and 0.3 mL of Celite 
suspension (Celite 545; Sigma) was added. After centrifugation (1800 x g, 5 min, 4 °C), 
the pellet was washed with cold ethanol (40%) and cold distilled water successively and 
suspended in 0.5 mL of NaNO2 (5%) and 0.5 mL of KHSO4 (95%). After 
centrifugation (1800 x g, 15 min), volumes of the supernatant were mixed with 12.5% 
NH4SO3NH2 followed by MBTH (3-methyl-benzo-2-thiazolone hydrazone HCl 
monohydrate; Sigma). After heating for 3 min, the supernatants were cooled, FeCl3 
6H2O (0.83%) was added and were allowed to stand for 30 min. The optical density at 
650 nm was read in a spectrophotometer. The chitin content was expressed as 
micrograms of glucosamine per left lung. Final measurements of chitin were corrected 
for the loss of volume of homogenate. 
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Galactomannan assay 
Concentrations of galactomannan in organs and serum were measured as described 
before [20,23]. Briefly, 300 µL of each sample of supernatant of left- or right lung-
homogenate or serum was used in a sandwich ELISA (Platelia Aspergillus, Sanofi 
Diagnostics Pasteur, Belgium). Each plate contained a calibration curve derived from 
rat serum or lung-homogenate samples containing 0, 1, 1.5, 2, 3, 4, 6, 8 and 12 ng/mL 
galactomannan. The concentration of galactomannan in positive test samples was 
expressed as amount of nanograms galactomannan per mL serum or lung homogenate. 
 
Cytokine ELISA 
Rat TNF-α, IFN-γ, IL-1β, IL-4, IL-6, IL-10, MIP-2 and MCP-1 were quantified in 
supernatants of left- and right lung-homogenates and serum using ELISA-kits 
(“Cytoscreen”, Biosource International, Camarillo, USA). Each kit contained a 
calibration curve with different concentrations of the respective cytokines.   
 
Statistical analysis 
Differences in rat survival rate were assessed by log rank test. Differences in parameters 
of fungal infection and cytokines were assessed by student’s T test. 
 
 
RESULTS 
 
Effect of amphotericin B treatment on rat survival rate 
The survival rate of neutropenic rats with IPA was compared in amphotericin B-
treated, infected rats and untreated, infected rats. Treatment was started at 16 h after 
fungal inoculation, at which time hyphal growth was established (data not shown).  Per 
group, 25 to 28 rats were used. Untreated, infected rats died from day 5 after fungal 
inoculation. Death of all rats had occured at day 11 (Figure1). Treatment with 
amphotericin B resulted in a significant increase in survival rate (P< 0.0001), with the 
first rats dying at day 6 after fungal inoculation, and 52% survival of rats at day 11. 
 
Effect of amphotericin B treatment on parameters of fungal load and cytokines 
Parameters of fungal load and levels of cytokines were compared in amphotericin B-
treated, infected rats and untreated, infected rats. Cytokines were also determined in 
uninfected rats. To avoid selection bias, time points were chosen at which all the rats in 
the three groups were still alive, i.e. at 0, 4, 8, 16, 24, 48, 72 and 120 h after fungal 
inoculation.  In each group, 5 to 6 rats per time point were used. 
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Pulmonary macroscopic lesions and histopathology 
In untreated, infected rats, dark-red coloured haemorrhagic pulmonary lesions were 
seen at 48 h and later, increasing in size over time. At 120 h after fungal inoculation the 
size of these lesions comprised on average 49 ± 4% of the total left lung surface.  
Histologicaly, these "angio-invasive " lesions showed extensive fungal broncho- and 
angio-invasion and tissue haemorrhagia. In amphotericin B- treated, infected rats, 
pulmonary lesions also increased over time, but the aspect of these lesions was 
different. A shift was seen from dark-red coloured angio-invasive lesions in untreated, 
infected animals to "responsive" lesions in amphotericin B-treated, infected rats. 
Histologically, these responsive lesions showed shorter hyphae, reduced fungal 
broncho-and angio-invasion and less tissue hemorrhagia compared to untreated, 
infected rats. At 120 h after fungal inoculation, these responsive lesions comprised 46 ± 
15% of the total left lung surface. 
 
Number of cfu 
In untreated, infected rats no increase was seen in number of cfu in the infected left 
lung over time, despite progression of the fungal infection (Figure 2). Treatment with 
amphotericin B did not significantly reduce number of left lung cfu compared to 
untreated, infected rats. Right lungs were positive for cfu in two untreated, infected rats 
at 120 h after fungal inoculation (mean: 1.15 10log cfu). In amphotericin B -treated, 
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Figure 1. Survival of rats with IPA. Rats received either treatment with AMB 1 
mg/kg/day i.v., starting at 16 h after fungal inoculation, or remained untreated. * = 
significantly different compared to untreated, infected rats (P<0.05) 
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infected rats all right lungs were negative. The difference was not significant (data not 
shown). 
 
Chitin content 
An increase was seen in chitin amount of the infected left lung in untreated, infected 
rats over time, especially between 48 h and 120 h after fungal inoculation (Figure 3).   
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 Figure 2. Number of cfu in the infected left lung of rats with IPA. Rats received 
either treatment with amphotericin B (AMB) 1 mg/kg/day i.v., starting at 16 h after 
fungal inoculation, or remained untreated. N = 5 to 6 rats per time point.
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Figure 3. Chitin content of the infected left lung of rats with IPA. N = 5 to 6 rats per 
time point. See legend Figure 1.  
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Amphotericin B  treatment resulted in significant suppression of chitin amounts at 72 h 
(P = 0.02) and 120 h  (P = 0.03) after fungal inoculation.  All right lungs were negative 
for chitin in both groups (data not shown) 
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Figure 4. Galactomannan (GM) concentrations in the infected left lung (A) and serum (B) 
of rats with IPA. N = 5 to 6 rats per time point. See legend Figure 1.  
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Galactomannan concentrations  
Concentrations of galactomannan in the infected left lung increased over time, both in 
untreated, infected rats and amphotericin B-treated, infected rats (Figure 4). Treatment 
with amphotericin B  suppressed the increase in galactomannan concentrations, with 
significant differences at 72 h (P = 0.03) and 120 h (P = 0.006). Similar data were seen 
for galactomannan concentrations in serum, with a significant difference between 
untreated, infected rats and amphotericin B-treated, infected rats at 120 h (P = 0.04). 
Galactomannan concentrations in the right lungs of both groups of rats were not 
significantly elevated compared to uninfected controls (data not shown). 
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Concentrations of cytokines 
Concentrations of the cytokines TNF-α, IFN-γ, IL-1β, IL-4, IL-6, IL-10, MIP-2 and 
MCP-1 were measured in the left lung, right lung and serum. The concentrations of 
TNF-α, IFN-γ, IL-1β, IL-4 and IL-10 did not differ significantly between the three 
groups of rats. In addition, differences in concentrations between infected left lung and 
uninfected right lung were not significant in all groups (data not shown). In contrast, 
IL-6 in the left lung of untreated, infected rats increased over time up to 6- fold 
compared to uninfected controls (Figure 5A). Amphotericin B  - treatment resulted in 
suppression of increase in left lung IL-6 levels, with significant differences compared to 
untreated, infected rats at 72 h (P=0.04) and 120 h (P=0.02). Concentrations of IL-6 in 
the right lung and serum were not significantly different between the three groups of 
rats (data not shown).  Concentrations of the chemokine MCP-1 in the left lung also 
increased over time (Figure 5B). Amphotericin B - treatment resulted in lower levels of 
this chemokine, with a significant difference compared to untreated, infected rats at 120 
h (P = 0.01). MCP-1 levels in right lung and serum were not different between all three 
groups of rats (data not shown). Similarly to IL-6 and MCP-1, levels of left lung MIP-2 
increased over time, and were suppressed in infected rats receiving amphotericin B - 
treatment (Figure 5C). The difference between untreated, infected rats and 
amphotericin B -treated, infected rats was significant at 120 h (P = 0.02). Also for this 
chemokine, concentrations in right lung and serum showed no significant differences 
between all three groups of rats (data not shown). 
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Figure 5. Concentrations of cytokines in left lungs of untreated, infected rats, 
amphotericin B (AMB)-treated, infected rats and uninfected rats (See also legend Figure 
1). N = 5 to 6 rats per time point. * = significant difference compared to untreated, 
infected rats (P<0.05), $ = significant difference compared to uninfected rats (P < 0.05).  
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DISCUSSION 
 
In a clinically relevant animal model of prolonged severe neutropenic rats, we 
investigated the pathogenesis of IPA by examining kinetics of parameters of fungal load 
and cytokines.  Standard amphotericin B  treatment of established pulmonary infection 
resulted in survival of only a proportion of rats, which reflects the clinical overall 
response rate in neutropenic patients with IPA [25]. In untreated, infected rats, the 
number of left lung cfu did not increase over time despite progression of disease. This 
is in agreement with the data obtained in several other animal models of IPA 
[15,16,24,26] In addition, in our model antifungal treatment did not reduce the number 
of cfu compared to untreated, infected rats, despite a significant increase in survival 
rate. These observations suggest that the number of cfu is not an adequate measure for 
quantifying hyphae. Filamentous hyphae composed of multiple cells may only be 
recorded as a single unit by traditional cfu methodology. Therefore we used other 
parameters representing the fungal load such as chitin and galactomannan. Chitin 
content is probably a better measure for fungal load than cfu, since this molecule is a 
component of the fungal cell wall and in vivo studies have shown that chitin amounts 
increase with hyphal growth [24,27]. Our study shows that, in contrast to cfu, left lung 
chitin content increased over time in untreated, infected rats and antifungal treatment 
resulted in  significantly decreased amounts of chitin.  We obtained similar results for 
concentrations of galactomannan, also a fungal cell-wall component, in left lung- and 
serum. The results indicate that treatment with amphotericin B suppresses increase of 
fungal load over time in our model, but does not lead to a reverse. Amphotericin B 
treatment also influenced histopathology of the infected lung. Treatment reduced 
fungal angio- and broncho-invasion, tissue haemorrhagia and the size of hyphae. 
Reduction in tissue damage and haemorrhagia and the formation of "resolving lesions" 
after treatment with amphotericin B has also been described for a rabbit model of IPA 
[8,28].  
Evidence is accumulating that cytokines play a key role in the host response against 
bacterial as well as fungal infections [29-32]. TNF-α is one of the first cytokines 
detectable following bacterial or endotoxic challenge, and has been implicated in the 
cardiopulmonary dysfunction, increased microvascular permeability and metabolic 
derangements that typify bacteraemic septic shock [33-35]. Increases in TNFα 
concentrations are also seen in infections with non-bacterial pathogens including 
rickettsiae, viruses and protozoa. These findings have been taken as evidence for a 
common host response mechanism involving TNF-α, irrespective of the taxonomic 
class of the organism [36,37]. In contrast to this hypothesis, levels of TNF-α in serum 
and infected lungs of rats with IPA in our model were not elevated compared to 
uninfected controls. Other investigators also found that experimental fungal infection 
did not result in increased levels of TNF-α. In a systemic rat model of lethal invasive 
candidiasis serum levels of TNF-α and IL-1α remained low, even at death. These 
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results were the same for immunocompetent and neutropenic rats. In contrast, when 
rats were infected with Escherichia coli or Staphylococcus aureus, large increases of TNF-α 
and IL-1α were seen [38,39]. These findings suggest that TNF-α is not an essential 
mediator in lethal fungal infections. The same may be true for IL-1β, since also this 
cytokine showed no increase in rats with IPA in our model. In contrast, IL-6, another 
pro-inflammatory cytokine, increased over time in the left lung of rats with IPA in our 
model. IL-6 can suppress levels of TNF-α, both in human monocytic cell lines and in 
intact mice [40], and has a function that limits the inflammatory sequelae of TNF and 
other inflammatory mediators [41]. It is therefore also possible that rapid development 
of high levels of IL-6 in our model may have down-regulated levels of TNF, and 
possibly also of IL-1. IL-6 has been shown to play a role in IPA, since IL-6 - deficient 
mice were more susceptible to IPA than wild-type mice [42], and IL-6 was increased in 
lungs of immunocompromised mice with IPA compared to uninfected controls [15]. A 
possible role for IL-6 in IPA might be the induction of granulocyte / macrophage 
colony-stimulating factor (GM-CSF) expression, which is a molecule known to activate 
macrophages [43], which in turn are known to be able to kill Aspergillus [44]. 
A number of studies in mice from one group of investigators suggest that survival in 
IPA was associated with a Th1 response, and succumbing to the infection with a Th2 
response [11-14,45].  In the present study the Th1 associated cytokine IFN-γ was not 
elevated in rats with IPA that survived and the Th2 associated cytokines IL-4 and IL-10 
were not elevated in rats that succumbed to the infection.  Interleukin-6, which is 
considered to be a Th2-associated cytokine in murine models [46], was elevated in both 
treated and untreated rats in our study. Therefore, it could be concluded that in our 
model, infection with Aspergillus resulted in a predominantly Th2 response, that was 
significantly decreased, but not reversed into a Th1 response as a consequence of 
amphotericin B treatment. The difference in cytokine profiles between our study and 
the above-mentioned studies may be explained by the use of a lower inoculum and 
persistently neutropenic animals in our study, factors that have been shown to have an 
effect on cytokine concentrations [16,29,47].   
In our model we found an increase over time of the left lung levels of the C-X-C 
chemokine MIP-2, as well as the C-C chemokine MCP-1. These chemokines are 
produced by a number of cells including macrophages, lymfocytes, endothelial and 
epithelial cells [43]. Possibly, the production of these chemokines during IPA is a result 
of endothelial damage during vasal invasion of the fungus and / or direct stimulation 
by fungal toxins.  Elevated levels of these chemokines in animal models of IPA have 
also been described by others [16,48]. In addition, antibody-mediated neutralization of 
the C-X-C receptor resulted in an invasive aspergillosis infection, and MCP-1 
neutralization decreased conidial clearance in otherwise immunocompetent mice 
[17,18]. This indicates that these chemokines may play a significant role in the host 
defense against A. fumigatus.  
Antifungal treatment of infected rats with amphotericin B in the present model resulted 
in decreased levels of IL-6, MIP-2 and MCP-1 compared to untreated, infected rats. 
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Possibly, this could be a direct effect of amphotericin B on the immune system, since 
this antifungal agent is known to have immunomodulatory characteristics [49]. 
However, this is not likely since amphotericin B was shown to induce, not suppress, 
gene expression for TNF-α, IL-1β, MCP-1 and the MIP-2 homologue IL-8 [50-52].  In 
addition experiments in our laboratory showed that amphotericin B treatment in 
uninfected rats did not influence cytokine levels in lungs and serum compared to 
untreated, uninfected rats (data not shown).  It is therefore more likely that the 
decreased cytokine response is a result of the reduction of the fungal load caused by 
amphotericin B treatment.  
From the present study it can be concluded that treatment with amphotericin B reduces 
the increase in fungal load over time. Probably, this reduction in fungal load results in a 
decreased local inflammatory response and hence decreased levels of IL-6, MIP-2 and 
MCP-1 in the infected lung. TNF-α does not play a role in IPA in neutropenic rats. 
These insights may be useful in the development of new immunomodulatory strategies 
for the treatment of IPA.  
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ABSTRACT 
 
Two diagnostic tests, Aspergillus-specific PCR and an ELISA for the quantitative 
determination of galactomannan, were compared for diagnosing and monitoring 
invasive pulmonary aspergillosis. Persistently neutropenic rats with left-sided invasive 
pulmonary aspergillosis were sacrificed at regular intervals after inoculation. Blood 
samples and BAL-fluid were cultured and tested for PCR as well as ELISA. 
Disseminated fungal infection to extra-pulmonary organs was determined. Sensitivity of 
ELISA was higher than that of PCR on all days of measurements, in both blood and 
BAL-fluid. Positive PCR or ELISA in blood was not significantly associated with 
disseminated fungal infection. Serial testing in a separate group of rats showed 
consistently increasing concentrations of circulating galactomannan during the course 
of disease, while positive PCR could be followed by negative results. The concentration 
of galactomannan was highly predictive for the time of survival (P<0.0001). It was 
concluded that in this model quantitative galactomannan detection is superior to PCR 
in diagnosing and monitoring invasive pulmonary aspergillosis. 
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INTRODUCTION  

The incidence of invasive pulmonary aspergillosis (IPA) has increased considerably in 
the past decade, and this infection is now a major cause of morbidity and mortality in 
immunocompromised hosts [1]. Patients with prolonged chemotherapy-induced 
neutropenia and transplant recipients receiving long term, high dose corticoid therapy 
are at greatest risk [2]. Although mortality rates of IPA remain high despite the use of 
antifungal therapy, observations suggest that the mortality rate may be reduced by early 
diagnosis and treatment [3,4]. However, no method has proven sufficiently sensitive 
and specific to allow a diagnosis at an early stage [5], and new diagnostic methods are 
therefore under investigation. 
Methods for the molecular and serological diagnosis of IPA in blood or broncho-
alveolar lavage fluid (BAL-fluid) have especially drawn attention. Using a PCR method 
for detecting Aspergillus-specific nucleotide sequences, Einsele et al. [6] found a 77% 
sensitivity in patients with IPA prior to antifungal therapy, increasing up to 100% when 
two blood samples were analysed. Among the techniques based on antigen detection 
the sandwich ELISA for the detection of galactomannan (GM) is at the moment the 
most promising. Studies in neutropenic patients report sensitivities between 70% and 
90%, when applying the test in serum [7-9]. It must be noted however, that in these 
clinical studies it is often not indicated how early during the course of the disease the 
test becomes positive in relation to the development of clinical and radiological signs. 
Actually, clinical investigations into sensitivity and specificity of tests for IPA are 
hampered by the absence of proven infection in many patients and by the fact that the 
time of onset of infection cannot be determined. 
In the present study PCR (two separate assays) and GM detection were evaluated in a 
rat model of IPA that has been developed in our laboratory [10]. Using this animal 
model we were able to compare both tests in the early phase of the disease, with a 
known time of onset of the infection. In addition, we determined the value of these 
tests for monitoring the course of the disease. 
 
 
 
MATERIALS AND METHODS 
 
Infection model of IPA 
The animal model was used as described before [10], with some modifications to 
lengthen the survival time. Specified pathogen free female RP strain albino rats (18-25 
weeks old, 185-225 g) were used. Neutropenia was induced by cyclophosphamide 
(Sigma-Aldrich Chemie, Steinheim, Germany) 75 mg/kg i.p. five days before 
inoculation, followed by repeated doses of cyclophosphamide 60 mg/kg i.p. at 1 day 
before and 3 and 7 days after inoculation. This protocol resulted in granulocyte counts 
of less than 0.1×109 / L on the day of inoculation. To prevent bacterial superinfections 
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animals received ciprofloxacin (660 mg/L) and polymyxin B (100 mg/L) in their 
drinking water during the whole experiment. Starting 1 day before inoculation, daily 
i.m. amoxicillin (40 mg/kg/day) was added to this regimen for the remainder of the 
experiment. On the day of inoculation i.m. gentamìcin (6 mg/kg) was added to the 
regimen. For infection of the rats a strain of Aspergillus fumigatus was used, that was 
originally isolated from an immunocompromised patient with IPA.  
Under general anaesthesia the left main bronchus was intubated. A cannula was passed 
through the tube and the left lung was inoculated with 2×104 A. fumigatus conidia. This 
resulted in a one-sided IPA. Mortality rate was ± 50% on day 7, and 90-100% on day 
12 after inoculation. At the end of experiments or at indicated intervals rats were 
sacrificed and the left lung, as well as the right lung, liver, spleen and brain were 
homogenised and cultured to determine the presence of disseminated fungal infection. 
In approximately half of the rats fungal dissemination to extra-pulmonary organs 
occurred, especially to the liver. Blood cultures for Aspergillus species always remained 
negative in this model. 
 
Blood sampling and broncho-alveolar lavage  
Groups of rats were sacrificed to obtain blood for PCR and GM detection and to 
determine the presence of disseminated fungal infection. Under CO2 anaesthesia blood 
samples were taken by cardiac puncture. Broncho-alveolar lavage (BAL) was performed 
by exposing the trachea and lavaging the lungs 3 times with 5 ml of phosphate-buffered 
saline (PBS). Of the BAL sample, 2 ml was used for culture, 1 ml for PCR and 300 µl 
for GM detection. To monitor the course of disease in individual rats, sequential blood 
sampling was performed by puncture of the orbital plexus. 
 
PCR 
Two different methods were used for the extraction of fungal DNA from fluids: the in- 
house method as developed in our laboratory by van Deventer et al. [11], and the 
method according to Einsele et al. [6, 12, 13], with some modifications. 
 
 
DNA extraction from fungal suspensions and BAL-fluid 
In the in-house method, 1 ml of fungal suspension or BAL-fluid was centrifuged at 
16,000 × g for 5 min. Pellets were resuspended in 0.2 ml of TEG buffer (50 mM 
glucose, 25 mM Tris-HCl [pH 8.0], 10 mM EDTA) containing 1.5 µl lyticase (900 
U/ml; Sigma Chemical Co., St. Louise.Mo.) and incubated for 1 h at 37 °C. 
Subsequently, 3.0 µl of pronase (15 mg/ml; Boehringer GmbH) and 10 µl of 10% 
sodium dodecyl sulfate (SDS) were added followed by incubation for 1 h at 37 °C. The 
sample containing fungal DNA was further purified.  
In the method according to Einsele, 1 ml of fungal suspension or BAL-fluid was 
centrifuged (16,000 × g, 10 min) and the pellet resuspended in 0.2 ml of white blood 
cell lysis buffer (WCLB: 10 mM Tris [pH 7.6], 10 mM EDTA, 50 mM NaCl, 0.2 % 
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SDS, 200 µg of proteinase K per ml) followed by incubation at 65 ºC for 45 min. After 
centrifugation (1500 × g, 10 min.) the pellet was resuspended in 0.2 ml zymolyase 
buffer (50 mM Tris [pH 7.5], 10 mM EDTA, 28 mM β-mercaptoethanol and 300 µg 
per ml zymolyase [20T ICN, Costa Mesa, California]) and incubated at 37 ºC for 45 
min. The solution was centrifuged (1500 × g, 10 min), and the pellet containing fungal 
DNA was further purified. 
 
DNA extraction from blood specimens 
In the in-house method according to van Deventer, 0.5 ml of lysis buffer (0.32 M 
sucrose, 10 nM Tris-HCl [pH 7.5], 5 mM MgCl2, 1% Triton X-100) was added to 0.5 ml 
of EDTA-blood. After lysis, samples were centrifuged (5 min, 16,000 × g) and the 
supernatant was discarded. The pellet was resuspended in 0.2 ml of lysis buffer. To 
remove free, non- fungal DNA, 7 µl of DNAse1 (10 mg/ml, Boehringer GmbH, 
Mannheim, Germany) was added and the samples were incubated at 37 °C for 1 h. 
After centrifugation at 16,000 × g for 5 min, pellets were resuspended in 0.2 ml of 
TEG buffer containing 1.5 µl lyticase (900U/ml) and incubated for a further 1 h at 37 
°C. Subsequently, 3.0 µl of pronase and 10 µl of 10% SDS were added followed by 
incubation for 1 h at 37 °C. The sample containing fungal DNA was further purified. 
In the method according to Einsele, a volume of 1.5 ml red blood cell lysis buffer 
(RCLB: 10 mM Tris [pH 7.6], 5 mM MgCl2, 10 mM NaCl) was added to 0.5 ml of 
EDTA- blood and incubated on a shaking platform for 10 min. The sample was 
centrifuged ( 1200 × g, 10 min.) and the pellet was treated again with 1.5 ml of RCLB 
and centrifuged. Subsequently the pellet was resuspended in 0.2 ml of WCLB and 
incubated at 65 ºC for 45 min. After centrifugation (1500 × g, 10 min) the pellet was 
resuspended in 0.2 ml zymolyase buffer and incubated at 37 ºC for 45 min. The sample 
was centrifuged (1600 × g, 10 min), and the pellet containing fungal DNA was used for 
further purification. 
 
 
Purification and amplification of DNA 
DNA was purified according to Boom [14]. Briefly, 1 ml of lysis buffer (0.1 M Tris-HCl 
pH 6.4, 40 mM EDTA pH 8.0, 1 % Triton X-100, 4 M guanidium isothiocyanate) and 
50 µl of a Celite suspension (200 mg/ml, Aoroa organics, Grel, Belgium) was added to 
sample or pellet containing fungal DNA and this suspension was shaken vigorously by 
hand, followed by incubation at room temperature for 10 min. The suspension was 
centrifuged (1 min, 15,000 × g) and the pellet was washed two times with a second lysis 
buffer (0.1 M Tris HCL pH 6.4, 4M guanidium isothiocyanate), two times with ethanol 
70 % and one time with acetone, respectively. After drying, the pellet was resuspended 
in 100 µl of bidestilled water and incubated for 10 min at 56 °C. The sample was 
centrifuged (15,000 × g, 10 min) and 10 µl of the supernatant was used for 
amplification.  
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The following primer set, amplifying a sequence of the multicopy 18S rRNA gene, was 
used: (5' ATTGGAGGGCAAGTCTGGTG 3') and (5' 
CCGATCCCTAGTCGGCATAG 3') [6]. PCR was performed in 100 µl of PCR 
solution containing 50 mM KCl, 10 mM Tris HCl (pH 8.3), 2.5 mM MgCl2, 200 µM of 
(each) dNTP, 50 pmol of each primer, 0.08 U of TAQ polymerase (SuperTAQ, 
Sphaero Q, Leiden, The Netherlands) and 10 µl sample specimen. Forty cycles of 
amplification were performed with a PCR processor (9600, Perkin Elmer). Each cycle 
consisted of a denaturation step at 95 °C for 30 s, a primer-annealing step at 55 °C for 
30 s and a chain elongation step at 72 °C for 45 s. 
 
Southern blot analysis of products 
20-microliter aliquots of each amplification product were electrophoretically separated 
on a 1.5% agarose gel in 0.5 × TBE buffer (Tris –borate EDTA). The DNA was 
transferred from agarose to Hybond-plus nylon filters (Amersham International, 
Amersham, United Kingdom) by electrophoretic transfer [15]. The PCR-products were 
analyzed with an Aspergillus specific DNA probe 
(CATGGCCTTCACTGGCTGTGGGGGGAACCA) [6]. Hybridisation was detected 
by ECL 3, oligolabeling and detection system (Amersham International).  
 
Sandwich ELISA for detection of GM 
The sandwich ELISA was performed as described by Stynen et al. [16] and was used to 
measure concentrations of GM quantitatively. Some minor modifications were made in 
the protocol to reduce the standard deviation in series of samples that were spiked with 
the same concentration of galactomannan. Briefly, 300 µl of each serum or BAL-fluid 
sample was mixed with 100 µl of treatment solution (4% EDTA) and the mixture was 
subsequently boiled for 5 min. After centrifugation (20,000 × g, 10 min), the 
supernatant was used for further testing. Fifty µl of conjugate was added to each well of 
an anti-galactomannan immunoglobulin M- coated micro-titer plate (Platelia 
Aspergillus, Sanofi Diagnostics Pasteur), followed by the addition of 50 µl of the 
treated sample. The plates were incubated at 37 ºC for 90 min. and subsequently 
washed 5 times with washing buffer (Tris NaCl pH 7.4 containing 1% Tween 20 and 
0.01% sodium merthiolate). 200 µl of substrate buffer containing 
orthophenylenediamine dihydrochloride was added to each well, and the plates were 
incubated for 30 min at room temperature in darkness. To stop the reaction, 100 µl 1.5 
M sulphuric acid was added, and optical density was measured at 450/620 nm. Each 
plate contained a calibration curve consisting of rat-serum samples containing 0, 1, 1.5, 
2, 3, 4, 6, 8 and 12 ng/ml GM (kind gift of Marc Tabouret, Sanofi Diagnostics Pasteur, 
Steenvoorde, France). A test sample was considered positive when optical density at 
450 nm was higher than the cut-off sample (i.e. 1.0 ng). The concentration of GM in 
positive test samples was expressed as amount of nanograms GM per ml. 
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Statistical methods 
Associations between GM concentrations and PCR results or disseminated fungal 
infection were analyzed by Mann-Whitney test. Association between PCR-result and 
disseminated fungal infection was analyzed by chi-square test. Spearman’s correlation 
was used to analyse relations between GM concentrations and time to death. 
 
 
RESULTS 
 
Validation of two DNA isolation methods  
Two methods were used for isolating Aspergillus DNA from blood: an in-house 
developed method [11], and the method described by Einsele et al. [6], with 
modifications. The in vitro sensitivities of both methods were compared by isolating 
fungal DNA from blood spiked with 10- fold serial dilutions of A. fumigatus conidia. 
The isolated DNA was then amplified and the amplification product hybridised with an 
Aspergillus-specific probe. Using both DNA isolation methods, 10 cfu per ml rat-blood 
could be detected. Sensitivity was not influenced by using larger blood volumes: when 
volumes of 0.1, 0.5 or 2.5 ml blood were spiked with equal concentrations of conidia, 
no increase in sensitivity was seen.   
 
Validation of quantitative ELISA 
The commercially available "Platelia" sandwich ELISA for detecting GM, was validated 
for quantitative use in rat serum. Concentrations of 0, 1, 1.5, 2, 3, 4, 6, 8 and 12 ng/ml 
GM were spiked in six-fold into rat-serum. In Figure 1 the resulting calibration curve is 
presented. In all samples tested, linear concentration - response curves were obtained 
between the range of 1 and 8 ng / ml (r = 0.994). The detection limit, defined as the 
concentration corresponding to the mean optical density of the blank + 3 SD, was 1.0 
ng / ml. 
 
PCR and ELISA in blood and association with disseminated fungal infection in 
rats with IPA 
Five groups of rats (number varying from 11 to 29) were sacrificed on day 1, 2, 3, 5 and 
7 after inoculation (Table 1). Controls (number varying 3 to 9) were inoculated with 
PBS. From each rat a blood sample was taken for PCR as well as ELISA. The presence 
of disseminated fungal infection was determined by culture of organs. In all 97 blood 
samples taken from infected rats, the in- house DNA isolation method was used, and in 
68 of these samples in addition the “Einsele” method was used. Both methods showed 
the same results in 66 samples. Results of the in-house PCR are shown in Table 1. PCR 
had a considerable lower sensitivity than ELISA, especially between day 2 and 5 after 
inoculation. Highest rates of positivity for both tests were found on the last day of 
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sampling (day 7): 41 % for PCR and 100% for ELISA. Median concentrations of GM 
increased from below detection limit in rats on day 1 to 46 ng/ml in rats on day 7. Of 
all 97 samples, 62% was positive for ELISA; 18% was positive for PCR, all these 
samples being also positive for ELISA. Specificity was high for both tests: of all 31 
blood samples taken from uninfected animals none were found positive for the ELISA, 
and only one of 31 samples for PCR. 
 
Table 1. PCR and ELISA in blood, and association with disseminated fungal infection in rats 
with IPA after dissection.  
No. Of animals  
positive (%) 
Day No. Of 
animals 
PCR1) ELISA 
Median concn  
(ng/ml) of GM  
(range) 
Dissemination2)   
(no. of rats  
positive [%]) 
1 24 0 (0%) 2 (8%) < 1 (< 1-3) 0 (0%) 
2 11 0 (0%) 3 (27%) < 1 (< 1-7) 0 (0%) 
3 18 2 (22%) 16 (89%) 7 (< 1-31) 0 (0%) 
5 15 3 (20%) 14 (93%) 19 (< 1-217) 0 (0%) 
7 29 12 (41%) 29 (100%) 46 (1.9-600) 11 (38%) 
1) In -house PCR method 
2) Extrapulmonary disseminated fungal infection 
0,0
0,5
1,0
1,5
2,0
2,5
3,0
0 1 2 3 4 5 6 7 8 9 10 11 12 13
Concentration GM (ng/ml)
O
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al 
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ity
Figure 1. Representative calibration curve of the sandwich ELISA, prepared in 6 - 
fold with known concentrations of GM in rat serum. Each point represents the mean 
± SD (bars). Optical density at 450 nm. The detection limit of the assay is indicated as 
a discontinuous line. 
                                   
 
 
 
                                    %JCRVGT                                                                PCR and GM detection in rats with IPA 
 
 
 63 
 
Results of rats on day 7 were further analyzed to investigate associations between PCR, 
concentration of GM and the presence of disseminated fungal infection. The median 
concentration of GM in blood samples that were positive for PCR was higher (48.0 
ng/ml, range 8.3 - 602 ng/ml) than the median concentration in PCR-negative samples 
(30.4 ng/ml, range 1.9 – 480 ng/ml).  
Although there was a trend, this difference was not significant (P = 0.09). 37 % of the 
rats on day 7 showed disseminated infection to extra-pulmonary organs, in all cases the 
liver was the affected organ. Percentage of rats with positive PCR was higher (57%) in 
rats with disseminated fungal infection compared to rats with pulmonary infection only 
(27%). In addition, higher concentrations of GM were found in rats with disseminated 
fungal infection (median 50.1 ng/ml, range 1.9-602 ng/ml) than without disseminated 
infection (median 15.8 ng/ml, range 21.0-294 ng/ml). However, both associations were 
not significant (P-values  0.35 and 0.14 respectively). 
 
PCR, ELISA and fungal culture of BAL-fluid and blood in rats with IPA 
Four groups rats (number varying from 5 to 8) were sacrificed on day 1, 3, 5 and 7 after 
inoculation respectively (Table 2). From each rat blood and BAL-fluid were used for 
PCR, ELISA and fungal culture. Blood cultures were all negative. Fungal cultures of 
BAL-fluid were all positive on day 1 after inoculation, the number of cfu decreasing 
over time. Most BAL-fluid cultures obtained from rats on days 5 and 7 after inoculation 
remained negative. PCR results were not related to culture findings: one to two positive 
samples were found on all days. Four rats (two on day 1, one on day 5 and one on day 
7) were found negative in blood and positive in BAL-fluid for PCR. ELISA in BAL-
fluid was more often positive on day 5 and 7 with increasing titers of GM over time, 
despite of negative cultures. Three rats (two on day 1, and one on day 5) were negative 
for ELISA in blood, but positive in BAL-fluid.  
 
Monitoring the course of disease by PCR 
Ten rats with IPA were sequentially sampled on day 1, 3, 5 and 7 after inoculation for 
PCR (Table 3). All rats were negative for PCR on day 1 after inoculation. On day 3, 
four out of ten rats were positive for PCR, on day 5 two out of eight and on day 7 two 
out of four. No clear increase in the rate of positive PCR tests was seen during the 
course of disease. Some rats (1 and 10) remained negative for PCR at all time points, 
even just prior to death. Two other rats (6 and 8) were positive at day 3, but were found 
to be negative thereafter.  
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Table 2. PCR, ELISA and fungal culture of BAL-fluid and blood of rats with IPA after 
dissection. 
 BAL-fluid 
Day No. of 
animals 
PCR 
(no. of rats 
positive) 
ELISA 
(no. of rats 
positive) 
Median concn 
(ng/mL) of GM 
(range) 
Culture 
(no. of rats positive 
[mean CFU/mL]) 
1 8 2 2 <1 (<1-2.7) 8 (4) 
3 5 1 2 <1 (<1-11) 3 (1) 
5 5 2 5 11.6 (5.4-157) 0 (0 
7 5 1 5 8.8 (3.9-114) 1 (0) 
Blood 
Day No. of 
animals 
PCR 
(no. of rats 
positive) 
ELISA 
(no. of rats 
positive) 
Median concn 
(ng/mL) of GM 
(range) 
Culture 
(no. of rats positive 
[mean CFU/mL]) 
1 8 0 0 <1 (<1-1) 0 (0) 
3 5 1 3 4.4 (<1-6.2) 0 (0) 
5 5 1 4 10.2 (<1-26.2) 0 (0) 
7 5 2 5 19.2 (7.6-48) 0 (0) 
 
 
Table 3. PCR in blood of 10 individual rats with IPA after sequential sampling  
PCR results on :  
Rat Day 1 Day 3 Day 5 Day 7 Day 8+ 
1 - - - Died on day 7  
2 - - + Died on day 7  
3 - + Died on day 5   
4 - - + Died on day 7  
5 - + + + Died on day 8 
6 - + - - Died on day 8 
7 - - - + Died on day 13 
8 - + - Died on day 6  
9 - - n.d.1) - Died on day 10 
10 - - - Died on day 6  
1)not determined 
 
Monitoring the course of disease by GM concentrations 
Nine infected rats were sequentially sampled for GM detection (Figure 2). A consistent 
increase in signal was seen during the course of disease. On day 1 all rats were GM 
negative, on day 3 all rats were positive for the ELISA and the median concentration of 
GM was 9.3 ng/ml. On day 5 and 7 median concentrations increased further to 25.8 
and 53.0 ng/ml respectively  Two rats with relatively high concentrations of GM (71 
and 240 ng/ml) on day 5 died the next day. One rat with a relatively low concentration 
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of GM on day 7 survived relatively long compared to other rats, and died on day 11. 
We investigated the relation between concentration of GM and time to death. An 
inverse relation was found that was highly significant (P-value < 0.0001) (Figure 2). 
 
 
 
DISCUSSION 
 
In the present study, we compared two diagnostic tests, Aspergillus-specific PCR and a 
sandwich ELISA for detecting GM with respect to their value in diagnosing and 
monitoring IPA in a rat model. Using an animal model, both tests could be evaluated in 
a controlled fashion in the early phase of the disease, with a known time of onset of 
infection. 
For the diagnosis of IPA in blood, we used two methods for PCR, including the 
method described by Einsele et al. [6]. These authors found a 77% - 100% sensitivity in 
patients with IPA. In our model of severe IPA, the maximum sensitivity that was found 
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Figure 2. GM in blood of individual rats with IPA after sequential sampling. One line 
represents one rat. Insert: relation between GM concentrations and time to death. 
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using both methods was only 41%, at a moment that more than 50% of the rats had 
already died (day 7 after inoculation). One explanation for this difference in sensitivity 
might be the relatively low blood volume (0.5 ml) used for PCR in our model, 
compared to the blood volume of 3–5 ml used in the study by Einsele et al. These 
authors suggested in their article that a larger blood volume might help to increase 
sensitivity of the assay due to the higher yield of fungal DNA. However, when we 
compared different blood volumes (range 0.1 up to 2.5 ml) obtained from infected rats, 
we did not observe any increase in sensitivity. Moreover, a higher blood volume may 
contain more competing DNA or other inhibiting substances which may interfere with 
the specific PCR signal [17]. In addition, the in vitro sensitivities of both PCR methods 
we used was 10 cfu per ml, which is similar to the test as described by Einsele et al.  
Compared to PCR, the sensitivity of the sandwich ELISA in serum was high in our rat 
model, up to 100% on day 7. In addition, the ELISA was positive earlier than was the 
PCR assay. No blood samples from infected animals were PCR positive and ELISA 
negative. This leads to the conclusion that, at least in our rat model, PCR is not only 
less sensitive to ELISA but also has no additional value to the ELISA in diagnosis of 
IPA. 
In monitoring the course of disease, PCR showed inconsistent results in the 
sequentially sampled rats. No clear increase in the fraction of positive animals was seen 
over time with this assay. Also, an on-off phenomenon was observed: some rats that 
were positive for PCR, became negative at a later stage in their disease. In the PCR 
methods we used, fungal DNA was extracted from the pellet obtained after blood cell 
lysis. Since the pellet contains fungal elements whereas free DNA may be present in the 
serum, our method could fail to detect circulating free DNA. It is possible that a PCR 
assay in which circulating DNA is detected in serum gives a better correlation with 
fungal load and severity of disease, and more consistent results [7, 18]. Comparison of 
PCR assays in serum with PCR methods as used in our study should be investigated in 
future studies. 
In contrast to PCR in our model, concentrations of GM increased consistently in the 
course of disease, which has also been reported by others in a rabbit model [19]. In 
addition, we found a highly significant inverse relation between concentration of GM 
and time to death of the rats. These findings indicate that concentrations of GM in 
serum are correlated with the severity of the disease in our model, and possibly with 
fungal load.  
Several other studies have compared PCR and GM detection for the diagnosis of IPA 
in blood. Hashimoto et al. compared PCR, a (1→ 3) β-D-glucan assay and GM 
detection in a rat model of IPA [18]. In their study the sensitivity of PCR was higher 
(80-87%) in the early phase of the disease than that of (1→ 3) β-D-glucan assay (60-
75%) and GM detection (71-80%). The same authors found similar results in a study in 
patients: 70 % sensitivity for PCR and 60 % for GM detection [20]. However, 
comparison of their findings with our data is difficult, since they used a latex 
agglutination test for detecting circulating GM, an assay which is about ten times as less 
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sensitive compared to the sandwich ELISA that we used [9]. Also, the authors used a 
different PCR method, i.e. a nested PCR in serum. Possibly, a nested PCR is more 
sensitive than conventional PCR. However, it has been stated that nested PCR is more 
prone to contamination in a routine hospital laboratory when it is used as a diagnostic 
tool (16). Bretagne et al. compared GM detection by sandwich ELISA with a PCR in 
serum of patients with IPA [7]. Similar to our animal study, the authors reported a 
higher sensitivity for the ELISA compared to the PCR: of the 18 patients with positive 
mycological data 78% had at least two ELISA-positive sera and 50% had at least one 
PCR-positive serum. They found only one sample that was positive for PCR and 
negative for ELISA, and noted that a PCR-positive signal was usually obtained when 
ELISA was highly positive. This is in accordance with our data: we found no samples 
that were ELISA negative and PCR positive, and the median concentration of GM 
tended to be higher in PCR positive samples. Finally, Roth et al. compared PCR by 
using the method described by Einsele and GM detection by sandwich ELISA in 34 
neutropenic patients, of which six with proven IPA [21]. In that study GM detection 
provided both a higher sensitivity and more consistent results during the course of 
disease than PCR. 
In our model, the yield of fungal cultures of BAL-fluid significantly decreased during 
the course of disease. Positive results of early cultures were probably related to conidia 
inoculated into the left lung. In contrast, the GM assay was more often positive later in 
the disease. Francis et al. found comparable results in a rabbit model of IPA. In their 
model cultures of BAL-fluid were rarely positive, in contrast to elevated levels of 
mannitol and GM [22]. These findings are in accordance with results reported by 
Kauffman et al. [23], who investigated the nature of antigenic determinants released by 
conidia and hyphae. They found that components that are released spontaneously from 
conidia are only weakly positive or negative in immunologic assays, in contrast to 
components released from hyphae. So, it is likely that a strongly immunogenic molecule 
like GM is released predominantly from hyphae, and in much lesser amounts from 
conidia. Therefore, GM in BAL-fluid is likely to be a better diagnostic indicator for 
hyphal growth than routine mycological culture of the organism. 
In conclusion, we demonstrated that quantitative GM detection in our model of IPA is 
superior to PCR, in diagnosing as well as monitoring the disease in both blood and 
BAL-fluid.  
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ABSTRACT 
 
We determined the value of galactomannan (GM) detection in CT-based BAL- fluid 
and serum for the diagnosis of invasive pulmonary aspergillosis (IPA) in haemato-
oncologic patients with neutropenia. CT of the thorax and BAL were performed 
systematically at pre-defined clinical indications. GM was determined by sandwich 
ELISA, clinicians being unaware of the results. Of 160 patients, 17 (10.6%) presented 
with proven, probable or suspected IPA. The sensitivity, specificity, positive predicting 
value (PPV) and negative predicting value (NPV) of GM detection in CT-based BAL-
fluid were all 100%. For GM detection in serially sampled serum the sensitivity was 
47%, the specificity 93%, the PPV 73% and the NPV 82%. A non-blinded follow-up 
study was performed to validate the results of GM detection in CT-based BAL-fluid. In 
this study, 22 of 198 patients (11.1%) presented with IPA and the sensitivity, specificity, 
PPV and NPV of GM detection in CT-based BAL-fluid were 85%, 100%, 100% and 
88% respectively. None of BAL-fluids obtained during antifungal treatment of 3 days 
ore more were positive. These results indicate that when CT is used systematically and 
early, GM detection in CT-based BAL-fluid has a high PPV for diagnosing IPA early in 
untreated patients.  
 
 
 
 
 
                                   
 
 
 
                                    %JCRVGT                                                 Galactomannan detection in patients with aspergillosis   
 
 
 73 
INTRODUCTION 
 
Invasive pulmonary aspergillosis (IPA) remains a major challenge in the management of 
immunocompromised patients. In neutropenic patients, mortality rates range from 50% 
to 90 % in different settings [1, 2]. This is probably due to the difficulty in obtaining a 
reliable diagnosis at an early stage and the relative poor efficacy of the currently 
available antifungal armentarium [1, 3]. The gold standard for the diagnosis of IPA is 
the histological demonstration of the fungus in a lung biopsy with concomitant fungal 
growth from the same specimen. However, biopsies are often precluded by 
trombocytopenia or by the critical condition of the patient. Therefore, the diagnosis of 
IPA before death is mostly based on clinical signs, computed tomography (CT)- scan 
findings and culture of respiratory specimens. The general symptoms -primarily fever 
refractory to antibacterial therapy, chest pain, cough, and dyspnea- are variable and 
non-specific. CT of the chest has been advocated for the early diagnosis of IPA as it 
often shows a “halo-sign” in the early phase of the disease in neutropenic patients with 
IPA [4-6]. However, the halo-sign is not specific for IPA as it is also seen in a number 
of other entities including mucormycosis, organising pneumonia and pulmonary 
haemorrhage [7]. The “air-crescent sign” and other signs of cavitations are highly 
suggestive for invasive pulmonary fungal infection, but they often appear in a late stage 
of the disease, after bone marrow recovery. Microscopical examination or culture of 
respiratory specimens such as broncho-alveolar lavage fluid (BAL-fluid) and sputum 
have limited sensitivity and do not discriminate between invasive disease, colonisation 
and contamination [8,9]. Hence, attention has focused on other ways to demonstrate 
IPA. In this respect, the detection of Aspergillus galactomannan (GM) in serum using a 
commercially available sandwich ELISA [10], has shown promising results [11-13]. The 
antigen can also be detected in urine [14,15], or BAL-fluid [16-18]. Few studies have 
compared GM detection in serum and BAL-fluid in neutropenic patients [18,19].  
In our institute CT and BAL are routinely used for evaluating haemato-oncological 
patients at risk for IPA. In this clinical setting we performed a study in two parts. In the 
first part, we investigated in a blinded study the value of GM detection in serum and 
BAL –fluid and their relation to CT, fungal culture, histopathology and antifungal 
treatment. In the second part, GM detection in CT-based BAL-fluid was evaluated as a 
tool for diagnosing IPA in a non-blinded study. 
 
 
PATIENTS, MATERIALS AND METHODS 
 
Study population and design 
The study consisted of two parts. First, between February 1999 and April 2000 we 
performed a prospective, blinded study. Thereafter, between June 2000 and October 
2001 a prospective, unblinded study was carried out. In both parts of the study 
haemato-oncologic patients were included that had an expected neutropenia (less than 
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0.5 x 109 cells per litre) for at least 10 days and were 18 years or older. All patients 
received oral ciprofloxacin (500 mg twice daily) for selective bowel decontamination. In 
addition, all patients received either fluconazole (200 mg/ day) or itraconazole (200 mg 
twice daily) as antifungal prophylaxis. During hospitalisation, patients were evaluated 
for the development of fever and respiratory signs and symptoms. Physical 
examinations were carried out daily. Chest X-rays were performed at admission and 
once-twice weekly during hospitalisation, or every other day during periods of fever (T 
> 38.3 ºC). In case of fever, broad-spectrum antibiotic treatment was administered.  
Chest CT’s were performed when fever of unknown origin lasted for 5 days of 
antibacterial treatment, or when chest X-rays showed abnormalities.  Broncho-alveolar 
lavage (BAL) was performed if feasible as soon as CT showed abnormalities.  
Antifungal treatment was started when new abnormalities emerged on chest X-ray 
under antibiotic treatment, when abnormalities were found on CT that were compatible 
with invasive fungal infection, when moulds were cultured from the respiratory tract, 
when blood cultures revealed fungi or when fever persisted under antibiotics for 7 days.  
In the first part of the study, serum samples were taken from all patients twice weekly, 
starting at the beginning of neutropenia. Sampling was stopped at the end of 
neutropenia or, in case of (possible) fungal infection, until the end of hospitalisation. 
Serum and BAL-fluid samples were stored at minus 20 °C. After discharge from the 
hospital of the patient, the obtained BAL – fluids and serum samples were tested for 
the presence of GM by a researcher who was unaware of the identity and clinical status 
of the patient. Clinicians were blinded from the laboratory results in this part of the 
study.  
In the first part of the study, BAL’s were performed in about half of the patients with 
IPA, due to cautiousness of the clinicians to perform the procedure in this fragile group 
of patients. To exclude selection bias, a second part of the study was performed in 
which BAL’s were performed in all patients with abnormalities on CT unless there was 
a strong contra-indication. In this unblinded investigation, BAL-fluid samples were 
tested for GM within three days after the sample was obtained and results were 
immediately reported back to the clinicians.  
The study concerned the routine development of new methodologies in the laboratory 
and did not involve investigational drugs or additional sampling. Therefore, the study 
was considered by the ethics committee to be a quality-control investigation of the 
hospital, and not experimentation with human beings that would require formal ethics 
review and informed consent. However, all patients signed a declaration that they 
allowed their clinical data and specimens to be used for research. The first part of the 
study was blinded and data of galactomannan detection were not used for patient-
management. After careful analysis of the data of the first part of the study, CT-based 
BAL’s and galactomannan detection in BAL-fluids were incorporated into the routine 
work-up of suspected patients, independent of the planning of the second part of the 
study. 
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Case definitions and classification 
Invasive fungal infections were classified according to the EORTC case definitions, 
with some modifications [20]. Results of GM detection were excluded from the criteria. 
1) Proven invasive pulmonary aspergillosis (IPA) was defined as histopathology or 
cytopathology showing acutely branched, septated hyphae from a needle aspiration 
or biopsy with evidence of associated tissue damage (either microscopically or 
unequivocally by imaging) and a positive culture for Aspergillus sp. from sputum or 
BAL-fluid. The isolation of Aspergillus sp. by a sterile procedure: transthoracic or 
open lungbiopsy / needle aspiration from lungs showing radiological abnormalities 
consistent with infection was also defined as proven IPA. 
2) Probable IPA was defined as a positive culture for Aspergillus sp. from sputum or 
BALF or cytopathology showing acutely branched, septated hyphae together with 
one major or two minor clinical criteria. Major clinical criteria included (a) halo 
sign,  (b) air-crescent sign or (c) cavitation on CT. Minor clinical criteria included: 
(a) symptoms of lower respiratory tract infection: cough, chest pain, hemoptysis or 
dyspnea; (b) physical finding of pleural rub; (c) any new infiltrate not fulfilling a 
major criterion 
3) Suspected IPA was defined as one major clinical criterion together with negative 
bacterial and fungal cultures from specimens related to lower respiratory tract 
infection and no evidence for viral disease.  Although this category is not included 
in the EORTC/MSG criteria, there was consensus between clinicians in our 
department that these patients should be classified as a separate group since they 
are more likely to have IPA than the patients defined in the “possible” IPA 
category, and less likely than the “probable” IPA category. 
4) Possible IPA was defined as either a) a positive culture or cytology for Aspergillus 
sp., b) at least two minor clinical criteria together with negative bacterial and viral 
cultures from specimen related to lower respiratory tract infection.  
5) Proven and probable other invasive fungal infections (IFI) were defined analogous 
to the respective IPA categories, with the identification of filamentous fungi by 
culture or cytology, other than Aspergillus sp.  
 
Computed tomography (CT) and classification 
CT scans were performed using a Siemens Somaton Plus 4 scan. A scanning protocol 
was used in which the whole lung fields were scanned with 3-mm thick sections. All CT 
scans were evaluated after the study by two observers who were unaware of the clinical 
status of the patients.  
 
Galactomannan (GM) detection 
The sandwich ELISA was performed as described by Stynen et al. [10]. Briefly, 300 µl 
of each serum or BAL-fluid sample was used in sandwich ELISA (Platelia Aspergillus, 
Sanofi Diagnostics Pasteur, Belgium). Positive and negative controls were included in 
each assay. All doubtful or positive samples were retested in parallel with recent 
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samples in the next assay. The OD index was calculated as the OD of the clinical 
sample divided by the OD of a control sample containing 1 ng /ml GM. As 
recommended by other authors [12,21], two subsequent serum samples with an index 
larger than 1.0 were considered positive. A BAL-fluid sample was considered positive 
when the index was larger than 1.0, as recommended by others [18,22]. 
 
Cytology and histopathology  
Cytology on BAL-fluids was done by calcofluor white (CFW) stain [23]. Histopathology 
was done by staining tissue sections with haematoxylin - eosin (H&E) and the other 
with Grocott’s methenamine silver Grocott stain, with haematoxilin-eosin contra-stain 
[24]  
 
Statistical analysis 
We defined the total group of patients with IPA as the sum of patients with proven 
IPA, probable IPA and suspected IPA. The total group of patients without IPA was 
defined as the patients that were not classified in any IPA category and did not receive 
empirical antifungal treatment. Calculations of sensitivity, specificity, positive predictive 
value (PPV) and negative predicting value (NPV) were based on these two groups. 
 
 
RESULTS 
 
5VWF[RCTVQPG
Comparison of value of GM detection in serum and CT-based BAL-fluid for 
diagnosing IPA  
 
Patients’ characteristics and diagnosis of IPA 
Between February 1999 and April 2000 160 patients were included, with a total of 249 
neutropenic episodes. The median age of the patients was 49 years (range 18 – 79 
years). Patients' characteristics are shown in Table 1. A total of 17 patients (10,6 % ± 
2.5 %) were diagnosed as having IPA. Two of these patients had proven IPA, eleven 
probable IPA and four suspected IPA.  In nine patients the causative organism was 
Aspergillus fumigatus, in one patient Aspergillus flavus and in one patient Aspergillus niger.  In 
two patients acutely branched, septated hyphae were seen in sputum and biopsy 
indicating Aspergillus sp..  In four patients with suspected IPA, clinical and radiological 
signs were strongly suggestive for IPA, whereas repeated cultures from respiratory 
specimens remained negative. Six out of 17 patients (35 %) with IPA died during 
hospitalisation. The cause of death in these patients was pulmonary bleeding due to 
aspergillosis (3) cerebral aspergillosis (2) and concomitant infection with "Pneumocystis 
carinii" (1). In four patients other invasive fungal infections were diagnosed: Rhizopus 
species (1), Mucor species (1), Saccharomyces cerevisiae (1) and Candida kruseï (1). Hundred 
seventeen patients did not have a diagnosis of IFI. 
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CT scan  
A total of 475 CT’s was performed in all patients, of which 111 CT’s in the 17 patients 
with IPA. Sixteen of 17 IPA patients showed halo-signs on CT, most of them in the 
earliest stage of disease (Figure 1). In 8 of the 17 IPA patients a crescent or cavitation 
sign was observed, mostly during bone-marrow recovery. In 15 of the IPA patients 
multiple nodular- or wedge-shaped lesions were seen, mostly after several weeks of 
antifungal therapy. The first CT in the neutropenic episode in which the IPA diagnosis 
was made, showed a halo-sign in 13 patients, multiple nodular lesions in two, non-
specific abnormalities in one, and no abnormalities in one patient.  
In 74 of 117 patients without IFI, CT showed non-specific abnormalities, which were 
caused by bacterial or viral infections (27), malignant lymphoma’s (24), other (19), or 
unknown aetiologies (4). A halo sign was seen on CT’s of 4 patients, but IFI was 
discarded because culture or histopathology revealed lymphoma cells (2 patients), 
influenza (1) and bacterial infection (1). Nodular or wedge shaped lesions were seen in 
two patients with pulmonary lymphoma. In the remaining 43 patients no CT’s were 
performed or CT’s showed no abnormalities.  
 
GM detection in serum  
A total of 1145 samples were tested for GM (mean 12.9 samples / patient). Of the 270 
samples taken from patients with IPA, 26 (9.6%) were positive, with a median  
index of 1.891 (range 1.000 - 4.326). Eight of 17 patients with IPA had two or more 
subsequent sera positive (2 x index ≥ 1.0) for GM. In only one patient with IPA more 
than three subsequent positive sera were found. In this patient GM was detected for a 
period of more than 3 months, and finally the antigenemia disappeared and the patient 
recovered (Figure 1).  In the other seven patients the antigenemia was transient, lasting 
no longer than one week.  In six of these seven patients antigenemia disappeared under 
antifungal treatment, whereas in one patient antigenemia disappeared spontaneously. 
GM was relatively more often detected in patients that died (4 out of 6, 66%) than in 
patients that survived (4 out of 11, 36%), but this difference was not significant (P = 
0.33). Of 18 patients with possible IPA, 4 patients were GM positive. 
Of 44 patients without IFI that were tested for GM, three (7%) were positive. In 
patient based analysis, the sensitivity of the test using the above criterion was 47 ± 7% 
(SEM), the specificity 93 ± 5%, the positive predictive value (PPV) 73 ± 6% and the 
negative predictive value (NPV) 82 ± 5%. When other criteria were used, the results 
were less favourable (Table 2). 
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Figure 1 
RTGXKQWUVYQRCIGU Timing of CT, GM detection, antifungal treatment , fever and 
culture/ histopathology in patients with IPA. Symbols:       = halo-sign,      = crescent-sign or 
cavitation,    =   wedge-shaped or nodular abnormalities,  x  = non-specific abnormalities. N = 
no abnormalities. GM detection:  = serum negative,  = serum positive, B+ = BAL-fluid 
positive, B - = BAL-fluid negative. Arrows: positive findings in culture/ histopathology.. 
 
To investigate the inter-laboratory reproducibility of our results, 125 sera taken 
randomly from patients with IPA, and 75 sera taken from patients with no IFI were 
retested in an external laboratory (Department of Medical Microbiology, University 
Medical Center Nijmegen, The Netherlands). The same results were found in 94% of 
the sera. In the external laboratory, one patient with IPA and one patient without IFI 
were found positive (2 x index ≥ 1.0) that had been tested negative in our own 
laboratory. In both cases the disconcordance was based on one serum sample.  
 
Table 2. Sensitivity, specificity and predictive values of GM detection in serum according to 
different criteria for assessment for positivity.  
Proven, probable and suspected IPA  
Criterion positive Sensitivity ± SEM Specificity ± SEM PPV NPV 
1 x index > 0.7 59% 61% 36% 80% 
2 x index > 0.7 53% 89% 64% 84% 
1 x index > 1.0 59% 75% 48% 83% 
2 x index > 1.0 47% 93% 73% 82% 
1 x index > 1.5 18% 84% 30% 73% 
2 x index > 1.5 12% 95% 50% 74% 
 
Table 3. GM detection in serum and BAL – fluid in neutropenic patients included in a blinded 
study between February 1999 and April 2000 
  GM detection in serum GM detection in BAL-fluid 
 No 
patients 
No 
patients 
tested 
No patients 
positive 
(2 x index > 1.0)
No 
patients 
tested 
No patients positive  
(1 x index > 1,0) 
Proven IPA 2 2 1 (50%) 1 1 (100%) 
Probable IPA 11 11 5 (45%) 6 6 (100%) 
Suspected IPA 4 4 2 (50%) 2 2 (100%) 
Possible IPA 18 18 4 (22%) 2 1 (50%) 
Empiric ampho B 4 4 1 (25%) 1 0 (0%) 
Other IFI 1) 4 4 0 (0%) 2 0 (0%) 
No IFI 117 44 5 (11%) 16 0 (0%) 
1) Invasive pulmonary fungal infections other than IPA, proven and probable 
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GM detection in CT-based BAL-fluid 
In part one of the study a total of 36 BAL-fluids were tested for GM. Of these, 14 
BAL-fluids were obtained from nine patients with IPA (see Table 3). In all nine patients 
with IPA, at least one BAL-fluid was positive for GM (index ≥ 1.0).  In all cases this 
was the first BAL-fluid that was obtained in the neutropenic episode in which IPA was 
diagnosed (Figure 1). The five BAL-fluids from the patients with IPA that were GM 
negative were either obtained after one or more weeks of anti-fungal treatment 
(amphotericin B or lipid formulation of amphotericin B in all cases), or obtained in 
another neutropenic episode than in the one in which IPA was diagnosed. Of the 14 
BAL-fluids obtained from patients with IPA, three revealed a positive culture for A. 
fumigatus and one for A. niger. All these four culture positive BAL-fluids were also 
positive for GM. One BAL- fluid was both positive for CFW and GM. Conversely, 
four BAL-fluids were positive for GM and both culture and CFW negative. Of the two 
patients with possible IPA that were tested, one had a BAL-fluid positive for GM. 
Nineteen BAL-fluids were taken from 18 patients without IPA. In none of these BAL-
fluids GM was detected. In patient based analysis, the sensitivity, specificity, PPV, and 
NPV were all 100%, using the criterion that at least one BAL-fluid should have an 
index ≥ 1.0.   
 
Time interval between onset of fever, signs on CT, antifungal treatment and GM 
detection 
In patients with IPA, CT-scans (halo/ crescent or cavitation sign), serum GM, BAL-
fluid GM and culture / histopathology were found positive on average 4.0 ± 0.8, 4.6 ± 
1.6, 6.9 ± 1.1 and 14.8 ± 5.0 days after onset of fever related to the emergence of IPA 
respectively. Antifungal treatment was started on average 6 ± 1.4 days after onset of 
fever. 

5VWF[RCTVVYQ
Prospective investigation to confirm the value of GM detection in CT-based 
BAL-fluid for diagnosing IPA 
 
Between June 2000 and October 2001 a total of 198 patients were included. The 
median age of the patients was 47 years (range 18 – 74 years). Twenty-two patients 
(11.1 %) presented with IPA: three proven, ten probable and nine suspected cases. A. 
fumigatus was the causative organism in eight patients, whereas A. flavus was found in 
the other culture-positive patient with IPA.  A total of 453 CT’s were performed, of 
which 95 in 22 patients with IPA.  Thirty of these 95 CT’s showed a halo-sign, 12 a 
crescent sign or cavitation and 29 nodular or wedge-shaped lesions. 
A total of 80 CT-based BAL-fluids were tested for GM. Of these, 31 BAL-fluids were 
obtained from 20 patients with IPA. In 17 of these 20 patients at least one BAL-fluid 
was positive for GM (Table 4). In 16 of these 17 patients, GM was detected in the first 
BAL-fluid that was obtained in the neutropenic episode in which the IPA diagnosis was  
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Table 4. GM detection in BAL – fluid in neutropenic patients included in a non- blinded study 
between June 2000 and October 2001 
 GM detection in BAL-fluid 
 No patients No patients tested No patients positive  
(1 x index > 1.0) 
Proven IPA 3 3 3 (100%) 
Probable IPA 10 9 8 (89%) 
Suspected IPA 9 8 6 (75%) 
Possible IPA 13 12 5 (42%) 
Empiric ampho B 2 2 0 (0%) 
Other IFI 1) 3 2 0 (0%) 
No IFI  158 21 0 (0%) 
1) Invasive pulmonary fungal infections other than IPA, proven and probable 
 
made, in one patient in the second obtained BAL-fluid. In four patients more than one 
BAL-fluid was positive. However, all BAL-fluids obtained during more than 2 days of 
antifungal treatment were GM negative. In all these cases antifungal treatment 
consisted of amphotericin B or lipid formulations of amphotericin B. Of all 21 BAL-
fluids from patients with IPA that were positive for GM, only six had positive cultures 
of Aspergillus sp. No BAL-fluids were GM negative and culture-or CFW positive. GM 
detection was negative in all BAL-fluids of three patients with IPA: one patient with 
probable and two with suspected IPA. Thirteen patients had possible IPA. A total of 56 
CT’s were made in these patients, 32 of these showed nodular or wedge-shaped lesions, 
21 showed abnormalities that were not suggestive for fungal infection and 3 showed no 
abnormalities. Twelve of 13 patients had nodular or wedge-shaped lesions on CT at 
some stage of the disease. GM detection in BAL-fluid was positive in 5 of 12 patients. 
In 3 of these patients the CT preceding the positive BAL-fluid showed nodular or 
wedge-shaped lesions, in one patient abnormalities not suggestive for fungal infection 
and in one patient no abnormalities. Of 12 patients with possible IPA, 5 patients had a 
BAL-fluid positive for GM. Three patients were diagnosed with other pulmonary 
fungal infections than IPA: two with Candida albicans and one with Candida kruseï . BAL-
fluids taken from these patients were all negative for GM.  
A total of 33 BAL-fluids were obtained from 23 patients without IFI. In none of these 
BAL-fluids GM was detected. In patient-based analysis, the sensitivity of the test was 
85 ± 8% SEM, the specificity and PPV were 100% and the NPV was 88 ± 7%, using 
the criterion of at least one BAL-fluid with an index ≥ 1.0.  
 
Combined calculation of values of GM detection in BAL-fluid in part one and 
two of the study 
Analysing the combined data of all 108 patients included between February 1999 and 
October 2001 in which one or more BAL’s were performed, the sensitivity for GM 
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detection in CT-based BAL-fluid was 90 ± 5.6%, the specificity and PPV were 100% 
and the NPV 93 ± 4%. 
 
 
DISCUSSION 
 
The diagnosis of IPA remains a difficult task, especially in neutropenic patients. Early 
diagnosis is of great importance since early start of antifungal treatment improves 
survival [25]. CT is recently recognised as an important tool for diagnosing IPA. Caillot 
et al. suggested that a systematic use of CT scan allowed earlier diagnosis of IPA and 
significantly improved survival when combined with early antifungal therapy [4]. 
However, the use of CT scan seems to differ between different centres. For example, in 
some studies CT’s were performed in only a minority of patients with IPA [22,26], 
whereas in the study by Caillot et al. CT’s were performed in all of 25 patients with 
IPA, with a mean of almost 3 CT’s per patient [4]. In our study CT’s were performed 
systematically and early in all patients with IPA, with a mean of 5.3 CT’s per patient and 
starting within four days after onset of fever. 
GM detection for diagnosing IPA has been investigated in several studies [11-
14,17,18,22,27,28]. The antigen can be detected by a latex agglutination test or by a 
sandwich ELISA, of which the latter has shown to have the higher sensitivity [28,29].   
Recently, several large, prospective studies in neutropenic patients reported sensitivities, 
specificities and predictive values above 90% for GM detection by ELISA in serum 
[11-13].  In our study these characteristics were less favourable: we found a sensitivity 
of GM detection in serum of 47%, a specificity of 93%, a PPV of 73% and a NPV of 
82%.  Differences in definitions of IPA may partly explain this disparity. Another 
reason for the observed difference may be that early and systematic use of CT in our 
study results in less advantageous characteristics of the test. Early detection of 
suspected lesions on CT might have resulted in an earlier start of antifungal treatment. 
Since antifungal treatment has been shown to suppress circulating GM levels [27], and 
we observed that serum GM often converted to negative as soon as antifungals were 
started, early start of treatment may have prevented detectable antigenemia in a number 
of patients. With a PPV of 73% and a NPV of 82%, GM detection in serum may still 
have some additional value for diagnosing IPA in the individual patient in our clinical 
setting. However, these values were only achieved when serum was sampled serially 
twice per week, and using the optimal criterion of two subsequent indexes ≥ 1.0.  
In a very recent, large study in oncological patients also less favourable test 
characteristics of GM detection in serum were reported, i.e. a sensitivity of 32%, a 
specificity of 95%, a PPV of 58% and a NPV of 85%. In this report the presence in 
patients of circulating anti-Aspergillus antibodies was suggested as a possible cause for 
the relatively low sensitivity and PPV [30].  
In contrast to GM detection in serum, we found a surprisingly high sensitivity (100%) 
and specificity (100%) for GM detection in CT based BAL-fluid in the first part of our 
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study. To confirm these figures a second investigation was started, in which BAL’s were 
performed more frequently. Overall, the sensitivity of GM detection in CT based BAL-
fluid was 90%, the specificity 100%, the PPV of 100% and NPV of 93%. However, 
these figures were based on BAL-fluids obtained before start of antifungal treatment. 
All BAL-fluids obtained under more than two days of antifungal treatment, and most 
BAL- fluids obtained after ceasing antifungal treatment were negative. This indicates 
that BAL for GM detection should be performed early, promptly after CT and before 
the start of antifungal treatment. Possibly, the use of antifungal treatment could explain 
the somewhat lower sensitivities of GM detection in BAL-fluid found in other studies, 
in which use of antifungals before or during BAL was not reported [17,18]. In 
accordance with our findings, Caillot et al. found higher sensitivities for GM detection 
in BAL fluid (73%-83%) than in serum (41-45%) using the latex agglutination test, in a 
clinical setting with early and systematic CT use [4,5].  
A number of studies have reported the use of PCR in BAL-fluid for diagnosing IPA 
[17,31-33]. However, the PPV of this test for diagnosing IPA may be compromised by 
the fact that this test does not distinguish between infection and colonisation [31,32]. 
This problem may be less when GM detection is used, as is suggested by the high PPV 
in our study. In addition, in our animal model of IPA it was shown that GM detection 
in BAL-fluid was more often positive during invasive fungal growth than during 
colonisation, in contrast to PCR [34].   
We also investigated the time interval between onset of fever, first halo-sign on CT, 
antigen detection and culture / histopathology in the first part of our study. CT was 
found positive already 4 days after onset of fever and GM was detected in BAL fluid 
after 7 days.  In comparison, culture / histopathology became positive only 15 days 
after onset of fever on average. This indicates that a diagnostic strategy in which GM 
detection in CT based BAL is used, results in an earlier confirmed diagnosis of IPA 
compared to classical methods.   
We conclude that, when CT is used early and systematically, GM detection in CT-based 
BAL fluid has a high PPV for diagnosing neutropenia-associated IPA in an early phase 
of the disease. BAL-fluids should be obtained before start of antifungal treatment, since 
under antifungal treatment GM detection becomes negative. GM detection in serum 
seems to be of less value, since its sensitivity and PPV are limited.  
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ABSTRACT 
 
Scintigraphic imaging in granulocytopenic patients can be very useful to detect and 
localize infections, which often do not show localizing signs and symptoms. We studied 
the potential of 99mTc-labeled polyethylene glycol (PEG)-coated liposomes and 99mTc-
labeled IgG to image bacterial and fungal infection in a granulocytopenic rat model. 
67Ga-citrate was used as a reference agent.  
Methods. 99mTc-PEG-liposomes, 99mTc-hydrazinonicotinate(HYNIC)-IgG or 67Ga-
citrate were administered to granulocytopenic rats with a Staphylococcus aureus abscess or 
with unilateral invasive pulmonary aspergillosis. Imaging and biodistribution studies 
were performed.  
Results. All agents visualized the Staphylococcus aureus infection from 1 h postinjection 
onwards. However, only with 99mTc-PEG-liposomes and with 99mTc-HYNIC-IgG 
activity in the infectious foci increased with time up to 24 h. 99mTc-PEG-liposomes and 
99mTc-HYNIC-IgG showed significantly higher accumulation in the infectious focus as 
compared to 67Ga-citrate (1.33 ± 0.31 %ID/g and 1.40 ± 0.16 %ID/g, respectively, vs. 
0.31 ± 0.04 %ID/g; 24 h p.i., p<0.05). At 24 h p.i. abscess-to-muscle ratios were 
highest for 99mTc-liposomes (72.1 ± 19.1), followed by 99mTc-HYNIC-IgG (18.3 ± 3.3) 
and 67Ga-citrate (4.4 ± 0.7). In pulmonary aspergillosis, both 99mTc-PEG-liposomes and 
99mTc-HYNIC-IgG showed significantly higher uptake in the infected lung than 67Ga-
citrate (3.6 ± 0.4 and 8.3 ± 0.8 %ID/g, respectively, vs. 1.3 %ID/g at 24 h p.i.; p<0.05).   
Conclusion. 99mTc-PEG-liposomes and 99mTc-HYNIC-IgG performed better than 
67Ga-citrate in the localization of peripheral bacterial infection and fungal infection in 
the lung in granulocytopenic rats. The high focal uptake and high target-to-nontarget 
ratios of 99mTc-PEG-liposomes and 99mTc-HYNIC-IgG indicate that both 
radiopharmaceuticals may become valuable agents to image infection in 
granulocytopenic patients. 
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INTRODUCTION 
 
Febrile episodes frequently occur in the treatment of cancer patients, particularly during 
the severe and often protracted neutropenic period induced by aggressive 
chemotherapeutic regimens. In granulocytopenic patients, more than 60 % of these 
febrile episodes are of infectious origin, causing substantial morbidity and mortality [1]. 
Prompt initiation of empiric broad-spectrum antibiotic therapy has shown to improve 
clinical outcome [2]. Rapid identification of a possible site of infection helps to tailor 
the instituted antibiotic regimen and reduces the occurrence of side-effects, of 
superinfection and the emergence of resistant micro-organisms. However, 
granulocytopenic patients often lack localizing signs or symptoms, hampering clinical 
identification of an infectious focus [3]. Scintigraphic techniques can be useful in the 
diagnostic process as they provide rapid whole-body evaluation based on functional 
processes, while they do not depend on morphological abnormalities. Imaging with 
labeled autologous leukocytes is very effective for detection of acute infection [4,5], but 
is obviously not feasible in granulocytopenic patients. Labeled donor leukocytes have 
been proposed as an alternative method [6,7], but are only seldomly applied because of 
the high risk for HLA-immunization, transfusion-associated graft-versus-host disease, 
and transmission  of viruses [8,9]. Therefore, gallium-67-citrate (67Ga-citrate) is 
currently the method of choice for scintigraphic evaluation of the febrile 
granulocytopenic patient [10,11]. Opportunistic respiratory infections in particular are 
adequately visualized with this radiopharmaceutical [11]. However, imaging with 67Ga-
citrate has several disadvantages: (1) the radiopharmaceutical has unfavourable imaging 
characteristics and causes high radiation exposure, (2) the physiological bowel uptake 
and the accumulation in malignant lymphomas limits its accuracy for the detection of  
(abdominal) infections, (3) optimal imaging often requires delayed recordings up to 72 
hours, whereas a timely diagnosis may have a major clinical impact in these patients.  
Several new agents are being developed for infection imaging. Nonspecific polyclonal 
human immunoglobulin labeled with indium-111 has shown high efficacy for 
visualizing focal infection in both immunocompetent and granulocytopenic patients 
[12,13]. A 99mTc-label would be more attractive, providing better image quality and 
lower radiation exposure. IgG labeled with 99mTc via the nicotinyl hydrazino derivative 
(HYNIC) has shown high accuracy for the detection of clinical infection and 
inflammation [14], but has not yet been studied in the granulocytopenic host. Sterically 
stabilized liposomes, also called PEG-liposomes, are another newly developed agent in 
the field of scintigraphic detection of inflammation and infection. The inclusion of 
polyethyleneglycol (PEG) into the lipid bilayer of these vesicles results in prolonged 
blood circulation time compared to conventional liposomes, due to reduced uptake by 
the mononuclear phagocyte system [15,16]. Experimental studies have shown excellent 
targeting of inflammatory foci with PEG-liposomes [17-19].  
In the present study, we evaluated the potential of 99mTc-PEG-liposomes and 99mTc-
HYNIC-IgG to visualize bacterial infection in granulocytopenic rats. In addition, the 
                                   
 
 
 
                                       %JCRVGT                                                 Scintigraphic imaging of bacterial and fungal infection 
 
 
 92 
performance of labeled liposomes and labeled IgG was evaluated in a clinically more 
relevant model of pulmonary aspergillosis, a frequent and serious fungal infection in 
immunocompromised patients. For comparison, 67Ga-citrate was included as a 
reference agent. 
 
 
MATERIALS AND METHODS 
 
Infection models 
Staphylococcus aureus. A focal S. aureus abscess was induced in granulocytopenic rats, as 
described by Oyen et al. [13] with minor modifications. Briefly, male randomly-bred 
Wistar rats, weighing 200-220 g, were injected with one dose of cyclophosphamide 
(Asta-Medica, Diemen, The Netherlands) 100 mg/kg intraperitoneally five days before 
bacterial inoculation (day –5), followed by one dose of  75 mg/kg on day -3. The rats 
had free access to standard rat chow and acidified drinking water. The degree of 
granulocytopenia was tested in a separate group of five rats. The mean WBC count was 
reduced from 11.3 ± 0.5 x 109/l on day -5 to 0.2 ± 0.1 x 109/l on day 0, and remained 
on this level until the end of the experiment. Differential counts showed that less than 
20% of the leukocytes were granulocytes, resulting in a granulocyte count of < 0.05 x 
109/l. Under ether anaesthesia, a focal abscess was induced by injecting approximately 1 
x 106 viable S. aureus (ATCC 25923) in 0.1 ml 50%:50% suspension of autologous 
blood and normal saline in the left calf muscle. Twenty-four hours after the inoculation, 
when swelling of the muscle was apparent, the respective radiopharmaceuticals were 
injected via the tail vein. 
Pulmonary aspergillosis. Pulmonary aspergillosis was induced in granulocytopenic rats 
according to the methods described by Leenders et al. with minor modifications [20]. 
Briefly, female RP strain rats, 18-25 weeks old and weighing 185-225 g, were injected 
with one dose of cyclophosphamide 75 mg/kg intraperitoneally five days before fungal 
inoculation (day -5), and one dose of  60 mg/kg on day -1. This protocol resulted in 
granulocyte counts of less than 0.1 x 109/l on the day of inoculation until the end of the 
experiment. To prevent bacterial superinfections, animals received ciprofloxacin (660 
mg/L) and polymyxin B (100 mg/L) in their drinking water during the whole 
experiment. Daily intramuscular amoxillin injections (40 mg/kg/day) were added to this 
regimen starting one day before inoculation. Pulmonary infection was established, using 
a strain of Aspergillus fumigatus isolated from an immunocompromised patient with 
invasive pulmonary aspergillosis. Under general anesthesia the left main bronchus was 
intubated. A cannula was passed through the tube and the left lobe of the lung was 
inoculated with 2 x 104 Aspergillus fumigatus conidia in 0.02 ml suspension of phophate 
buffered saline (PBS, pH 7.4). This procedure resulted in a left-sided invasive 
pulmonary infection; signs of mycelial disease were usually seen at 16 h after 
inoculation [20]. Three rats were inoculated with 0.02 ml normal saline and served as 
controls. 
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Radiopharmaceuticals 
99mTc-PEG-liposomes. Glutathione-containing PEG-liposomes were prepared as 
described previously [19]. The mean size of the liposome preparations as determined by 
dynamic light scattering measurements was 100-110 nm with a polydispersity index < 
0.1. Preformed glutathione-containing liposomes were labeled with 99mTc essentially as 
previously described [21]. Briefly, the liposomes (70 µmole phospholipid/ml) were 
incubated for 15 min at room temperature with freshly prepared 99mTc-HMPAO (6 
MBq/µmole phospholipid). Labeling efficiency was between 70 and 80%. Removal of 
unencapsulated 99mTc-HMPAO was achieved by gel filtration on a PD-10 column 
(Pharmacia, Woerden, The Netherlands) with 5% glucose as the eluent. Radiochemical 
purity as determined on a gelfiltration column (PD-10) was higher than 95%. 
99mTc-HYNIC-IgG. Hydrazinonicotinamide (HYNIC) was synthesized and conjugated 
to human polyclonal IgG (Gammagard, Baxter/Hyland, Lessines, Belgium) according 
to the methods of Abrams and colleagues [22]. Approximately one HYNIC group was 
coupled per IgG molecule, as determined spectrophotometrically. The purified 
HYNIC-conjugated IgG was diluted to 4 mg/ml in 0.15 M acetate (pH 5.85), sterilized 
by membrane filtration and stored at -20 0C in 0.5 ml aliquots. After thawing 0.5 ml 
HYNIC-IgG-solution, the conjugate was radiolabeled with 99mTc by adding 0.1 mg N-
[Tris(hydroxymethyl)-methyl]glycine (Tricine, Fluka), 0.01 mg SnSO4, and 99mTc 
pertechnetate (50 MBq/mg). The mixture was incubated for 15 min at room 
temperature. The radiochemical purity was determined by instant thin layer 
chromatography on silica gel strips (Gelman Lab., Ann Arbor, MI) with 0.15 M acetate 
(pH 5.85) as the mobile phase. Labeling efficiency was always higher than 95%. HPLC 
analysis on a size exclusion column indicated that the preparation contained less than 
5% aggregates, as described previously [30]. 
67Ga citrate.. 67Ga-citrate (DRN 3103) was purchased  in kit form (Mallinckrodt Medical, 
Petten, The Netherlands). 
 
Study design 
S. aureus abscess. Twenty-four hours after bacterial inoculation, groups of three rats were 
injected via the tail vein with either 10 MBq 99mTc-PEG-liposomes or 10 MBq 99mTc-
HYNIC-IgG or 10 MBq 67Ga-citrate. The animals were anesthetized with a mixture of 
halothane, nitrousoxide and oxygen, and were placed prone on a single head gamma 
camera equipped with a parallel-hole, low-energy collimator for the 99mTc studies or a 
medium-energy collimator for the 67Ga studies. Each group of rats was imaged at 5 min 
and 1, 2, 4, 10 and 24 hr after injection. Images (300,000 counts/image; at 24 hr p.i. 
100.000 counts/image) were obtained and stored in a 256 x 256 matrix. The 
scintigraphic results were analyzed by drawing regions of interest over the abscess, the 
noninfected contralateral calf muscle (used as background region), the heart 
(representing blood-pool activity) and the whole animal. Abscess-to-background ratios 
and the percentage residual activity in the abscess (abscess-to-whole body ratio) were 
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calculated at various timepoints. The ex-vivo biodistribution of the radiolabels was 
determined in a separate experiment. Twenty-four hours after bacterial inoculation, 
groups of five rats were injected intravenously via the tail vein with either 4 MBq 99mTc-
PEG-liposomes or 4 MBq 99mTc-HYNIC-IgG or 0.4 MBq 67Ga-citrate. Twenty-four 
hours after injection of the radiopharmaceutical, the rats were killed with 30 mg 
phenobarbital injected i.p.. Blood was obtained by cardiac puncture. After cervical 
dislocation, tissue samples (right calf muscle, infected left calf muscle, lung, spleen, 
kidney and liver) were dissected, weighed and their activity was measured in a shielded 
well-type gamma counter (Wizard, Pharmacia-LKB, Sweden). To correct for physical 
decay and to calculate uptake of the radiopharmaceuticals in each tissue sample as a 
fraction of the injected dose, aliqouts of the injected dose were counted simultaneously. 
The results were expressed as percent injected dose per gram (%ID/g). Abscess-to-
blood and abscess-to-muscle ratios were calculated. 
Pulmonary aspergillosis. Forty-eight hours after inoculation, groups of six infected rats 
were injected intravenously via the tail vein with either 10 MBq 99mTc-PEG-liposomes 
or 10 MBq 99mTc-HYNIC-IgG or  10 MBq 67Ga-citrate.  The non-infected control rats 
received 10 MBq 99mTc-PEG-liposomes. Imaging studies were performed as described 
above. The rats were imaged at 2, 8 and 24 h after injection. After obtaining the final 
image, the rats were killed to determine the ex-vivo distribution of the radiolabels. After 
assessment of macroscopic abnormalities, small samples of  the right and left lung were 
collected for microbiological examination. The remainders of  the right and left lung 
were weighed and their activity was measured in a shielded well-type gamma counter. 
Tissue samples of other organs were processed as described above. Results were 
expressed as percent injected dose per gram (%ID/g).  Left-to-right lung, left lung-to-
blood and left lung-to-muscle ratios were calculated. 
 
Microbiological and histopathological studies 
S. aureus abscess. S. aureus infection was induced in two granulocytopenic rats and two 
immunocompetent rats, as described above. Samples of infected left calf muscle and 
noninfected right calf muscle were dissected, formalin-fixed and embedded in paraffin. 
Sections were cut and stained with hematoxylin-eosin for lightmicroscopic examination. 
Pulmonary aspergillosis. Samples of  the right and left lung were aseptically removed. A 
sample was smeared on Colombia III agar blood plates (Becton & Dickinson, Etten-
Leur, The Netherlands) which were incubated at 37 0C for 48 h to examine possible 
bacterial co-infection. The remainders of the lung tissues were fixed in buffered 
formalin. After measurement of radioactivity, the tissues were embedded in paraffin 
and histopathological studies were done on sections that were stained with 
hematoxylin-eosin or Grocott methenamine silver. 
 
Statistical analysis 
All values are given as percent injected dose per gram tissue (%ID/g) or ratios ± one 
standard error of the mean (SEM). Statistical analysis of tissue distribution was 
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Figure 1. Hematoxylin-eosin stained tissue of S. 
aureus-induced abscess in immunocompetent 
rats (A) and granulocytopenic rats (B). Note the 
massive leukocyte infiltration in A, not present 
in B. Magnification x 400. 
performed using the one-way-analysis-of-variance (ANOVA). Tukey-Kramer multiple-
comparison tests were applied. A corrected p value of < 0.05 was considered 
significant. 
 
 
RESULTS 
 
S. aureus abscess. Although a relatively small inoculum was used (1 x 106 viable bacteria in 
granulocytopenic rats vs 1 x 109 viable bacteria in immunocompetent rats), gross 
swelling of the left calf muscle was apparent in all granulocytopenic rats 24 hours after 
bacterial inoculation. Cross-sections of the abscess samples showed an encapsulated 
collection of purulent material. No haemorrhages were observed.  Microscopic 
examination revealed necrosis of muscle tissue, but only minimal leukocyte infiltration 
in contrast to the massive leukocyte influx seen in immunocompetent rats (Figure. 1). 
Figure 2 shows the scintigraphic images of the respective radiopharmaceuticals at 1 and 
24 hours postinjection. All agents 
visualized the abscess as early as 1 hr 
postinjection. Furthermore, improving 
contrast between abscess and 
background on the subsequent 
scintigrams was observed with the 
99mTc-labeled agents, but not with 
67Ga-citrate. Quantitative analysis of 
the images showed that abscess uptake 
of 67Ga-citrate only slightly increased 
with time and reached a maximum of 
6.8 ± 1.2 %ID at 10 hr postinjection. 
The abscess-to-background ratio at 24 
h postinjection did not exceed 2.0 and 
was significantly lower than that of the 
two other agents (p<0.01). In 
contrast, both 99mTc-PEG-liposomes 
and 99mTc-HYNIC-IgG showed 
increasing accumulation in the abscess 
throughout the 24 hour period, 
resulting in significantly higher abscess 
uptake (16.6 ± 1.9 %ID and 16.3 ± 
1.6 %ID, respectively) and abscess-to-
background ratios (16.6 ± 1.1 and 12.8 
± 1.4, respectively), as compared to 
67Ga-citrate (p<0.05). Blood clearance 
of 67Ga-citrate was significantly faster 
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than that of the 99mTc-labeled compounds (p<0.01 at 1 hr p.i.; data not shown): the 
initial t½ was approximately 1.5 hr compared to approximately 6 hr and 10 hr for the 
99mTc-liposomes and 99mTc-HYNIC-IgG, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Scintigrams of granulocytopenic rats with S. aureus infection in the left 
calf muscle imaged at 1 h and 24 h after injection of 99mTc-PEG-liposomes (A), 
99mTc-HYNIC-IgG (B) and 67Ga-citrate (C). 
 
 
 
24 hr
A 
1 hr 
C 
B 
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Figure 3. Lung tissue of granulocytopenic 
rats  with invasive pulmonary aspergillosis 
showing abundant septate hyphae of 
Aspergillus with only minimal cellular 
infiltration. (A) Hematoxylin-eosin stain. (B) 
Grocott methenamine silver stain. 
Magnification x 300. 
Table 1. Biodistribution of 99mTc-PEG-liposomes, 99mTc-HYNIC-IgG and 67Ga-citrate  
in granulocytopenic rats with S. aureus abscess 24 hr p.i. (%ID/g ± SEM) 
Organ Liposomes IgG Ga-67 
Blood  0.87 ± 0.06 1.22 ± 0.25 0.07 ± 0.004 
Muscle  0.02 ± 0.001 0.08 ± 0.01 0.07 ± 0.01 
Abscess  1.33 ± 0.31 1.40 ± 0.16 0.31 ± 0.04 
Lung  0.32 ± 0.02 0.72 ± 0.12 0.14 ± 0.01 
Spleen  5.75 ± 0.74 2.11 ± 0.16 2.30 ± 0.46 
Kidney  2.53 ± 0.20 1.27 ± 0.04 0.44 ± 0.03 
Liver  0.58 ± 0.07 1.06 ± 0.05 0.64 ± 0.03 
Abscess/blood   1.57 ± 0.41 1.29 ± 0.27 4.71 ± 0.66 
Abscess/muscle 72.1 ± 19.1 18.3 ± 3.3 4.40 ± 0.71 
Abscess/spleen 0.22 ± 0.03 0.68 ± 0.09 0.16 ± 0.04 
Abscess/liver 2.28 ± 0.37 1.32 ± 0.10 0.49 ± 0.07 
 
The biodistribution data of the 
radiolabels following injection of the 
three radiopharmaceuticals are given in 
Table 1. In accordance with the 
scintigraphic results, 99mTc-PEG-
liposomes and 99mTc-HYNIC-IgG 
showed significantly higher uptake in the 
infectious focus at 24 hr postinjection 
than 67Ga-citrate (p<0.05). The very low 
uptake of the labeled liposomes in 
normal muscle resulted in an abscess-to-
muscle ratio of 72.1 ± 19.1, four to 
sixteen times higher than the ratios 
obtained with 99mTc-HYNIC-IgG 
(p<0.05) and 67Ga-citrate (p<0.01). Due 
to the relatively low blood level of 67Ga-
citrate, the abscess-to-blood ratio of 
gallium was higher than for the other 
two agents (p<0.01). Biodistribution of 
the three radiopharmaceuticals in the 
various organs showed relatively high 
splenic uptake with 99mTc-PEG-
liposomes (5.75 ± 0.74 %ID/g; p < 
0.01), while liver uptake was highest 
with 99mTc-HYNIC-IgG (1.06 ± 0.05 
%ID/g; p < 0.001). 
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Pulmonary aspergillosis. Gross haemorrhagic infarctions were macroscopically visible at 
the base of the infected left lung. In the IgG-group, the infarctions appeared to be 
more extensive than in the other two groups (mean affected lung surface 25% vs. 15%), 
but the difference was not statistically significant. Histological examination revealed 
abundant septate branching hyphae invading blood vessels and lung tissue, but only 
minimal leukocyte infiltration (Figure 3). No mycelial disease was observed in right lung 
tissue or in lung tissue of the control rats. Negative microbiological findings excluded 
bacterial co-infection. The scintigraphic images of the radiopharmaceuticals are shown 
in Figure 4. At 24 hr p.i., increased uptake in the left lung could be noted with 99mTc-
liposomes and 99mTc-HYNIC-IgG. At earlier time-points, pathologic uptake in the 
region of the left lung could not unequivocally be observed since adequate delineation 
of the infection was hampered by the relative small size of the animals and the vicinity 
of activity in the cardiac pool. With 67Ga-citrate, minimal uptake was noted in the left 
lung at all time points. No increased pulmonary uptake was observed in the control 
rats, who had been injected with labeled PEG-liposomes. Quantitative analysis of the 
images revealed that both 99mTc-PEG-liposomes and 99mTc-HYNIC-IgG displayed 
relatively long half-lives; the absolute values were remarkably higher than in the S. 
aureus experiment (initial t½ approximately 20 and 30 hr, respectively, vs. 6 and 10 hr; 
data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
DBA C
Figure 4.  Scintigraphic images of granulocytopenic rats with invasive pulmonary 
aspergillosis 24 hr after injection of 99mTc-PEG-liposomes (A), 99mTc-HYNIC-IgG (B) 
or 67Ga-citrate (C). (D) Non-infected control rats, injected with 99mTc-PEG-liposomes, 
24 hr p.i.. Arrows indicate pathological uptake in the left lung. 
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The biodistribution data of the three radiopharmaceuticals, given in Table 2, show that 
uptake in the infected lung was significantly higher with 99mTc-PEG-liposomes and 
99mTc-HYNIC-IgG than with 67Ga-citrate (p<0.05 and p<0.001, respectively). Due to 
the relatively high uptake of labeled IgG in normal lung tissue, the liposomes displayed 
the highest left-to-right lung ratio (3.4 ± 0.4) of the two 99mTc-agents, and had also a 
higher ratio than 67Ga-citrate (1.1 ± 0.1). Furthermore, the left lung-to-muscle ratio was 
significantly higher with the liposomes (96.6 ± 17.1) than with 67Ga-citrate (21.1 ± 5.5; 
p<0.001). The left lung-to-blood ratio was similar for the three radiopharmaceuticals. 
The biodistribution of labeled liposomes in normal lung tissue was highly similar for 
rats with or without lung infection. The lung uptake in non-infected tissue was higher 
than observed in the S. aureus experiment.  
 
 Table 2. Biodistribution of 99mTc-PEG-liposomes, 99mTc-HYNIC-IgG and 67Ga-citrate in   
 granulocytopenic rats with pulmonary aspergillosis 24 hr p.i. (%ID/g ± SEM) 
Organ Liposomes 
(asp) 
IgG (asp) Ga-67 (asp) Liposomes 
(contr) 
blood 2.89 ± 0.25 5.90 ± 0.42 0.65 ± 0.11 2.74 ± 0.97 
muscle 0.04 ± 0.01 0.15 ± 0.01 0.07 ± 0.02 0.13 ± 0.02 
left lung 3.59 ± 0.44 8.31 ± 0.80 1.30 ± 0.36 1.13 ± 0.38 
right lung 1.08 ± 0.10 3.03 ± 0.28 0.55 ± 0.16 1.02 ± 0.38 
spleen 10.60 ± 1.54 7.30 ± 0.73 1.62 ± 0.40 13.28 ± 2.55 
kidney 2.58 ± 0.30 3.21 ± 0.71 2.04 ± 0.34 3.00 ± 0.18 
liver 1.38 ± 0.13 4.18 ± 0.46 1.85 ± 0.35 1.49 ± 0.15 
left/right lung 3.4 ± 0.4 2.8 ± 0.3 2.4 ± 0.4 1.1 ± 0.1 
left lung/muscle 96.6 ± 17.1 58.2 ± 6.1 21.1 ± 5.5 10.5 ± 5.3 
left lung/blood 1.2 ± 0.1 1.4 ± 0.1 2.2 ± 0.7 0.4 ± 0.02 
 asp = Aspergillus infection; contr = control. 
 
 
 
DISCUSSION 
 
The paucity of diagnostic clues in the febrile granulocytopenic patient and the 
limitations of current radiopharmaceuticals stimulate the search for agents capable to 
rapidly and effectively visualize infectious foci, not depending on the patients' leukocyte 
count and/or immune status. Our study shows that 99mTc-PEG-liposomes and 99mTc-
HYNIC-IgG can localize focal bacterial infection in granulocytopenic rats. Compared 
to 67Ga-citrate, 99mTc-PEG-liposomes and 99mTc-HYNIC-IgG had the highest absolute 
abscess uptake (up to 1.40 %ID/g). A very high abscess-to-muscle ratio (>70) was 
observed with 99mTc-PEG-liposomes, exceeding the values of all other agents. The 
relatively high uptake of the 99mTc-PEG-liposomes is in line with our observations in 
previous studies [23], and most likely is due to physiological filtration rather than 
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phagocytosis by spleen macrophages [24]. In addition to high focal uptake in bacterial 
infection, labeled PEG-liposomes and labeled IgG also showed preferential 
accumulation in lung tissue infected with Aspergillus. Uptake with these 99mTc-labeled 
agents (up to 8.3 %ID/g) was significantly higher than with 67Ga-citrate (1.3 %ID/g). 
Furthermore, target-to-nontarget ratios exceeded the ratios obtained with 111In-IgG in 
rats with Pneumocystis carinii pneumonia (PCP), another opportunistic respiratory 
infection [19]. As 111In-IgG as well as 67Ga-citrate have proven their clinical usefulness 
for the detection of these type of infections [25], the results of our study hold promise 
for the clinical application of 99mTc-labeled liposomes and 99mTc-HYNIC-IgG for the 
detection of aspergillus infection. The excellent targeting of pulmonary aspergillosis 
with labeled liposomes is remarkable, since this agent failed to localize experimental 
PCP [19]. Apparently, the causative microorganism and its histopathological features 
affect preferential localization. Invasive pulmonary aspergillosis in granulocytopenic 
subjects typically shows abundant hyphae and hemorrhagic infarctions with virtual 
absence of neutrophilic and monocytic lesions [26,27], whereas tissue damage is less 
prominent in PCP and a mononuclear infiltrate prevails [28]. Perhaps in PCP the 
relatively large size of liposomes prevents adequate extravasation compared to the the 
smaller IgG molecules.  
Currently, a series of radiolabeled peptides (f-MetLeuPhe, interleukin-1, interleukin-1 
receptor antagonist, interleukin-2, tuftsin, leukotriene, platelet factor 4, and others) is 
tested for their ability to image infection and inflammation scintigraphically [29]. It is 
expected that this approach will eventually lead to a 99mTc-labeled agent for infection 
imaging that will allow rapid and specific localization of infection and inflammation. 
However, these peptides are directed against receptors expressed on cells that infliltrate 
in inflammatory foci and their localization relies on cellular infiltrates. As we have 
shown here, in neutropenic subjects only minimal leukocyte infiltration may occur. 
The uptake in the abscess and the abscess-to-muscle ratio of both 99mTc-PEG-
liposomes and 99mTc-HYNIC-IgG were higher than found in previous studies in 
immunocompetent rats with focal infection [19,30]. This may be related to the stronger 
inflammatory response seen in neutropenic animals; it has been shown that the 
proinflammatory cytokine response in neutropenic mice is stronger than in 
immunocompetent mice [31], which may have led to relatively more endothelial 
damage and vascular leakage. In addition, a stronger outgrowth of bacteria could have 
occurred in the immunocompromised animals. Still, the results are remarkable, as we 
had to use a relatively low dose of S. aureus to avoid overwhelming sepsis and acute 
mortality (106 viable bacteria in granulocytopenic rats vs. 109 viable bacteria in 
immunocompetent rats).  Obviously, no such comparative data are available for 
pulmonary aspergillosis. In the Aspergillus experiment, the radiopharmaceuticals showed 
higher uptake in non-infected tissue than in the S. aureus experiment, which was 
probably due to differences in breed. 
The results of our study confirm that localization of labeled IgG and liposomes in 
infectious foci does not depend on interaction with inflammatory cells, as both 
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infection models displayed a conspicious absence of leukocytes, while focal uptake in S. 
aureus abscess was at least as high as in immunocompetent animals. Indeed, several 
studies have indicated that labeled liposomes as well as labeled IgG extravasate into 
inflammatory areas just by virtue of locally enhanced vascular permeability [32,33]. 
Thus, the blood level of the radiopharmaceutical is considered to be the driving force 
for accumulation at the site of infection. Consequently, the improved infection 
targeting of PEG-liposomes compared to that of conventional liposomes is attributed 
to their enhanced blood circulation time [34]. 
The moderate performance of 67Ga-citrate in both infection models is remarkable, as 
previous studies have shown the usefulness of 67Ga-citrate for the localization of 
infectious foci in immunocompromised patients [11]. However, these studies were 
mainly performed in patients who were not deeply neutropenic. Although the 
mechanism of 67Ga-citrate concentration in areas of inflammation is still subject to 
debate, it is suggested that lactoferrin present in polymorphonuclear leukocytes binds to 
67Ga and thus contributes to focal accumulation [35]. This concept could possibly 
explain the performance of 67Ga-citrate in our granulocytopenic rat model.  
In view of the histopathological findings in pulmonary aspergillosis, it is conceivable 
that besides increased vascular permeability, focal bleeding may have contributed to 
focal uptake of labeled liposomes and labeled IgG. This could have biased the results in 
favour of IgG given the more extensive hemorrhagic infarctions in the IgG group. The 
contribution of focal bleeding to the uptake of the two agents could be of importance 
to determine their potential role in the diagnostic management of Aspergillus infection. 
Although the incidence of infarctions has no relation with the amount of viable 
microorganisms and bleeding can occur early in Aspergillus infection [27], further studies 
are needed to evaluate the performance of labeled liposomes and IgG in relation to 
duration and severity of the disease.  
If application under granulocytopenic conditions is feasible, 99mTc-labeled agents are 
preferred over 67Ga-citrate – currently the agent of choice for opportunistic infections 
in immunocompromised patients – because of lower radiation exposure, more 
favourable imaging characteristics and greater availability. In addition, the higher focal 
uptake of 99mTc-PEG-liposomes and 99mTc-HYNIC-IgG, and the higher target-to-
nontarget ratios compared to 67Ga-citrate, suggest improved infection targeting in 
granulocytopenic patients when these agents are employed.  
 
 
CONCLUSION 
 
 In a granulocytopenic rat model, 99mTc-PEG-liposomes and 99mTc-HYNIC-IgG 
provided good visualization of S. aureus induced inflammation early after i.v. injection, 
and showed high focal uptake and target-to-nontarget ratios compared to 67Ga-citrate. 
In granulocytopenic rats with pulmonary aspergillosis, 99mTc-PEG-liposomes and 
99mTc-HYNIC-IgG showed significantly higher uptake than 67Ga-citrate. These results 
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indicate that 99mTc-PEG-liposomes and 99mTc-HYNIC-IgG might be useful in the 
evaluation of the febrile granulocytopenic patient, and therefore warrant further clinical 
studies. 
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ABSTRACT
The value of scintigraphic imaging using 99mTc-labelled poly(ethyleneglycol) (PEG) -
liposomes for detecting invasive pulmonary aspergillosis at different stages of the
disease was investigated in a rat model. At 24, 48, 72, 120 and 168 h after fungal
inoculation scintigraphic images were obtained and biodistribution of the radiolabel was
determined. Findings were compared with serum galactomannan detection and other
parameters of progression of fungal infection.
At 48 h  liposomal uptake in the infected left lung was increased significantly and 82%
of the scintigraphic images was assessed positive. Serum galactomannan was only
detected at 72 h and later. Liposomal uptake in the infected left lung increased over
time and was significantly correlated with both the size of the pulmonary hemorrhagic
lesion and the levels of circulating galactomannan. It was concluded that scintigraphic
imaging using 99mTc-PEG-liposomes allows early detection of invasive pulmonary
aspergillosis in this model, and that liposomal uptake in the infected lung was strongly
associated with the severity of the disease.
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INTRODUCTION
Invasive pulmonary aspergillosis (IPA) is a major cause of morbidity and mortality in
neutropenic patients [1]. Early detection and diagnosis of the infection is of great
importance, since it has been shown that early antifungal treatment significantly
improves outcome [2,3]. In the diagnostic process of IPA, a positive CT scan is one of
the first indicators for the disease. CT scanning is more sensitive than radiography and
may reveal consolidations suggestive of fungal infection such as the “halo”  and “air-
crescent” signs [4].  Other steps in the diagnostic process are efforts to culture the
fungus from sputum, broncho-alveolar lavage fluid (BALF) or material obtained by
(transcutaneous) lung biopsies. IPA can be proven by providing histopathological
evidence of mycelial growth in pulmonary tissue. However, none of these methods can
reliably detect or diagnose IPA in its very early stage.  New diagnostic tests are
therefore under investigation. In this respect, the detection of circulating
galactomannan has shown promising results [5].
Scintigraphic imaging techniques may have an additional value in the diagnostic process
of IPA. In contrast to radiological imaging methods such as X- ray and CT,
scintigraphic imaging does not depend on structural changes in the lung caused by the
presence of the fungus, but on physio-chemical changes in the lung induced by the
microorganism [6].  Also, this technique offers the possibility of a rapid whole-body
evaluation, and therefore may be useful for the detection of extra-pulmonary
disseminated fungal infection. At present, 67Ga-citrate is the radiopharmaceutical of
choice for the imaging of lung / thoracic infections in neutropenic hosts [7]. However,
this imaging agent has unfavourable imaging characteristics and causes relatively high
radiation exposure [8,9].  Several other scintigraphic agents are currently under
investigation. 111Indium-labeled non-specific human- immunoglobulin G (HIG) has
shown good results in detecting infection in febrile granulocytopenic patients [10] .
Other promising newly developed imaging agents are radioactively labelled long-
circulating liposomes.  Coating the liposomal surface with poly(ethyleneglycol) (PEG)
avoids rapid  recognition by the mononuclear phagocyte system and as a consequence
results in prolonged residence time of the liposomes in the circulation which results in
substantial liposomal localisation in infected tissue [11-13].  Increased capillary
permeability with resulting liposomal extravasation is thought to be important for this
localisation, but the exact mechanism by which PEG-liposomes localise is not yet well
understood [14,15].  Liposomes can be labelled with 67Ga, 111In or 99mTc. Of these three
labels 99mTc provides better image quality and lower radiation exposure compared to
the other two agents [16].
In a previous study we found that IPA in neutropenic rats could be detected by
scintigraphic imaging at 72 h after fungal inoculation [17]. In this study 99mTc-
PEG-liposomes had scintigraphic imaging qualities that were superior to 67Ga-
citrate and slightly better than those of labelled polyclonal IgG (99mTc-HYNIC-
IgG). In the present study scintigraphic imaging using 99mTc-PEG-liposomes
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was performed in different stages of the fungal disease.  The value of
scintigraphic imaging for early detection of IPA was determined. In addition,
the relation between imaging characteristics and parameters for progression and
severity of infection was investigated.
MATERIALS AND METHODS
Infection model of IPA
The animal model used was based on the rat model of Klebsiella pneumoniae pneumonia
described by Bakker-Woudenberg et al. [18], and adapted for Aspergillus fumigatus
[19,20]. Some modifications were made to lengthen the survival time of the rats.
Specified pathogen free female RP strain albino rats (18-25 weeks old, 185-225 g) were
used. Neutropenia was induced by cyclophosphamide (Sigma-Aldrich Chemie,
Steinheim, Germany) 75 mg/kg i.p. five days before inoculation, followed by repeated
doses of cyclophosphamide 60 mg/kg i.p. at 1 day before and 3 and 7 days after
inoculation. This protocol resulted in granulocyte counts of less than 0.1×109 / L on
the day of inoculation and afterwards. To prevent bacterial superinfections animals
received ciprofloxacin (660 mg/L) and polymyxin E (100 mg/L) in their drinking water
during the whole experiment. Starting one day before inoculation, daily i.m. amoxicillin
(40 mg/kg/day) was added to this regimen for the remainder of the experiment. On the
day of inoculation i.m. gentamìcin (6 mg/kg) was added. For infection of the rats a
strain of A. fumigatus was used, that was originally isolated from an
immunocompromised patient with IPA. Once every month the strain was passed into
rats to maintain its virulence. The rats were anaesthetised with Hypnorm (Janssen,
Belgium), 0.1 ml / rat i.m. together with Nembutal (Sanofi Sante, The Netherlands), 0.3
ml / rat i.p. of a 4 times diluted solution in distilled water). Under general anaesthesia
the left main bronchus was intubated. A cannula was passed through the tube and the
left lung was inoculated with 2×104 A. fumigatus conidia in 0.02 ml phosphate buffered
saline (PBS, pH 7.4). This resulted in a one-sided IPA. Mortality rate was ± 50% on day
7, and 90-100% on day 12 after inoculation. In approximately half of the rats fungal
dissemination to extra-pulmonary organs occurred, especially to the liver. Blood
cultures for Aspergilli always remained negative. Rats that served as controls were
inoculated with 0.02 ml PBS or non-viable conidia.  Non-viable conidia were obtained
by incubating conidia in 10% formaldehyde solution in PBS for 24 h and subsequent
repeated washing with PBS.  No viable conidia remained in this suspension, as checked
by culture on Sabouraud- agar (Oxoid, Basingstoke, UK).
The experimental protocols adhered to the rules laid down in The Dutch Animal
Experimentation Act (1977) and the published Guidelines on the Protection of
Experimental Animals by the Council of the EC (1986). The present protocols were
approved by the Institutional Animal Care and Use Committee of the Erasmus
University Rotterdam.
                                    Chapter 7                                                Scintigraphic imaging in rats with invasive aspergillosis
109
Radiopharmaceuticals
99mTc-PEG-liposomes were prepared as described previously [21] . The liposomes were
composed of egg phosphatidylcholine (EPC), the poly(ethylene derivative of
distearoylphosphatidyl-ethanolamine (PEG-DSPE), cholesterol and the hydrazino-
nicotinamide derivative of distearoylphosphatidylethanolamine (HYNIC-DSPE) in a
molar ratio of 1.85:0.15:1:0.07. The particle size distribution was determined by
dynamic light scattering with a Malvern 2000 system equipped with a 25 mW Neon
laser (Malvern Instruments Ltd, Malvern, UK). As a measure of particle size
distribution of the dispersion, the polydispersity index was determined. This index
ranges from 0.0 for an entirely monodisperse dispersion, up to 1.0 for a completely
polydisperse dispersion. The mean diameter of the liposomes was 85 nm with a
polydispersity index of 0.1. Preformed HYNIC-PEG-liposomes were labelled with
99mTc as described previously [21]. The radiochemical purity of the labelled PEG-
liposomes was determined using instant thin-layer chromatography (ITLC) on ITLC-
SG strips (Gelman Sciences, Inc., Ann Arbor, MI) with 0.15 M sodiumcitrate (pH 5.0)
as the mobile phase and verified by elution on a PD-10 column. Labelling efficiency
exceeded 95% and the 99mTc-PEG-liposomes were administered i.v. without any
further purification.
Study design
At 0, 24, 48, 96, and 144 h after fungal inoculation, groups of rats were injected i.v. via
the tail vein with 10 MBq 99mTc-PEG--liposomes (± 1 µmol phospholipid per rat).
Imaging with this agent was optimal 24 h after injection [17] . At this time point the
animals were anaesthetised with a mixture of halothane, nitrousoxide and oxygen, and
were placed prone on a single head camera equipped with a parallel hole, low energy
collimator.  Images (100,000 counts per image) were obtained and stored in a 256 x 256
matrix.  After acquiring the image, rats were killed with pentobarbital i.p. and dissection
was performed.  Blood was obtained by aortic puncture. Left and right lung, liver,
kidneys and spleen were removed, weighed, and their radio-activity was measured in a
shielded well-type gamma counter (Wizard, Pharmacia-LKB, Sweden). To correct for
physical decay and to calculate uptake of the radiopharmaceuticals in each tissue sample
as a fraction of the injected dose, aliquots of the injected dose were counted
simultaneously. Lungs and liver were homogenised and cultured quantitatively on
Sabouraud-agar.
Assessment of scintigraphic images
All scintigraphic images were evaluated by two observers (both medical specialists in
nuclear medicine) who were unaware of the image being obtained from an infected or
uninfected rat. Images were scored as either negative (no preferential accumulation of
activity in the left lung region), positive (preferential accumulation of activity in the left
lung region) or strongly positive (strong preferential accumulation accumulation of
activity in the left lung region). When there was disagreement between the observers
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they discussed the result of the scintigraphic image with each other until they reached
the same conclusion.
Pulmonary macroscopic hemorrhagic lesion size
Macroscopic pulmonary pathology of the left lung was determined by measuring the
size of the hemorrhagic lesion as percentage of the total lung surface. This was scored
from photographs of the lungs taken immediately after dissection by measuring the
lesion size on the photograph.
Histology
Separate groups of rats were sacrificed on indicated intervals after inoculation. The left
and right lung were fixed with formalin and embedded in paraffin. Every lung was cut
at 3 levels ± 1 mm apart. At every level 2 adjacent sections were obtained, of which one
was stained with haematoxylin - eosin (H&E) and the other with Grocott’s
methenamine silver [22].  Lesions were graded based on the following five parameters:
(1) hyphal growth, (2) leukocyte accumulation, (3) tissue invasion, (4) hemorrhagic
infarction, (5) tissue necrosis. In each category a semi-quantitative score was assigned.
Hyphal growth was scored as: only conidia visible (-), mostly small hyphae (< 20 µm)
present (+), or  mostly large hyphae (> 20 µm) present with the majority of the hyphae
showing branching (++). Leukocyte accumulation was scored as:  no infiltrate visible (-
),  few leukocytes or thin leukocytic rim around the fungal foci (+), or clear leukocytar
infiltrate around the fungal foci (++).  Tissue invasion was scored as : conidia or
hyphae confined to bronchial lumen (-), invasion of bronchial wall (+),  invasion of
bronchial wall and angioinvasion (++), or extensive hyphal growth through tissue and
extensive angioinvasion (+++). Hemorrhagic infarction was scored as: no
haemorrhagia visible (-), hemorrhagic infarction visible only direct around fungal foci
(+), or extensive hemorrhagic infarction throughout the lung tissue (++). Necrosis was
scored as: no necrosis visible (-), necrosis only inside and directly around the fungal foci
(+), or extensive tissue necrosis (++).
Fungal culture
From the rats the left and right lung, liver and kidneys were aseptically removed and
disrupted in 20 ml phosphate buffered saline (PBS) using a tissue homogeniser for 45
sec at 10,000 rpm. Serial ten-fold dilutions were spread onto Sabouraud agar plates and
incubated at 37 °C for 36 h, after which colony forming units (cfu) were counted.
Galactomannan detection
Concentrations of circulating galactomannan were measured as described before [23]
Briefly, 300 µl of each serum sample was used in a sandwich ELISA (Platelia
Aspergillus, Sanofi Diagnostics Pasteur). Each plate contained a calibration curve
derived from rat serum samples containing 0, 1, 1.5, 2, 3, 4, 6, 8 and 12 ng/ml
galactomannan. A test sample was considered positive when optical density at 450 nm
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was higher than the cut-off sample (i.e. 1.0 ng/ml). The concentration of
galactomannan in positive test samples was expressed as amount of nanograms
galactomannan per ml serum.
Statistical methods
Linear regression was used to analyse the increase of left / right lung radioactivity
ratio’s over time. Associations between left / right lung ratios and assessment of
scintigrams, pulmonary hemorrhagic lesion size, and circulating galactomannan levels
were analysed by Pearson’s correlation test.
RESULTS
Groups of neutropenic rats with left-sided IPA (n=7 to 18 per group) and uninfected
controls (n=3 to 4 per group) were injected with 99mTc-PEG-liposomes at 0, 24, 48, 96
and 144 h after inoculation.  One group of rats (n = 6) was inoculated with non-viable
conidia and injected with labelled liposomes at 0 h only. 24 h after injection of
liposomes (i.e. 24, 48, 72, 120 and 168 h after inoculation) a radioscintigram was
obtained and biodistribution of the radiolabel and parameters of fungal disease were
determined.
Biodistribution of  99mTc-PEG-liposomes
Uptake of the radiolabel was determined in the left lung, right lung, blood, spleen, liver
and kidneys. The ratio of the activity per gram infected left lung tissue and gram
uninfected right lung tissue was calculated to express liposomal uptake in infected vs.
uninfected tissue. In uninfected rats, mean liposomal uptake in the left lung (% ID / g)
was below 2 % at all time points (range 0.55-1.94%). Mean left / right lung ratio’s in
these rats were approximately 1 (range 0.76- 1.12) at all time points (data not shown).
In contrast, in infected animals mean liposomal uptake in the left lung was above 2 %
of ID /g at all time points, and a significant increase over time was found in left / right
lung ratio’s (P < 0.001) (Table 1). Mean left / right lung ratio’s in infected animals were
significantly elevated compared to uninfected animals at 48 h post inoculation (P =
0.03) and at all later time points (P = 0.04 to 0.0001) . The highest mean left / right
lung ratio and mean % ID / g left lung was found at 168 h after inoculation. Also, at
this time point liposomal uptake in the left lung was higher than in blood, as indicated
by the left lung / blood ratio (1.94). Rats that were inoculated with non-viable conidia
did not show increased left / right lung ratio’s (Table 1). In the extra-pulmonary organs,
the liposomes accumulated to a certain extent in the liver and spleen. Blood activity
decreased over time, which was  partly due to increased organ uptake and probably
partly due to increased excretion of the tracer during the course of the disease.
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99mTc liposomal pulmonary uptake and scintigraphic imaging results related to
parameters of fungal infection
Representative scintigraphic images of rats with and without left-sided IPA are shown
in Figure 1.
Assessment of scintigrams
Assessment scores of scintigrams and parameters of fungal infection progression are
shown in Table 2. Of 17 uninfected controls, only positive for infection. In infected
animals, the percentage of scintigrams that was assessed positive increased over time
and was significantly correlated with the left / right lung ratio (P=0.003).  At 24 h after
inoculation a small percentage (13%) of the scintigrams were assessed positive. At 48 h
after inoculation however, the majority of the scintigrams (82 %) were scored positive.
Between 48 h and 120 h the total percentage of positive scintigrams was about
constant, whereas the percentage of strongly positive scintigrams was higher at 72 h
and 120 h. At 168 h, all scintigrams were assessed positive, with the majority (67%)
being strongly positive.
Left lung pulmonary macroscopic lesion size
When the left lungs of infected animals were examined macroscopically, hemorrhagic
lesions were seen that increased in size during the course of the disease. There was a
highly significant correlation between the size of these hemorrhagic infarcts and the left
/ right lung ratio (P<0.0001, R=0.758) (Figure 2).
     Uninfected                 168h after fungal inoculaion
Figure 1. Scintigraphic images of rats with and without left-sided invasive pulmonary
aspergillosis. Arrows indicate areas of elevated liposomal uptake in the left lung.
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Fungal culture and disseminated fungal infection
Fungal culture of the left lung revealed highest number of cfu at 24 h after inoculation
followed by an decrease at later time points. No association was found between
number of cfu and progression of fungal disease or left / right lung ratio. Disseminated
fungal infection from the left lung to the right lung was present in two out of seventeen
rats at 120 h and one out of eight rats at 168 h, mean log cfu of Aspergillus being 1.78 ±
0.50.  Disseminated fungal infection in the liver was present in one rat at 120 h and two
rats at 168 h, mean log cfu being 2.03 ± 0.22.  In none of the rats dissemination to both
the right lung and the liver was found.  The presence of disseminated fungal infection
could not be observed on scintigrams. Also, the presence of disseminated fungal
infection in either right lung or liver did not result in significantly increased uptake of
99mTc-PEG-liposomes in these organs. Mean liposomal uptake in the right lungs (%
ID/g) of rats with disseminated infection in this organ was 1.08 ± 0.10, compared to
0.96 ± 0.07 in animals without disseminated infection. Mean uptake in livers (% ID/g)
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Figure 2. Correlation between size of pulmonary macroscopic hemorrhagic lesion and
liposomal uptake, expressed as left / right lung ratio. Symbols mark the different time
points after inoculation at which measurements were performed.
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was 2.99 ± 0.63 in rats with, and 2.43 ± 0.15 in rats without disseminated infection in
this organ.
Galactomannan detection
The proportion or rats positive for circulating galactomannan increased with
progression of the disease. Compared to scintigraphic imaging, galactomannan
detection was positive at a later stage in the course of the disease. At 48 h after
inoculation 82% of the scintigraphic images was assessed positive and left / right lung
ratio’s in infected rats were elevated significantly compared to uninfected controls.  At
this time point in none of the rats circulating galactomannan could be detected. The
first rats that were positive for galactomannan were found at 72 h after inoculation.
From that time, mean levels of circulating galactomannan increased over time, and
there was a significant association between galactomannan levels and
left / right lung ratio (P<0.0001, R= 0.8333) (Figure 3).  Overall, there was a significant
correlation between positivity of scintigrams and galactomannan detection. Of all rats
in which scintigrams were assessed positive, in 72% also galactomannan was detected,
whereas of all rats in which scintigrams were assessed negative, in 27% galactomannan
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Figure 3.  Correlation between concentration of galactomannan in serum and liposomal
uptake expressed as left / right lung ratio. Symbols mark the different time points after
inoculation at which measurements were performed.
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was detected (P< 0.001). In addition, in all rats in which scintigrams were assessed
strongly positive, galactomannan was detected .
Histopathology
In a separate experiment, 5 groups of 3 rats with IPA were sacrificed at 24 h, 48 h, 72
h, 120 h and 168 h after fungal inoculation, respectively. The lungs were removed and
examined for histopathology. Results are shown in Table 3. Short hyphae were seen at
24 h after inoculation. Hyphae increased in length over time and showed radial growth
and branching at later time points. Infiltrating leukocytes, predominantly granulocytes,
were seen at all time points. The numbers of leukocytes were low, only seen as a thin
granulocytic rim around the fungal foci, and there was no clear increase in amount of
leukocytes over time. Tissue invasion was seen at 48 h and later, showing especially
broncho-invasion at earlier stages, progressing to increasing angio-invasion at later
stages. Small hemorrhagic infarcts were seen in some histological sections at 48 h,
increasing over time to extensive tissue infarction at 168 h. Tissue necrosis was seen
relatively late in the course of the disease, first observed at 72 h and increasing at later
time points to significant tissue necrosis with widespread fungal growth.
Table 3.  Histopathology of left lungs of rats with invasive pulmonary aspergillosis at different
stages of the disease.
Time after inoculation 24 h 48 h 72 h 120 h 168 h
Hyphal growth + +/++ +/++ ++ ++
Leukocyte accumulation + + + + +
Broncho and angio- invasion - + + ++ ++/+++
Hemorrhagic infarction - -/+ + +/++ ++/+++
Tissue necrosis - - -/+ + +/++
DISCUSSION
In the present study, we investigated whether scintigraphic imaging using 99mTc-PEG-
liposomes could have an additional value in the diagnosis of IPA. In our rat model of
left-sided IPA, we found that the majority of scintigraphic images (82%) were assessed
positive already at 48 h after fungal inoculation. At that time liposomal uptake in the
infected left lung was elevated significantly compared to the uninfected contralateral
lung. Preferential accumulation of liposomes was associated with the presence of live
fungal elements, since inoculation with saline only or killed conidia did not cause
increased liposomal uptake. The mean left / right lung ratio in infected rats at 48 h was
2.67, and increased significantly over time until reaching a value of 5.9 at 168 h. Based
on the findings of imaging of PCP using 111In-IgG in two different studies, an infected
tissue- to background ratio in rat lungs larger than 2 may predict successful imaging in
patients [24,25].
                                  Chapter 7                                                Scintigraphic imaging in rats with invasive aspergillosis
118
We compared the results of scintigraphic imaging with a relatively new test for
diagnosing IPA, the detection of circulating galactomannan. Favourable results using
circulating galactomannan detection by sandwich ELISA were reported by Maertens et
al. [5].  In their study of 71 patients with confirmed IPA, the sensitivity and specificity
of this test was 92.6 and 95.4%, respectively. In more than half of the cases,
antigenemia was detected before clinical suspicion of IPA (median, 6 days before),
which indicates that antigenemia may occur early in the course of the fungal disease. In
our rat model, at 48 h scintigraphy was positive in most rats, but circulating
galactomannan could be detected only at 72 h and thereafter. Our rat model was
characterised by an acute IPA, with around 50% of rats dying at day 7 after fungal
inoculation. In humans the course of IPA generally extends over a longer period in
time than in our animal model, therefore time differences may be larger and more time
may be gained in early diagnosis of IPA.
Clinically, it may be especially interesting to investigate the value of scintigraphy
neutropenic patients with fever, in which IPA is a major hazard. Currently, high-
resolution computed tomography (HRCT)-scans are often used in these patients to
evaluate the lungs after several days of fever refractory to antibiotics. Nevertheless,
these CT scans may reveal negative or inconclusive results in the very early phase of
IPA. Imaging using PEG- liposomes may have an additional value here, since CT-
imaging depends on structural changes whereas scintigraphic imaging also depends on
physio-chemical changes induced by the micro-organism. Also, the whole body can be
evaluated at once by scintigraphy and therefore extrapulmonary localisations may be
more easily located, whereas whole-body evaluations by CT are seldomely used.  It
must be noted however, that preferential localisation of PEG- liposomes at the site of
infection is, as is also the case with CT-scan,  not specific for invasive aspergillosis. In
several other infection models, including a granulocytopenic rat model of bacterial
pneumonia caused by K. pneumoniae in our institute [14], preferential localisation of
PEG- liposomes has been described.  Therefore, to diagnosediagnose IPA, a strategy in
which scintigraphy is combined with more fungal-specific techniques such as
galactomannan detection in serum and in fluid from site-directed broncho-alveolar
lavage is necessary.
In our model, the uptake of  99mTc-PEG-liposomes increased over time, showing a
clear correlation with the size of the hemorrhagic lesion (P < 0.0001).  Also, in rats that
were sacrificed at the same time point, we observed a relation between the macroscopic
lesion size and the amount of labelled liposomes per gram lung. In addition, liposomal
uptake was correlated with circulating galactomannan concentrations, which has been
shown to be associated with severity of disease [23].  These results indicate that
scintigraphy using radiolabelled PEG–liposomes may not only be useful for the early
detection, but also for assessing the severity of disease. These findings are in agreement
with data from our rat model of K.pneumoniae [11], showing a significant correlation
between the amounts of localising PEG- liposomes in the infected left lung and the
intensity of infection.
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The mechanism by which PEG-liposomes accumulate in infected tissue is thought to
be mediated by extravasation into inflammatory area as a result of locally enhanced
vascular permeability [14,26,27], or by vascular leakage. In the early phase of infection
in our study, liposomal uptake in the infected left lung was significantly elevated, while
histopathological sections did not reveal hemorrhagic infarcts, and macroscopically no
or very small hemorrhagic lesions were present. Therefore, it is likely that liposomal
localisation at this time point was mainly due to increased vascular permeability. At later
time points, hemorrhagic bleedings increased, as assessed macroscopically and by
histological sections, indicating pulmonary bleeding also attributed to increase in
liposomal localisation.
The involvement of leukocytes in liposomal extravasation was investigated by
Schiffelers et al. in the model of K. pneumoniae pneumonia in rats [14]. They showed that
liposomal localisation in the infected lung in leukopenic rats was similar to that in
immunocompetent rats, demonstrating that the contribution of circulating leukocytes is
limited. This explains why in our leukopenic rat model of invasive aspergillosis showing
a minimal leukocytar infiltrate, a substantial localisation of liposomes was seen.
We conclude that in our model of persistently neutropenic rats scintigraphic imaging
could be of value for the early detection of IPA, and that liposomal uptake correlates
with severity of fungal disease. Although it must be noted that accumulation of
liposomes in areas of inflammation is not specific for IPA, scintigraphy could be a
useful tool in the diagnosis of human IPA.
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ABSTRACT 
 
In common with a proportion of patients with invasive pulmonary aspergillosis, the 
efficacy of AmBisome® treatment regimens in our rat model remains suboptimal.  To 
investigate whether this might be the result of initially low antifungal activity of 
amphotericin B at the site of infection when administered in the liposomal form, 
Fungizone® was added to AmBisome® at start of treatment.  
Groups of granulocytopenic rats with left-sided invasive pulmonary aspergillosis 
received 10-day-treatment regimens with either AmBisome® 10 mg/kg/day (n=25) or 
AmBisome® 10 mg/kg/day combined with a single dose of Fungizone® 1 mg/kg at day 
1 (n=27). Parameters of treatment response included survival, serum galactomannan, 
size and quality of pulmonary macroscopic lesions, lung weight, viable fungal counts 
(cfu) and chitin content of the infected lung, and extra-pulmonary disseminated fungal 
infection. In a separate experiment the significance of early start of treatment to obtain 
therapeutic efficacy was investigated.  
Compared to untreated controls, both treatment regimens showed a significant increase 
in survival and change in parameters of fungal infection except left lung cfu. The 
combination treatment showed a significant increase in survival compared to 
AmBisome® monotherapy (P= 0.02) and a significant decrease in left lung chitin 
content (P=0.03). Differences in circulating galactomannan concentrations between the 
two treatment regimes approached significance (P=0.06). Delay in start of treatment 
from 16 h to 24 h after fungal inoculation resulted in a significant decrease in 
therapeutic efficacy (P=0.02).  
It is concluded that efficacy of AmBisome® therapy can be enhanced by the addition of 
Fungizone® at the start of treatment. This is probably a result of active amphotericin B 
being immediately available in the lung at start of treatment.  
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INTRODUCTION 
 
During the past decade, invasive aspergillosis has become an increasingly common 
opportunistic infection appearing primarily in patients receiving cancer chemotherapy 
or immunosuppressants [1]. Amphotericin B  (Fungizone) remains the first drug of 
choice in the treatment of patients with invasive pulmonary aspergillosis (IPA) [2]. 
However, treatment with Fungizone is often unsuccessful [3,4] and its use is limited 
by its dose-related nephrotoxicity [5].  Several lipid-based formulations of amphotericin 
B have been developed to reduce the toxicity associated with conventional 
amphotericin B [6]. One of these lipid formulations is liposomal amphotericin B 
(AmBisome).  AmBisome can be administered in higher dosages than Fungizone, 
which may result in a better therapeutic index. However, although the efficacy of high-
dose AmBisome is equal to or better than Fungizone, failure rates still give cause for 
concern [7,8].  One explanation for the limited success of AmBisome in a proportion 
of patients might be a substantial reduction in the immediate bioavailability of free 
amphotericin B when the drug is liposome- encapsulated [9]. Clinical studies have 
shown that early start of treatment with amphotericin B is important for a successful 
outcome [10,11] therefore, low initial antifungal activity may cause a decrease in 
therapeutic efficacy. Evidence to support this hypothesis was found previously in our 
institution. Experimental studies showed that the addition of a single dose of 
Fungizone at the start of a 10-day AmBisome®- regimen significantly increased 
survival of granulocytopenic mice with disseminated candidiasis [12]. 
In the present study, it was investigated whether the efficacy of AmBisome in our 
model of IPA in persistently granulocytopenic rats could be improved by the addition 
of Fungizone in the early phase of the disease. Several parameters for assessment of 
therapeutic response were used.  
 
 
MATERIALS AND METHODS 
 
Infection model of IPA 
Our animal model, first described by Leenders et al. [13], was used with a few 
modifications. Specified pathogen free female RP strain albino rats (18-25 weeks old, 
185-225 g) were employed. Profound granulocytopenia was induced by intraperitoneally 
(i.p.) administration of 75 mg/kg cyclophosphamide (Sigma-Aldrich Chemie, 
Steinheim, Germany) 5 days before inoculation, followed by repeated doses of 60 
mg/kg 1 day before and 3 and 7 days after fungal inoculation. This protocol resulted in 
granulocyte counts of less than 0.1×109 / L on the day of fungal inoculation. To 
prevent bacterial superinfections, animals were given daily doses of 40 mg/kg 
amoxicillin intramuscularly (i.m.) starting 1 day before inoculation and a 6 mg/kg dose 
of gentamycin i.m. on the day of inoculation. In addition, rats received ciprofloxacin 
(660 mg/L) and polymyxin B (100 mg/L) in their drinking water throughout the 
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experiment. Rats were inoculated with a clinical isolate of Aspergillus fumigatus originally 
isolated from an immunocompromised patient with IPA.  In accordance with NCCLS 
procedures [14], the MIC of amphotericin B for this strain was 0.4 µg/mL. Infection 
was established by intubation of the left main bronchus under general anaesthesia. A 
cannula was passed through the tube and the left lung was inoculated with 6×104 A. 
fumigatus conidia suspended in 20 µL of phosphate buffered saline (PBS).  
Prior to experiments in infected rats, treatment regimes were administered to 
uninfected, granulocytopenic rats in which no noticeable toxicity was observed. 
The experimental protocols adhered to the rules laid down in The Dutch Animal 
Experimentation Act (1977) and the published Guidelines on the Protection of 
Experimental Animals by the Council of the EC (1986). The present protocols were 
approved by the Institutional Animal Care and Use Committee of the Erasmus 
University Rotterdam. 
 
Antifungal treatment  
Antifungal agents were administered intravenously via the lateral tail vein to groups of 
rats daily. Treatment was started at 16 h after fungal inoculation, at which time hyphal 
growth was established.  Fungizone was obtained from Bristol-Meyers BV (Woerden, 
The Netherlands), and was diluted in 5% dextrose. AmBisome was obtained from 
NeXstar pharmaceuticals (Wilrijk, Belgium) and diluted in 5 % dextrose.  The following 
treatment regimens were investigated: 1) AmBisome 10 mg/kg/day for 10 days;  2) 
AmBisome 10 mg/kg/day for 10 days combined with a single dose of Fungizone 1 
mg/kg at day 1. When Fungizone and AmBisome were combined on the same day, 
AmBisome was administered first and Fungizone within 20 minutes thereafter. 
Controls received no treatment, since previous studies showed that placebo treatment 
with either 5% dextrose or empty liposomes did not influence survival, levels of 
circulating galactomannan or other parameters of fungal infection (data not shown).  
 
Parameters for efficacy of antifungal treatment 
 
The survival rate of rats was monitored twice daily until day 11 after fungal inoculation.  
Circulating galactomannan (GM) was measured on days 3, 5, 7, 9 and 11 after fungal 
inoculation.  At the end of the antifungal treatment rats had died or survived. Rats 
surviving on day 11 were sacrificed and dissected. In rats that died and sacrificed rats, 
the size of the pulmonary lesion of the left lung was measured, left lung weight was 
determined, organs were cultured for fungi and chitin assays were performed on the left 
lung homogenates. 
 
GM detection 
Blood for GM detection was sampled by puncture of the orbital venous plexus in the 
lateral canthus of the orbita. When cyclophosphamide, antifungal agents or antibiotics 
were administered to the rats on the same day as GM detection was performed, blood 
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samples for GM detection were taken within 2 hours before injection of these agents. 
Concentrations of circulating GM were measured as described previously [15]. Briefly, 
300 µL of each serum sample was used in a sandwich ELISA (Platelia Aspergillus, 
Sanofi Diagnostics Pasteur, Belgium). Each plate contained a calibration curve derived 
from rat serum samples containing 0, 1, 1.5, 2, 3, 4, 6, 8 and 12 ng/mL GM.  
 
Pulmonary macroscopic lesions and left lung weight 
Pulmonary macroscopic lesions were observed in both untreated rats and treated rats. 
Angio-invasive lesions, seen as macroscopic dark-red lesions, were histologicaly 
characterised by extensive hyphal broncho- and angio-invasion and haemorrhagic 
infarction. Responsive lesions, seen as macroscopic light-red coloured lesions were 
histologicaly characterised by the presence of relatively short hyphae and little angio- 
and bronchio-invasion with resulting less hemorrhagic infarction. The size of the two 
types of pulmonary lesions was expressed as percentage of the total lung surface. The 
pulmonary lesion size was measured from photographs of the anterior of the lungs 
taken immediately after dissection.  
 
Fungal cultures of organs  
Left and right lungs were disrupted in 12 mL, livers in 20 mL phosphate buffered saline 
(PBS) using a tissue homogeniser (The Virtis Co. Inc., Gardiner, NY, USA) for 45 sec 
at 10,000 rpm. Colony forming units (cfu) in right lungs and livers were counted in 1:10 
and undiluted homogenates. cfu in left lungs were counted in 1:10 and 1:100 dilutions, 
and the remaining 10.68 mL of homogenate was used for chitin assay. Dilutions of 
homogenates were spread onto Sabouraud agar plates. Undiluted homogenates were 
cultured according to the pour plate method. After incubation at 37 °C for 36 h the cfu 
were counted. 
 
Chitin assay  
A 10.68 mL aliquot of left lung homogenate was used for chitin assay, as described by 
Lehmann et al. [16]. In brief, the homogenate was centrifuged, resuspended in 4 mL of 
3% sodium lauryl sulfate (SDS, Sigma chemical co., St Louis, USA) and heated at 100 
°C for 15 min. After cooling, the pellet was washed once with distilled water, 
resuspended in 3 mL of 120% KOH solution and heated to 130 °C for 1h. 
Subsequently, 8 mL of ice-cold 75% ethanol was added, tubes were kept at 4 °C for 15 
min and 0.3 mL of Celite suspension (Celite 545; Sigma) was added. After 
centrifugation, the pellet was washed with cold ethanol (40%) and cold distilled water 
respectively and suspended in 0.5 mL of NaNO2 (5%) and 0.5 mL of KHSO4 (95%). 
After centrifugation, volumes of the supernatant were mixed with 12.5% NH4SO3NH2 
followed by MBTH (3-methyl-benzo-2-thiazolone hydrazone HCl monohydrate; 
Sigma). After heating for 3 min, the supernatants were cooled, FeCl3 6H2O (0.83%)  
was added and were allowed to stand for 30 min. The optical density at 650 nm was 
read in a spectrophotometer. The chitin content of the organs was expressed as 
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micrograms of glucosamine per organ. Final measurements of chitin were corrected for 
the loss of volume of homogenate. 
 
Toxicity 
To check for the presence of toxicity following antifungal treatment, renal and hepatic 
functions were monitored in treated rats. Renal function was measured by serum 
creatinine and blood urea antigen (BUN) after ten days of antifungal treatment. Hepatic 
function was measured by serum aspartate aminotransferase (ASAT) and alanine 
aminotransferase (ALAT).  
 
Influence of treatment start-time on survival 
In a separate experiment the influence of start time of treatment on therapeutic efficacy 
was investigated. In this experiment, treatment was started at 16 h after fungal 
inoculation in one group, and at 24 h in the other and survival of the rats was 
compared.  All rats received the combination therapy. 
 
Statistical methods 
Differences in survival were assessed by the log rank test. Differences in proportions of 
animals with dissemination to the right lung and liver were examined by Fisher’s exact 
test. Differences in parameters of fungal infection were assessed by student’s T test 
with exception of differences in chitin amounts, which were calculated using Mann 
Witney’s test.  
To analyse circulating GM concentrations, logarithmically transformed GM values were 
taken, showing an approximate normal distribution. The mean increase of 10log GM 
concentration with time was determined for each group of rats using repeated 
measurements ANOVA (random coefficients regression model) using the SAS Proc 
Mixed statistical computer package. The correlation between the measured 
concentrations of GM and mortality was assessed using Cox regression with 10log GM 
concentration as the time-dependent variable. 
 
 
RESULTS 
 
Survival rate 
Ninety-six percent of untreated rats died < 11 days after fungal inoculation. Both 
treatment regimens significantly improved survival compared to the untreated controls 
(P < 0.0001 for both treatment regimens), as shown in Figure 1.  The addition of a 
single dose of Fungizone 1 mg/kg at the start of treatment (day 1) to the 10-day 
AmBisome regimen significantly improved survival compared to AmBisome 
monotherapy (P = 0.02).  
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Figure 1. Survival of rats with IPA during antifungal treatment. Treatment was started 
16 h after fungal inoculation and continued for 10 days. Diamonds, AmBisome 10 
mg/kg/day + Fungizone 1 mg/kg on day 1; squares, AmBisome 10 mg/kg/day; 
circles, untreated controls.*  P = 0.02 compared with AmBisome monotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentrations of circulating GM 
In both the untreated group and the treated groups, concentrations of circulating GM  
increased consistently over time (Table 1).  The mean daily increases in 10 log GM 
concentrations for controls, AmBisome monotherapy and combination therapy were 
0.33 (± 0.02 SEM),  0.12 (± 0.02) and 0.08 (± 0.01) respectively. The mean increases in 
GM for the two treatment regimens were significantly lower than in controls (P < 0.001 
for both regimens).  The difference in 10 log GM increase between AmBisome 
monotherapy and combination therapy approached significance (P = 0.06). 
Using Cox regression, it was found that there was a significant correlation between GM 
concentration and mortality (P < 0.001). A ten-fold increase in GM concentration was 
associated with an approximate 6 – fold increase in mortality (relative death rate: 5.6; 95 
% CI: 3.0-10.3). This correlation between GM concentration and mortality was not 
significantly influenced by the type of treatment administered (P = 0.12). 
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Table 1. Galactomannan serum concentrations in rats with IPA during different antifungal 
treatment regimens†  
 
Day1) 
Untreated controls AmBisome 
10 mg/kg/day 
AmBisome10 mg/kg/day + 
Fungizone 1 mg/kg on day 1 
 No of 
rats 2) 
10log GM 
conc 
No of 
rats 
10log GM 
conc 
No of 
rats 
10log GM conc 
Day 3 20 0.83 ± 0.10 20 0.32 ± 0.12 17 0.26 ± 0.06 
Day 5 19 1.42 ± 0.12 20 0.67 ± 0.14 17 0.51 ± 0.12 
Day 7 11 1.95 ± 0.12 19 1.00 ± 0.11 16 0.85 ± 0.14 
Day 9 5 2.55 +0.22 16 0.87 ± 0.17 16 0.69 ± 0.12 
Day 11 1 2.65 13 0.78 ± 0.12 16 0.93 ± 0.14 
Data are shown as mean ± SEM.  
† Treatment was started 16 h after fungal inoculation and continued until day 10. 
1) Day after fungal inoculation. 
2) Galactomannan measurements were performed on all rats that survived at the indicated days after fungal 
inoculation.  
 
 
Table 2. Parameters of fungal infection in rats with IPA receiving different antifungal  
treatment regimens 
 Untreated controls 
AmBisome 
10 mg/kg/day 
AmBisome10 mg/kg/day + 
Fungizone1 mg/kg on day 1 
No of rats 1) 28 25 26 
Angio-invasive lesion left 
lung (%) 78 ± 5.8 27 ± 6.7* 17.6 ± 6.3* 
Responsive lesion left 
lung (%) 5.7 ± 2.7 47 ± 7.2* 50 ± 7.7* 
Weight left lung (g) 1.16 ± 0.07 0.74 ± 0.05* 0.73 ± 0.05* 
10log cfu in left lung 3.06 ± 0.08 3.05 ± 0.09 2.80 ± 0.07*  
Culture positive right 
lung (%) 79 ± 8 24 ± 9* 12 ± 6* 
10log cfu in right lung 1.62 ± 0.19 0.47 ± 0.18* 0.19 ± 0.12* 
Culture positive liver (%) 75 ± 8 0 ± 0.0* 0 ± 0.0* 
10log cfu in liver 1.01 ±0.09 0 ± 0.0* 0 ± 0.0* 
Left lung chitin content 2) 
(µg glucosamine) 15.4 (0-36.0) 4.7 (0-42.7)* 0.5 (0-57.5)*
  
Data are shown as mean or percentage ± SEM, except 2) chitin contents, which are shown as median 
(range).  
1) Measurements were performed on rats that died during treatment and on rats that were sacrificed at the 
end of treatment. 
* P < 0.05 compared to untreated controls 
 P < 0.05 compared to rats receiving AmBisome® monotherapy 
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Pulmonary macroscopic lesions and left lung weight 
Antifungal treatment had an effect on the weight and macroscopic appearance of the 
left lung (Table 2). A shift was observed from angio-invasive lesions in untreated 
animals to responsive lesions in both treatment groups. Histologicaly, angio-invasive 
lesions showed extensive fungal broncho- and angio-invasion and tissue hemorrhagia, 
all of which in responsive lesions were clearly reduced. Compared to controls, left lung 
weight was significantly lower in both treatment groups (P < 0.001 for both regimens). 
Compared to the AmBisome monotherapy group, the number of angio-invasive 
lesions was lower in the combination therapy group, but this difference was not 
significant (P = 0.31). 
 
Fungal cultures of organs 
AmBisome monotherapy did not reduce cfu cultured from the left lung (Table 2). In 
contrast, the combination therapy significantly reduced the cfu in the left lung 
compared to both the untreated controls (P < 0.001) and AmBisome monotherapy 
group (P = 0.04). Both treatment regimens completely prevented dissemination of the 
liver.  
 
Chitin content of the infected lung 
Both the AmBisome monotherapy and the combination therapy reduced chitin 
content in the left lung compared to untreated controls (P = 0.03 and P < 0.01 
respectively). Compared to AmBisome monotherapy, the combination therapy 
significantly reduced left lung chitin content (P = 0.03).  
 
Toxicity 
There were no significant differences between the treatment groups in serum 
creatinine, BUN, ALAT and ASAT concentrations after 10 days of treatment (data not 
shown). 
 
Influence of treatment start-time on survival 
In a separate experiment, it was investigated whether delay of start of treatment would 
have an effect on the therapeutic efficacy in our model. We compared the efficacy of 
the combination therapy when started at 16 h (n = 10), or at 24 h after fungal 
inoculation (n = 12) (Figure 2).  A significant reduction in survival was seen when start 
of treatment was delayed from 16 h to 24 h (P=0.02) 
 
 
 
 
 
 
                                   
 
 
 
                                       %JCRVGT                                  Enhanced antifungal efficacy by adding Fungizone to AmBisome  
 
 
 132 
 
 
Correlation between parameters of fungal infection and survival in treated rats 
To investigate which parameters of fungal infection were associated with survival in  
rats receiving antifungal treatment (either AmBisome® monotherapy or combination 
therapy), we compared the results of rats that died during treatment with those of rats 
that survived until the end of treatment (Table 3). In the surviving animals the size of 
the responsive lesion was significantly larger, while the angio-invasive lesion was 
smaller. In addition, the parameters of fungal load were lower in surviving animals with 
the left lungs containing significantly less cfu and chitin compared to animals that died. 
The number of cfu in the right lungs was also lower in surviving rats and the difference 
in the percentage of rats with dissemination approached significance. 
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Figure 2. Survival of rats with IPA during antifungal treatment with AmBisome 10 
mg/kg/day plus Fungizone 1 mg/kg on day 1.  Treatment was started 16 h after fungal 
inoculation in one group of rats and at 24 h in the other. Squares, start of treatment at 16 
h; triangles, start of treatment at 24 h; circles, untreated controls. * P = 0.02 compared 
with rats in which therapy was started at 24 h.
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Table 3. Comparison of the parameters of fungal infection in rats that died during treatment† 
with rats that were sacrificed at the end of treatment 
 
Treated rats that 
died before end of 
treatment 
Treated rats that 
survived until end 
of treatment P value 
No of rats 15 35  
Angio-invasive lesion left lung(%) 41 ± 9 14 ± 5 0.008 
Responsive lesion left lung (%) 15 ± 5 35 ± 6 < 0.001 
Weight left lung (g) 0.74  ± 0.06 0.74  ±  0.04 0.982 
10 log cfu in left lung 3.1 ±  0.09 2.83 ±  0.07 0.02 
Culture positive right lung (%) 33 ±  12 11 ± 5 0.06 
10 log cfu in right lung 0.66 ±  0.25 0.18 ± 0.09 0.04 
Left lung chitin content1)  
(µg glucosamine) 20.4 (0-42.7) 5.1 (0-57.5) 0.004 
Data are shown as mean or percentage ± SEM, except 1)chitin contents which is shown as median (range).  
† Treatment was started 16 h after fungal inoculation and continued until day 10. 
 
 
 
DISCUSSION 
 
In this study, we compared the therapeutic efficacy of two treatment schedules using a 
clinically relevant animal model of invasive pulmonary aspergillosis (IPA) during 
persistent neutropenia.  In this model,  Leenders et al. showed that a 10-day treatment 
with high doses (10 mg/kg) of AmBisome did not result in increased survival 
compared to a 10-day treatment with Fungizone 1 mg/kg [13].  Clinical studies in 
neutropenic patients have also shown that AmBisome treatment is not always superior 
to standard Fungizone therapy [7,8,17]. 
The aim of our study was to investigate whether the efficacy of high doses of 
AmBisome  could be enhanced by increasing the immediate availability of the 
biologically active drug in the early phase of treatment. This hypothesis was based on 
studies performed in our laboratory by van Etten et al. in a mouse model of invasive 
candidiasis [9,12,18]. In biodistribution studies that measured the levels of amphotericin 
B in the lung at various time points, after a single injection of 0.3 mg/kg Fungizone 
they found that amphotericin B could be detected in the lung at all time points from 5 
min to 12 h. In contrast, after a single injection with 7 mg/kg AmBisome, 
concentrations of amphotericin B in the lung could not be detected until 12 h and later.  
In addition,  they reported that the in vitro antifungal activity of AmBisome during 
short-term exposure (6 h) of Candida albicans  was significantly less than that of 
Fungizone. The latter finding was explained by a relatively slow release of 
amphotericin B from the liposomes. Furthermore, they found that addition of a single 
                                   
 
 
 
                                       %JCRVGT                                  Enhanced antifungal efficacy by adding Fungizone to AmBisome  
 
 
 134 
dose of Fungizone to a 5-day regimen of AmBisome® at the start of treatment 
significantly increased survival and decreased fungal load in the kidney of 
granulocytopenic mice with disseminated candidiasis.  
Our findings are in accordance with these studies. In our rat model of IPA we have also 
observed that rat survival increased significantly when a single dose of Fungizone® was 
initially added to a 10-day AmBisome® regimen. When higher doses of AmBisome® (up 
to 30 mg/kg) were administered on day one and 10 mg/kg AmBisome® on day 2 to 10, 
no improvement compared to AmBisome® monotherapy was seen (data not shown), 
indicating that changing the absolute amount of AmBisome on day one had no 
significant impact. Multiple doses of Fungizone 1 mg/kg (at day 1,3 and 5, or at day 1 
and 6, or twice at day 1 combined with the 10-day AmBisome regimen did not further 
enhance survival  compared to a single addition of Fungizone 1 mg/kg at day 1 (data 
not shown).  This indicates that only addition of Fungizone® at day one is relevant for 
improving survival.  In addition, an early antifungal activity was shown to be a highly 
important factor since an 8-hour delay in starting antifungal treatment resulted in 
significant reduction in survival. Therefore, it is likely that the improved antifungal 
efficacy by the addition of Fungizone® to the AmBisome® regimen at day 1 is caused 
by increased bioavailability of amphotericin B in the lung in the early phase of the 
disease.  
In addition to survival, we investigated the value of several parameters of fungal 
infection as markers for treatment response. Antifungal treatment appeared to have an 
effect on most of these parameters. Concentrations of serially sampled serum GM were 
significantly lower in both treatment groups compared to untreated controls while the 
difference between treatment groups approached significance. Other investigators have 
also described a suppressive effect of antifungal treatment on circulating GM 
concentrations in both animal models and patients with IPA [19,20]. In addition, 
increases in GM concentrations in our model were associated with a significantly 
increased mortality. This indicates that serum GM concentrations are a relevant 
parameter for measuring treatment response.  
 Antifungal treatment resulted in a reduction in lung weight and size of the dark-red 
coloured haemorrhagic angio-invasive lesion and an increase of the size of the light-red 
coloured responsive lesion. The size of this responsive lesion was also associated with 
increased survival, as opposed to the angio-invasive lesion. Others have also described 
decreased haemorrhagic lesions in a rabbit model of IPA and increased lighter coloured 
“resolving” lesions under antifungal treatment [21]. These findings suggest that these 
lesions reflect an important aspect of the pathogenesis of IPA. Since responsive lesions 
represented areas with reduced  broncho-angio invasion and hemorrhagia, inhibition of 
the invasive spread of the fungus is probably important for successful antifungal 
treatment.  
The numbers of cfu cultured from the left lungs of rats receiving combination therapy 
were lower than those of rats receiving AmBisome® monotherapy. However, compared 
to untreated controls the cfu of the AmBisome® monotherapy group were not 
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significantly decreased.  This may be explained by the fact that the number of cfu does 
not represent the real viable fungal load: larger hyphae represent a larger fungal load but 
not necessarily a larger number of cfu [22]. In accordance with this, several studies 
reported that the numbers of cfu cultured from the organs in their animal models of 
IPA did not significantly increase over time [16,23,24], in contrast to quantitatively 
measured fungal DNA in one of these studies [24]. Chitin may be a more reliable 
indicator for fungal load than cfu, since it is a constituent from the fungal cell wall and 
the amount of chitin increases with the growth of the hyphae [16].  Indeed, we found a 
significant decrease in chitin amount in the left lung in both treatment groups 
compared to untreated rats, as well as significant differences between the two treatment 
groups.  
In conclusion, we have demonstrated that the addition of a single dose of  Fungizone 
at the start of AmBisome treatment enhanced therapeutic efficacy of AmBisome 
monotherapy. Apart from survival, parameters of fungal disease that best represented 
increased treatment response were left lung chitin content and serum GM 
concentrations.  
 
 
ACKNOWLEDGEMENTS  
 
We thank Lorna Stearne for critical reading of this manuscript
                                   
 
 
 
                                       %JCRVGT                                  Enhanced antifungal efficacy by adding Fungizone to AmBisome  
 
 
 136 
REFERENCES 
 
1. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem 
epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33(1):23-32. 
2.  Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991;28 Suppl B:27-38. 
3.  Meyer RD, Young LS, Armstrong D, Yu B. Aspergillosis complicating neoplastic disease. Am J Med 
1973;54(1):6-15. 
4. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium 
supplementation. Arch Intern Med 1988;148(11):2389-94. 
5. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during 
remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 
1994;73(8):2099-106. 
6. Leenders AC, de Marie S. The use of lipid formulations of amphotericin B for systemic fungal 
infections. Leukemia 1996;10(10):1570-5. 
7. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal 
amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and 
suspected neutropenia-associated invasive fungal infections [see comments]. Br J Haematol 
1998;103(1):205-12. 
8. Blau IW, Fauser AA. Review of comparative studies between conventional and liposomal amphotericin 
B (AmBisome) in neutropenic patients with fever of unknown origin and patients with systemic 
mycosis. Mycoses 2000;43(9-10):325-32. 
9. van Etten EW, ten Kate MT, Stearne LE, Bakker-Woudenberg IA. Amphotericin B liposomes with 
prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis 
in leukopenic mice. Antimicrob Agents Chemother 1995;39(9):1954-8. 
10. Barnes AJ, Oppenheim BA, Chang J, Morgenstern GR, Scarffe JH. Early investigation and initiation of 
therapy for invasive pulmonary aspergillosis in leukaemic and bone marrow transplant patients. Mycoses 
1999;42(5-6):403-8. 
11. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al. Improved management 
of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic 
scan and surgery. J Clin Oncol 1997;15(1):139-47. 
12. van Etten EW, Snijders SV, van Vianen W, Bakker-Woudenberg IA. Superior efficacy of liposomal 
amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic 
mice. Antimicrob Agents Chemother 1998;42(9):2431-3. 
13. Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. Liposomal 
amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B 
deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. J Antimicrob Chemother 
1996;38(2):215-25. 
14. Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixon D, et al. Comparative and 
collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. 
Antimicrob Agents Chemother 1995;39(2):314-9. 
15. Becker MJ, de Marie S, Willemse D, Verbrugh HA, Bakker-Woudenberg IA. Quantitative 
galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary 
aspergillosis in an experimental rat model. J Clin Microbiol 2000;38(4):1434-8. 
16. Lehmann PF, White LO. Chitin assay used to demonstrate renal localization and cortisone- enhanced 
growth of Aspergillus fumigatus mycelium in mice. Infect Immun 1975;12(5):987-92. 
17. Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, et al. Need for alternative trial 
designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 
2001;33(1):95-106. 
18. van Etten EW, Otte-Lambillion M, van Vianen W, ten Kate MT, Bakker-Woudenberg AJ. 
Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate 
                                   
 
 
 
                                       %JCRVGT                                  Enhanced antifungal efficacy by adding Fungizone to AmBisome  
 
 
 137 
(Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. 
J Antimicrob Chemother 1995;35(4):509-19. 
19. Patterson TF, Miniter P, Ryan JL, Andriole VT. Effect of immunosuppression and amphotericin B on 
Aspergillus antigenemia in an experimental model. J Infect Dis 1988;158(2):415-22. 
20. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole 
ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. 
Antimicrob Agents Chemother 2000;44(12):3381-8. 
21. Allende MC, Lee JW, Francis P, Garrett K, Dollenberg H, Berenguer J, et al. Dose-dependent 
antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary 
aspergillosis. Antimicrob Agents Chemother 1994;38(3):518-22. 
22. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. 
Antimicrob Agents Chemother 1998;42(11):3018-21. 
23. Duong M, Ouellet N, Simard M, Bergeron Y, Olivier M, Bergeron MG. Kinetic study of host defense 
and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect 
Dis 1998;178(5):1472-82. 
24. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, et al. Quantitative PCR 
assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: 
demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001;45(12):3474-81. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  138 
 
  Chapter 9
Summarising discussion 
 
 
 
 
 
 
 
 
 
 
 
Martin J. Becker 
 
 
                                   
 
 
 
                                    %JCRVGT                                                                                         Summarising discussion 
 
 
 140 
SUMMARISING DISCUSSION 
 
Invasive pulmonary aspergillosis (IPA) is still a major problem among severely 
immuno-compromised patients, especially haemato-oncological patients receiving 
chemotherapy. The reasons for this are the following: 
• There is still no reliable tool to diagnose the disease with high sensitivity and 
specificity in an early phase of the disease. 
• There is no treatment regime that results in sufficiently high cure rates, and 
therefore the mortality and morbidity of the disease are still unacceptable high. 
Numerous studies performed in an effort to improve the therapeutic outcome of 
patients with IPA have been published. However, several problems are encountered 
when investigating IPA: 
• Clinical studies on IPA are difficult to perform because histologically proven cases 
are rare and patient groups can be heterogeneous. Therefore, it is difficult to test 
and compare new diagnostic – and treatment regimes.  
• Adequate animal models of IPA are rare, and models vary widely and are often 
poorly defined. 
• Little is known about the exact pathogenesis of IPA. Improved insight into the 
pathogenesis may lead to new diagnostic- and treatment strategies. 
 
The present thesis addresses the above-mentioned problems as follows: 
• The pathogenesis and host response in IPA were investigated in a rat model in 
order to gain more insight into the mechanisms of the course of the disease, and to 
obtain a better definition of our animal model. 
• New tools for diagnosing IPA, i.e. galactomannan (GM) detection, PCR and 
scintigraphy were evaluated in the rat model.  
• GM detection in serum and broncho-alveolar lavage (BAL)-fluid was evaluated 
haemato-oncological patients receiving chemotherapy. 
• Pulmonary lesions, number of colony forming units (cfu), GM concentrations and 
chitin amounts were evaluated for monitoring IPA in the rat model. 
• New treatment regimes were investigated in the animal model using a new 
antifungal drug formulation, i.e. liposomal amphotericin B (L-AMB). 
 
 
PATHOLOGY, PATHOPHYSIOLOGY AND HOST RESPONSE 
 
Pathology 
Macroscopic and microscopic pathology were investigated in our rat model in 
Chapters 3, 6 en 7. Macroscopically, dark-red pulmonary infarcts, increasing in size 
over time, were seen. Microscopically, broncho-and angio-invasion was seen, necrotic 
lesions with radial growth of hyphae, surrounded by a leukocytic rim and tissue 
haemorrhagia.  These findings indicate that histo-pathology in our model was 
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comparable to patients with IPA, and serve as an additional argument that the rat 
model is suited to study the pathophysiology of IPA. 
 
Pathophysiology 
Very little is known about the pathophysiology of IPA in patients, whereas more insight 
into the disease may help develop new diagnostic and / or treatment strategies. In 
addition, more insight into the pathophysiology of IPA in our rat model will help 
define our model better. For example, wether the cause of death of our rats with IPA is 
due to respiratory or circulating failure was unclear. Chapter 2 describes the 
pathophysiology of IPA in our animal model, with emphasis on pulmonary function. 
Rats with IPA showed a decrease over time in body temperature and in body weight.  
An increase in respiratory distress was seen over time, suggesting severe pulmonary 
dysfunction. Compliance and lung-surfactant function were significantly decreased in 
the infected left lungs of rats with IPA. However, O2 and CO2 levels in arterial blood 
were not significantly different between infected rats and uninfected controls. Probably, 
the uninfected right lung compensated for the dysfunction of the infected left lung until 
a late stage in the disease.  
Arterial blood pressure was significantly decreased in infected rats compared to 
uninfected rats. Thus, circulatory failure was a major feature in the terminal phase of 
IPA in our model, and it is likely that this plays a more important role in causing death 
of the rats than pulmonary dysfunction. Whether the same is true for patients with IPA 
is not reported in the literature and is an interesting subject of investigation. 
 
Host response 
In the pathogenesis of severe bacterial infections, cytokines and chemokines play an 
important role.  Septic shock for example, is thought to be mediated by pro-
inflammatory cytokines, especially TNF-α. There is evidence that cytokines and 
chemokines also play an important role in invasive aspergillosis.  Studies showed that 
resistance to systemic invasive aspergillosis was associated with increased production of 
Th1-associated cytokines, whereas Th2-associated cytokines were related with disease 
progression.  In Chapter 3, we investigated the pro-inflammatory cytokines TNF-α 
and IL-1β, the Th1- associated cytokine IFN-γ, the Th2 associated cytokines IL-4, IL-6 
and IL-10 and the chemokines MIP-2 and MCP-1 in lungs and serum of rats with IPA. 
None of the pro-inflammatory cytokines was elevated in rats with IPA. This is a 
remarkable observation, since this is substantially different compared to severe bacterial 
infections. As described in Chapter 2, in rats with severe IPA circulatory failure 
occurred. Apparently, this circulatory failure develops independent of TNF-α and IL-1. 
Possibly, other factors may play a role in IPA, such as a direct effect of fungal toxins on 
the host. Of the other cytokines, only IL-6 was elevated in the infected left lung. This 
indicated a Th2 response in our model, which is in agreement with other studies in 
models of invasive aspergillosis. 
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The chemokines MCP-1 and MIP-2 were also elevated in the left lungs of rats with 
IPA. These substances have a function in attracting macrophages and neutrophils, 
which form the first and second line of the immune-defence against Aspergillus. 
Actually, in our study granulocytes were seen in microscopic sections of the infected 
lungs, around fungal foci (Chapter 7). This suggests that also in the neutropenic host 
these chemokines have a role in the defense against A. fumigatus, and are produced by 
the host in an attempt to attract macrophages and neutrophils.  
 
 
DIAGNOSIS, MONITORING AND SCINTIGRAPHIC IMAGING 
 
Diagnosis 
Two new techniques for the early diagnosis of IPA have especially drawn attention the 
last few years: PCR and GM detection. Both tests have shown promising results in 
clinical settings. We first evaluated these tests in our animal model (Chapter 4). The 
advantage of using the model is that it is certain whether the animals have the disease 
or not, in contrast to patients. In addition, the exact time point of onset of the disease 
is known, allowing comparison of the tests in an early phase of the disease, which is 
relevant with respect to diagnosis. Compared to PCR, GM detection in blood /serum 
was earlier positive, and showed higher sensitivity. At day 7 after fungal inoculation, all 
rats were positive for GM, whereas only 41% of rats were positive for PCR. Also in 
BAL-fluid, GM detection was more often positive than PCR, especially in the later 
phase of the disease. In addition, GM detection in BAL-fluid was associated with 
hyphal growth of the fungus, whereas PCR was more associated with fungal 
colonisation. In conclusion, in the animal model, GM detection was an appropriate tool 
for the early diagnosis of IPA. This prompted us to evaluate this tool in patients at risk 
for IPA, which is described in Chapter 5. A clinical study was performed in 
neutropenic patients in three haemato-oncological wards. The GM test was applied in 
serum samples and computed tomography (CT)-based BAL-fluid samples. Despite 
serial sampling, the results for GM detection in serum were somewhat disappointing: 
sensitivity 47%, specificity 93%, positive predictive value (PPV) 73% and negative 
predictive value (NPV) 82%. In contrast, the results for GM detection in CT-guided 
BAL-fluid were much better: sensitivity 90%, specificity and PPV 100% and NPV 93%. 
In conclusion, in patients GM detection in BAL-fluid was clearly more useful than GM 
detection in serum. As a result, GM detection in BAL-fluid is now routinely used in our 
hospital in patients undergoing chemotherapy with a suspicion of IPA. 
With increasing reports in the literature the results of GM detection in serum appears 
to vary widely from one centre to the other. The explanation for these inconsistent 
results might be differences between centres in patient populations, in antifungal 
treatment strategies or in antifungal prophylactic regimes. However, these are only 
speculative conclusions.  
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The role of the PCR in diagnosing IPA remains to be explained. In our animal model, 
results were disappointing. As with GM detection, results for PCR in diagnosing IPA in 
patients differ considerably between centres. This may partly be due to different PCR 
methods that are used. An additional problem with PCR is that it often lacks specificity. 
However, PCR techniques for diagnosing IPA are improving. Especially when a 
commercially available, sensitive technique would be on the market, PCR may be quite 
useful in diagnosing IPA, perhaps in combination with GM detection. 
 
Monitoring 
In animal models of IPA, progression of disease and effect of antifungal treatment is 
usually measured by animal survival rate. However, other parameters of fungal infection 
may also be useful to monitor the disease, and may increase the sensitivity in the 
detection of differences in efficacy between various treatment regimes. 
In Chapter 3, we investigated a number of parameters of fungal disease for their 
usefulness in monitoring the disease, and measuring effect of treatment. Treatment 
consisted of a standard dose of amphotericin B 1 mg/kg/day for 10 days. In untreated 
rats, dark-red haemorhagic pulmonary lesions were seen that increased in size with 
progression of disease. In the left lung, cfu did not increase over time, and even showed 
a decrease, despite progression of disease. Left lung GM concentrations and chitin 
amount increased over time, as did serum GM levels. In Chapter 4, these serum GM 
levels were shown to be strongly inversely correlated with rat survival time. In treated 
rats, the aspect of pulmonary macroscopic lesions changed from dark-red to light-red. 
Histopathology of these “responsive lesions” revealed decreased broncho- and angio-
invasion and decreased tissue haemorrhagia. Left lung cfu was not changed. Left lung 
chitin amounts, left lung GM concentrations and serum GM levels al significantly 
decreased under treatment.  
In conclusion, cfu was not an appropriate parameter for monitoring progression of 
disease or measuring treatment effect.  Size and aspect of pulmonary lesions, left lung 
GM and chitin amounts were indicators for fungal load. The most useful parameter to 
monitor disease progression and treatment effect was serum GM, since this parameter 
can be sampled serially, dissection of the animal is not necessary, concentrations are 
strongly associated with animal survival and levels are significantly suppressed by 
antifungal treatment. Most of the parameters were used in the treatment study 
described in Chapter 8. 
 
Scintigraphic imaging 
Scintigraphic imaging may have value in the early diagnosis of IPA. In contrast to X-ray 
and CT, it can detect physio-chemical changes, and detection of IPA is not dependent 
on structural changes in the lung caused by the presence of the fungus. The “gold 
standard” for scintigraphy of infections is the leucocyte scan, but for obvious reasons 
this is not feasible in neutropenic patients. In these patients, the technique that is most 
commonly used is de 67Ga-citrate scan. In Chapter 6, we compared 67Ga-citrate with 
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two new scintigraphic agents: 99MTc-PEG-liposomes and 99MTc-HYNIC-IgG in the rat 
model of IPA. 99MTc was used, because this substance has better imaging properties and 
lower radiation exposure than 67Ga.  PEG-liposomes and IgG were used because these 
substances have the property to localise at the site of infection. Both 99MTc-PEG-
liposomes and 99MTc-HYNIC-IgG showed significantly higher accumulation in the 
infected lung than 67Ga-citrate. These data suggest improved infection targeting in 
patients with IPA when the two newer agents are employed.  99MTc-PEG-liposomes 
demonstrated slightly better uptake than 99MTc-HYNIC-IgG, and therefore this agent 
was further evaluated in the rat model in Chapter 7 and compared with GM detection 
in serum. It was demonstrated that liposomal uptake in the infected left lung increased 
during the course of the disease. In a very early phase of the disease, liposomal 
accumulation was significantly elevated and the majority of scintigrams were assessed 
positive, even before GM detection became positive. This suggests that scintigraphy 
may be positive very early in the course of the disease in patients with IPA, when 
structural changes caused by the fungus in the lung are still small, and X-ray and CT 
may therefore still be negative. A disadvantage of scintigraphy is that it is not specific 
for aspergillosis. Therefore, the technique should be combined with specific methods 
such as GM detection in BAL-fluid or transthorical biopsies.  An advantage of 
scintigraphy is the possibility of rapid whole-body evaluation. In theory, this would 
allow detection of extra-pulmonary fungal disseminations.  In our model we could not 
demonstrate enhanced liposomal uptake in sites of dissemination. However, fungal 
dissemination occurs late in our rat model, and therefore measurements in the early 
phase of the infection not demonstrate a significant difference. Hence, we consider the 
scintigraphic approach as being worthwhile for examination in febrile neutropenic 
patients. 
 
 
TREATMENT 
 
Until recently, treatment of IPA with amphotericin B-deoxycholate (AMB) has been 
the standard treatment in many centres. As in neutropenic patients with IPA, treatment 
efficacy in our rat model of IPA using AMB is still suboptimal.  This is partly due to the 
limited therapeutic range of AMB, as a result of its toxicity. Less toxic lipid-
formulations of AMB have been developed, that can be administered in higher doses. 
Liposomal amphotericin B (L-AMB) is one of these new lipid formulations. However, 
L-AMB doses as high as 10 mg/kg/day did not show improved survival compared to 
standard 1 mg/kg AMB treatment in earlier studies in our model. Before the study 
described in Chapter 8, we tried to improve treatment efficacy by administration of 
even higher doses L-AMB, i.e. up to 30 mg/kg/day. However, this did not improve 
treatment outcome (unpublished data). It was hypothesised that the therapeutic efficacy 
of L-AMB could be improved by increasing the bio-availability of amphotericin B in 
the early phase of treatment. In Chapter 8, a treatment regime of L-AMB 10 
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mg/kg/day was compared with a regime consisting of L-AMB 10 mg/kg/day plus 
AMB 1 mg/kg on the first day of treatment. The addition of the single dose of AMB 
resulted in a significant increase in survival, probably by increasing bio-available 
amphotericin B.at the start of treatment. Also, left lung cfu and chitin content were 
significantly decreased in the combination regime.  
These results may have important consequences for patients with suspected fungal 
infection in which treatment is started with L-AMB. It should be realised that this 
treatment may not be optimal when no efforts are undertaken to compensate for the 
delayed bio-availability of amphotericin B when administered in the liposomal form.  
 
 
FINAL REMARKS 
 
This thesis did not address one aspect of the management of IPA, which is prophylaxis. 
This is an important aspect of the management of IPA, since treatment regimes are still 
suboptimal. At the moment, we are carrying out a double-blind, placebo-controlled 
clinical trial, in which neutropenic patients receive prophylactic nebulisations of L-
AMB, in an attempt to reduce the incidence of IPA. The advantage of using L-AMB, is 
that it is less toxic than AMB. The trial is performed in the haemato-oncological wards 
of the Erasmus MC in Rotterdam.  
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SAMENVATTING VOOR NIET-INGEWIJDEN
De vloek van de mummie
Nadat in 1922 het graf van Toetanchamon ontdekt werd stierf een groot aantal mensen
die de tombe hadden betreden een raadselachtige dood. De slachtoffers werden vaak
binnen enkele weken na het bezoek aan het graf ziek en kregen hoge koorts. Al snel
was de wereld in de ban van deze “vloek van Toetanchamon”.
Vele jaren later, in 1995, maakte de Amerikaanse kunsthistorica Sheryl Munson haar
droomreis: een bezoek aan Egypte en het graf van Toetanchamon. Toen ze de tombe
betrad was ze volledig gefascineerd door  de prachtige muurschilderingen die ze daar
zag. Haar leraar had gezegd dat als ze ooit in de tombe kwam, ze dan de verf moest
aanraken, want die kans zou ze geen tweede keer meer krijgen. Ze boog dan ook
voorover naar de prachtige rode en blauwe schilderijen en wreef met haar hand over de
verf. Drie weken na thuiskomst moest ze af en toe hoesten, hetgeen steeds erger werd.
Haar man zei dat ze naar de dokter moest gaan, maar ze weigerde. Ze had een zware
strijd gestreden tegen de ziekte van Hodgkin (een soort kanker van de lymfeklieren). Ze
had chemotherapie gehad, ze was bestraald, alles wat je doormaakt als je kanker hebt.
Ze wilde nooit meer een dokter zien, maar er was geen andere keus. Bij opname in het
ziekenhuis was ze afgevallen, zwak en kortademig. Er was iets met haar longen, wat ook
bleek uit een afwijkende longfoto, maar de artsen konden niet precies duiden wat het
was. Het ging snel achteruit met Sheryl, en 10 dagen na opname overleed ze. Vlak voor
haar overlijden werd een longbiopsie gedaan en werden de longen gespoeld. Zowel uit
het longbiopt als het longspoelsel werd de schimmel Aspergillus gekweekt. Op basis van
deze bevinding besloten onderzoekers het graf van de Farao aan een nader onderzoek
te onderwerpen. Zij ontdekten dat de zwarte, afgebladderde verf op de muren van de
tombe geen verf was maar een schimmel, en wel Aspergillus. De schimmel voelde zich
prima thuis in het vochtige, warme milieu in de tombe. Het zou dus zeer goed mogelijk
kunnen zijn dat Sheryl hier de besmetting met de schimmel had opgelopen. Bij nader
onderzoek van de mummie bleek deze te wemelen van de bacteriën en schimmels,
waaronder grote hoeveelheden Aspergillus. Dit zou de dood kunnen verklaren van drie
mannen die in de jaren twintig de mummie in stukken hadden gehakt in een poging de
kostbare amuletten die de Farao bij zich droeg van het lichaam los te wrikken (figuur 1).
Mogelijk zouden hierbij grote hoeveelheden schimmel- sporen zijn vrijgekomen die
vervolgens door de mannen werden ingeademd. De schimmel zou verder een
verklaring kunnen zijn voor een aantal van de andere mysterieuze sterfgevallen van
mensen die de tombe bezochten.
Kenmerken invasieve aspergillose
lnvasieve aspergillose wordt veroorzaakt door de schimmel Aspergillus. Deze schimmel
is algemeen aanwezig: hoge concentraties komen bijvoorbeeld voor in potgrond,
vochtige kelders en stoffige ruimtes. Aspergillus soorten die vooral in de kliniek van
belang zijn, zijn Aspergillus fumigatus en Aspergillus flavus. De schimmel is voor mensen
met een normale immunologische weerstand niet pathogeen, maar in patiënten met
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een verminderde weerstand kan Aspergillus ernstige infecties geven. Met name
patiënten met een neutropenie (verlaagd aantal neutrofiele granulocyten in het bloed)
lopen risico. Patiënten die behandeld worden voor een hematologische maligniteit
(bloed kanker, zoals leukemie) vormen een belangrijke groep. In 80-90% van de
gevallen is de long het aangedane orgaan (pulmonale aspergillose), na besmetting via
het inademen van de sporen van de schimmel.
Ziektebeloop en behandeling
Wanneer de ziekte niet behandeld wordt is deze vrijwel altijd dodelijk wanneer de
afweer gestoord is. Therapie bestaat uit het intraveneus toedienen van de antischimmel
medicijn amphotericine B of voriconazol. Soms wordt ook wel itraconazol gegeven. In
veel gevallen helpt de behandeling echter niet. Een belangrijke reden hiervoor is dat de
diagnose vaak pas laat gesteld wordt, wat komt doordat er nog steeds geen goede test
is om de ziekte in een vroeg stadium aan te tonen. Bovendien heeft m.n.
amphotericine B toxische bijwerkingen en kan daardoor niet al te hoog gedoseerd
worden.
 
Figuur 1 De archeoloog Howard Carter onderzoekt de mummie van
Toetancharnon. Later zou blijken dat de mummie hoge concentraties schimmels
en bacteriën bevatte..
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DIT PROEFSCHRIFT
In het onderliggende proefschrift worden de volgende aspecten van invasieve
pulmonale aspergillose (IPA) onderzocht:
• De pathofysiologie (ziekte-mechanisme) en afweerrespons van IPA werden
onderzocht in een rat-model van links-zijdige invasieve pulmonale aspergillose.
• Nieuwe diagnostische technieken om de ziekte in een vroeg stadium aan te tonen
werden uitgetest in het rat-model en in patiënten.
• Testen om het ziekteverloop te monitoren werden onderzocht.
• Behandeling met een nieuwe, minder toxische formulering van amphotericine B,
namelijk liposomaal amphotericine B, werd geoptimaliseerd in het rat-model.
Pathologie, pathofysiologie en afweerrespons
In de hoofdstukken 3, 6 en 7 werd de macroscopische en microscopische pathologie
van de longen in het rat-model onderzocht. Macroscopisch werden donkerrode
infarcten  in de geïnfecteerde linker long gezien, toenemend in grootte in het verloop
van de ziekte. Microscopisch werd invasieve groei van de schimmel in bloedvaten en
bronchi, radiale groei van de schimmel en weefsel necrose gezien. Deze kenmerken
komen overeen met die van patiënten met IPA, en suggereren daarom dat het
diermodel geschikt  is  voor de bestudering van de pathofysiologie van IPA.
Pathofysiologie
Hoofdstuk 2 beschrijft de pathofysiologie van IPA in het rat-model, met de nadruk op
de longfunctie. In het verloop van de ziekte lieten de ratten met IPA een daling in
lichaamstemperatuur en gewicht zien. Tevens werd een toename gezien in “respiratoire
distress”  (bemoeilijkt ademhalen), wat een verminderde longfunctie suggereerde.
Compliance (long-elasticiteit) en functie van surfactant (oppervlaktespanning
verlagende stoffen in de longblaasjes) bleken verminderd in de geïnfecteerde linker
longen van ratten met IPA. Echter, zuurstof en CO2 spanning in het bloed bleken niet
verlaagd te zijn. Kennelijk was de niet-geïnfecteerde rechter long in staat te
compenseren voor de verminderde functie van de geïnfecteerde linker long. De
bloeddruk daarentegen was wel  significant verlaagd in ratten met IPA, en dit zou dan
ook een belangrijke (mede-) oorzaak kunnen zijn bij het overlijden van de ratten aan
IPA.
Afweerrespons
Bij de  pathogenese van infecties spelen cytokines en chemokines (signaal-stofjes tussen
cellen van het immuunsysteem) een belangrijke rol. In hoofdstuk 3 werden
verschillende cytokines waarvan gedacht wordt dat ze wellicht een rol spelen bij IPA
gemeten in de longen en bloed van ratten: de  pro-inflammatoire (vroeg in de infectie
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uitgescheiden) cytokines TNF-α  en IL-1β, de T-helper cel 1 (Th1, bepaald subtype
witte bloed cellen) geassocieerde cytokine IFN-γ, de Th2 geassocieerde cytokines IL-4,
IL-6 en IL-10 en de chemokines (stoffen die bepaalde witte bloed cellen kunnen
aantrekken) MIP-2 en MCP-1. De pro-inflammatoire cytokines waren niet verhoogd in
ratten met IPA. Dit is in tegenstelling tot de situatie bij veel bacteriële infecties.
Kennelijk was de sterke bloeddrukdaling in ons rat-model (hoofdstuk 2) onafhankelijk
van deze cytokines en spelen wellicht andere stoffen (bv toxische stoffen, uitgescheiden
door de schimmel) een rol. Van de andere cytokines was alleen IL-6 in de geïnfecteerde
long verhoogd, duidend op een Th2 respons, zoals ook in andere diermodellen van IPA
eerder is beschreven. Ook MCP-1 en MIP-2 waren verhoogd, wat mogelijk duidt op
een poging van het afweersysteem om meer witte bloedcellen naar de plaats van de
infectie aan te trekken.
Diagnostiek, monitoring en scintigrafische beeldvorming
Diagnostiek
In hoofdstuk 4 werden twee nieuwe, veelbelovende, technieken voor de diagnostiek
van IPA uitgetest in het rat-model: de PCR (polymerase-ketting reactie, waarmee DNA
van de schimmel kan worden aangetoond) en galactomannan (GM) detectie (GM is een
bestanddeel van de celwand van de schimmel en kan d.m.v. een antistof-test worden
aangetoond).  In vergelijking met de PCR, was GM detectie in bloed bij meer ratten
positief, en was deze test ook vroeger in het ziekteverloop positief. Ook in BAL-
vloeistof (longspoelsel) was GM detectie vaker positief en beter geassocieerd met
invasieve schimmelgroei dan PCR.
Hoofdstuk 5 beschrijft de evaluatie van de GM detectie-test in leukemie patiënten die
chemotherapie kregen, en daardoor een verhoogd risico hadden op IPA. Ondanks
regelmatig afname (2 maal per week) van bloed bij deze patiënten vielen de resultaten
tegen: bij slechts 47% van de patiënten met IPA was de test positief. Daarentegen was
de gevoeligheid de test in BAL-vloeistof  van de patiënten met IPA veel hoger, nl 90%.
Als gevolg van deze studie wordt de GM test nu routinematig uitgevoerd in de BAL-
vloeistof van patiënten die verhoogd risico lopen op IPA.
Monitoring
In dier-modellen van IPA, wordt de progressie van de ziekte en de effectiviteit van
therapie over het algemeen gemeten door het meten van de overleving van de dieren.
In hoofdstuk 3 werden verschillende andere parameters om de ziekte te monitoren
onderzocht in het rat-model: laesiegrootte en aspect van de geïnfecteerde long, aantal
cfu (aantal schimmel-kolonies dat groeit na fijnmalen geïnfecteerde long), GM
concentratie in bloed en geïnfecteerde long, en chitine hoeveelheid in de geïnfecteerde
long.   Behalve het aantal cfu, namen alle parameters toe met voortschrijden van de
ziekte. Standaard therapie met amfotericine B deed alle parameters, behalve aantal cfu,
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afnemen. Concluderend was het aantal cfu geen goede parameter om de ziekte te
monitoren en de andere parameters wel. De meeste van de genoemde parameters
werden gebruikt in de therapiestudie beschreven in hoofdstuk 8.
Scintigrafische beeldvorming
Bij scintigrafische beeldvorming worden radioactieve stoffen bij een patiënt met en
infectie-verdenking ingespoten. Wanneer de radioactiviteit dan ophoopt op de plek van
de infectie, kan deze met behulp van een speciale camera in beeld gebracht, en daarmee
gelokaliseerd worden. In hoofdstuk 6 hebben we 3 verschillende radioactief gelabelde
stoffen met elkaar vergeleken en gekeken welke van de stoffen het beste lokaliseerde ter
plaatse van de infectie in het rat-model van IPA. Onderzocht werden 67Ga-citraat
(radioactief Gallium), 99MTc-PEG-liposomen (radioactief gelabelde liposomen) en
99MTc-HYNIC-IgG (radioactief  gelabelde antistoffen). Van de liposomen en
antistoffen werd  gehoopt dat deze beter ter plaatse van de infectie zouden lokaliseren
dan het tot nu toe meest gebruikte Gallium. Dit bleek inderdaad zo te zijn: beide
stoffen lieten een hogere opname in de geïnfecteerde long zien dan 67Ga-citraat, en
99MTc-PEG-liposomen werden iets beter opgenomen dan 99MTc-HYNIC-IgG. In
hoofdstuk 7 werd scintigrafie met 99MTc-PEG-liposomen verder geëvalueerd in het rat-
model en vergeleken met GM-detectie. Er werd gevonden dat opname van de
liposomen in de geïnfecteerde linker long toenam met progressie van de ziekte. Verder
was reeds in een vroeg stadium van de ziekte de liposomale opname significant
verhoogd en werd dit ook zichtbaar op  scintigrammen (radioactiviteit-foto’s) van de
longen, zelfs voordat GM in het bloed positief werd. Dit geeft aan dat scintigrafie vroeg
in het verloop van de ziekte positief wordt, en dat zou wellicht ook het geval kunnen
zijn bij patiënten met IPA.
Therapie
Tot voor kort was amfotericine B (AMB) vaak de standaard therapie bij IPA. Echter,
AMB kan niet te hoog worden gedoseerd vanwege toxiciteit, en daarom zijn andere,
minder toxische  formuleringen van AMB ontwikkeld die hoger gedoseerd kunnen
worden, zoals liposomaal AMB (L-AMB). Echter, ook wanneer L-AMB in hogere
doseringen gebruikt wordt zijn er nog steeds patiënten met IPA die niet genezen. Ook
in het rat-model van IPA leidde het toedienen van hoge doses L-AMB slechts tot
overleven van een deel van de ratten.  In hoofdstuk 8 werd in het rat-model
onderzocht of de effectiviteit van L-AMB verbeterd kon worden door dit middel te
combineren met AMB. De hypothese hierachter was dat de biologische
beschikbaarheid van amfotericine B, wanneer toegediend via de liposomale vorm, in het
begin van therapie laag zou zijn door het langzaam vrijkomen van amfotericine B uit de
liposomen.  In hoofdstuk 8 werd een  behandelingsschema van L-AMB 10 mg/kg/dag
gedurende 10 dagen vergeleken met een schema van L-AMB 10 mg/kg/dag gedurende
10 dagen plus AMB 1 mg/kg op dag 1 van therapie.  Het resultaat van de toevoeging
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van AMB op dag 1 was een significante toename in overleving en een significante
daling in het aantal cfu en chitine hoeveelheid in de geïnfecteerde linker long. De meest
waarschijnlijke verklaring voor deze verbetering in therapie resultaat was dat het
toevoegen van AMB aan L-AMB aan het begin van therapie de biologische
beschikbaarheid  in de long bij start van therapie verhoogt.
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LIST OF ABBREVIATIONS
AMB amphotericin B
BAL broncho-alveolar lavage
BMT bone marrow transplant
cfu colony forming unit
CT computed tomography
DOC desoxycholate
67Ga 67Gallium
GM galactomannan
IA invasive aspergillosis
IFN interferon
IL interleukin
i.p. intraperitoneal
IPA invasive pulmonary aspergillosis
i.v. intravenous
L-AMB liposomal amphotericin B
MCP monocyte chemoattractant protein
MIC minimal inhibitory concentration
MIP macrophage inflammatory protein
NPV negative predictive value
PCR polymerase chain reaction
PEG polyethylene glycol
PPV positive predictive value
99MTc 99MTechnetium
Th T-helper cell
TNF tumor necrosis factor
spp. species
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Uiteindelijk is het “Dankwoord” toch het leukste onderdeel om te schrijven. Het geeft
je de kans geeft om iedereen nog eens uitdrukkelijk te bedanken, je kunt het publiceren
zonder het eerst te laten “peer reviewen”, en het is ook nog eens het meest gelezen deel
van het proefschrift.
Siem de Marie en Irma Bakker, mijn beide co-promotoren wil ik zeer bedanken voor
hun intensieve begeleiding van het onderzoek. Altijd waren jullie bereid om regelmatige
werkbesprekingen te houden en op korte termijn manuscripten, praatjes e.d. door te
nemen en van nuttige kritiek te voorzien. Jullie grote inzet en enthousiasme zijn zeer
belangrijk geweest voor de totstandkoming van dit proefschrift.
Mijn promotor, Prof.dr. Verbrugh: Henri, bedankt voor je begeleiding in de belangrijke
fases van het onderzoek.  Zowel bij het onderzoek als de opleiding was je altijd de
belangrijke steun op de achtergrond waarop ik kon rekenen.
De overige leden van de leescommissie,  Prof.dr. B. Löwenberg, Prof.dr. H.C.
Hoogsteden en Prof.dr. P.E. Verweij wil ik bedanken voor het kritisch doorlezen van
het manuscript.
De overige leden van de promotie commissie, Dr. B.E. de Pauw, Dr. A.G. Vulto en Dr.
J.W. van ’t Wout wil ik bedanken voor hun toezegging deel te nemen in de oppositie.
Marcel Fens: Marcel, bedankt voor het vele werk, dag en nacht, dat je voor het
onderzoek gedaan hebt. Je was soms zo enthousiast dat we wel eens dachten dat we je
eigenlijk een beetje af moesten remmen. Maar ja, het was toch wel mooi dat er weer en
paar experimenten extra waren gedaan dus aan dat afremmen zijn we eigenlijk nooit
toegekomen…
Wim van Vianen: Wim, allereerst bedankt dat je straks in rok naast mij wilt staan (nee,
geen dansje deze keer). Verder wil ik je o.a. bedanken voor allerlei diverse activiteiten
zoals drinkwaterflesjes wegen, een paar ritjes Nijmegen met 80 ratten in de kofferbak
en het vertellen van één  van de beste grappen die ik in mijn tijd op de 17e gehoord heb
(over de rattenfluisteraar, alleen als ik hem aan anderen vertel snapt niemand hem).
Marian ten Kate, jou ik wil ik bedanken voor het mij geduldig bijbrengen van de dier-
experimentele technieken, ritjes Nijmegen en bijstand bij lastige experimenten
(subcutaan prikken van de ratten: dat ik nooit gebeten ben is volledig aan jou te
danken).
Diana Willemse en Cindy van der Schee, bedankt voor jullie nuttige werk op het gebied
van PCR en ELISA, Lorna Stearne bedankt voor je correctie van mijn eigen-stijlse
Engels.
Alle anderen van de (ex-) ”17e”: Raymond, Liesbeth, Liesbeth, Carla, Tannie, Marianne,
John, Jolanda, Els, Roel, bedankt voor de gezellige koffiepauzes en borrels.
Een van de leuke dingen van het onderzoek was de prettige samenwerking met andere
afdelingen. Ik wil alle medewerkers / co-auteurs van de afdelingen Nucleaire
Geneeskunde in Nijmegen, Anesthesiologie en Hematologie in het Erasmus MC
hiervoor bedanken.
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De datum van mijn promotie zal niet alleen de afsluiting zijn van pakweg 7 ½ jaar
onderzoek, ook is het eindpunt van mijn opleiding tot arts-microbioloog. De
assistenten Heiman, Wim, Damian, Jos, Peggy, Margreet, Katja, Juliette, Jan, Tom,
Dorine, Mireille,  Patricia en Oscar wil ik bedanken voor de gezellige lunches, zeer
leerzame studieavonden, onderwijsjes en andere hoogtepunten. Jos, jou wil ik nog met
name bedanken omdat je straks in mijn paranimf wilt zijn. Wim, bedankt voor het
kritisch lezen van enkele delen van het proefschrift. Verder wil ik alle stafleden,
analisten, secretaresses en andere medewerkers van de afdelingen MMIZ, Virologie en
SSDZ bedanken voor de leerzame momenten en prettige contacten.
Tot slot de belangrijkste mensen in mijn leven, aan wie dit boekje opgedragen is. Mijn
ouders: jullie wil ik bedanken voor jullie onvoorwaardelijke steun en betrokkenheid bij
elke fase van de afgelopen 30 jaar studie / opleiding. Mijn zoontje Thomas: bedankt
voor je enthousiaste lach elke dag dat ik thuiskom, ook als ik moe en chagrijnig ben.
Lieve Nurma, bedankt voor de mooie layout van dit boekje, maar bovenal bedankt
voor je liefde, steun en zelfopoffering. Nog even en dan kan het familiefeestje in
tropische sferen van start gaan!
                                                                                                                                                       Curriculum vitae
159
CURRICULUM VITAE
Martin Becker werd geboren te Baarn op 5 mei 1968.  Het VWO diploma werd behaald
aan het Eemland College in Amersfoort in 1986. Hetzelfde jaar startte hij met de studie
Medische Biologie aan de Rijks Universiteit Utrecht, welke in 1992 werd afgerond. Aan
dezelfde universiteit werd in 1990 aangevangen met de studie Geneeskunde. Deze
studie werd onderbroken door de militaire dienstplicht (1993-1994) waarbij de functie
van wachtmeester-verkenner bij de veld-artillerie werd vervuld. Het arts examen werd
behaald in 1997. Eind 1996 werd aan de afdeling Medische Microbiologie en
Infectieziekten van het Erasmus MC als AIO gestart met het onderzoek dat tot het
huidige proefschrift leidde, onder directe begeleiding van Dr. I.A.J.M. Bakker-
Woudenberg en Dr. S. de Marie.  In 1998 werd begonnen met de opleiding tot arts-
microbioloog, aan dezelfde afdeling (opleider: Prof. dr. H.A. Verbrugh).
Sinds 1999 is hij getrouwd met Nurma Nur Rochmah. In 2003 werd hun zoontje
Thomas geboren.

